U.S. patent application number 16/216702 was filed with the patent office on 2019-04-18 for 2-phenethenyltetrahydro isoquinolines useful as anti-hiv compounds.
The applicant listed for this patent is Prosetta Antiviral, Inc.. Invention is credited to Andy ATUEGBU, Clarence R. HURT, Anatoliy KITAYGORODSKYY, Dennis SOLAS.
Application Number | 20190111044 16/216702 |
Document ID | / |
Family ID | 55069168 |
Filed Date | 2019-04-18 |
![](/patent/app/20190111044/US20190111044A1-20190418-C00001.png)
![](/patent/app/20190111044/US20190111044A1-20190418-C00002.png)
![](/patent/app/20190111044/US20190111044A1-20190418-C00003.png)
![](/patent/app/20190111044/US20190111044A1-20190418-C00004.png)
![](/patent/app/20190111044/US20190111044A1-20190418-C00005.png)
![](/patent/app/20190111044/US20190111044A1-20190418-C00006.png)
![](/patent/app/20190111044/US20190111044A1-20190418-C00007.png)
![](/patent/app/20190111044/US20190111044A1-20190418-C00008.png)
![](/patent/app/20190111044/US20190111044A1-20190418-C00009.png)
![](/patent/app/20190111044/US20190111044A1-20190418-C00010.png)
![](/patent/app/20190111044/US20190111044A1-20190418-C00011.png)
View All Diagrams
United States Patent
Application |
20190111044 |
Kind Code |
A1 |
ATUEGBU; Andy ; et
al. |
April 18, 2019 |
2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV
COMPOUNDS
Abstract
This invention provides, among other things,
tetrahydroisoquinolines useful for treating viral infections,
pharmaceutical formulations containing such compounds, as well as
methods of inhibiting the replication of a virus, such as HIV, or
treating a disease, such as AIDS.
Inventors: |
ATUEGBU; Andy; (Dublin,
CA) ; SOLAS; Dennis; (San Francisco, CA) ;
HURT; Clarence R.; (Los Altos, CA) ; KITAYGORODSKYY;
Anatoliy; (San Francisco, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Prosetta Antiviral, Inc. |
San Francisco |
CA |
US |
|
|
Family ID: |
55069168 |
Appl. No.: |
16/216702 |
Filed: |
December 11, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15536104 |
Jun 14, 2017 |
10195189 |
|
|
PCT/US2015/065893 |
Dec 15, 2015 |
|
|
|
16216702 |
|
|
|
|
62092115 |
Dec 15, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 217/02 20130101;
C07D 217/04 20130101; A61P 31/18 20180101; C07D 401/06 20130101;
A61K 31/472 20130101; C07D 217/06 20130101 |
International
Class: |
A61K 31/472 20060101
A61K031/472; C07D 401/06 20060101 C07D401/06; C07D 217/02 20060101
C07D217/02; C07D 217/04 20060101 C07D217/04; C07D 217/06 20060101
C07D217/06 |
Claims
1. A compound which is: ##STR00338## in which R.sup.1 is H or
unsubstituted alkoxy or phenyl substituted alkoxy; R.sup.2 is H or
CF.sub.3 or unsubstituted alkoxy or phenyl substituted alkoxy;
R.sup.3 is H or --C(O)OR.sup.4 or --C(O)R.sup.4 or
--C(O)NR.sup.4R.sup.5 wherein R.sup.4 and R.sup.5 are independently
selected from unsubstituted alkyl, unsubstituted phenyl, or
unsubstituted pyridinyl; A is substituted or unsubstituted phenyl,
or a hydrate, solvate, or salt thereof.
2. The compound of claim 1, which is: ##STR00339## or a hydrate,
solvate, or salt thereof.
3. The compound of claim 1, which is: ##STR00340## or a hydrate,
solvate, or salt thereof.
4. The compound of claim 1, which is: ##STR00341## or a hydrate,
solvate, or salt thereof.
5. The compound of claim 1, which is: ##STR00342## or a hydrate,
solvate, or salt thereof.
6. A pharmaceutical formulation comprising: a) a compound of a
preceding claim, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically acceptable excipient.
7. A method of inhibiting the replication of a virus in an animal,
comprising: a) administering a compound or a pharmaceutical
formulation of a preceding claim to the animal, wherein the animal
is in need of treatment thereof thereby inhibiting the replication
of the virus in an animal.
8. The method of claim 7, wherein the virus is a member of the
Orthoretroviridae family.
9. The method of claim 7, wherein the virus is HIV.
10. A method of treating a disease in an animal, comprising: a)
administering a compound or a pharmaceutical formulation of a
preceding claim to the animal, wherein the animal is in need of
treatment thereof thereby treating the disease in the animal.
11. The method of claim 10, wherein the disease is AIDS.
12. The method of claim 7, wherein the animal is a human.
13. A method of treating an HIV infection in a human, the method
comprising administering to said human a therapeutically effective
amount of a compound according to claim 1.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 15/536,104 filed Jun. 14, 2017, which claims
National Stage of International Patent Application No.
PCT/US2015/065893 filed Dec. 15, 2015 and published as WO
2016/100391 A1, which claims priority to U.S. Provisional
Application No. 62/092,115 filed Dec. 15, 2014, the entire contents
of which applications is incorporated herein for all purposes by
this reference.
BACKGROUND OF THE INVENTION
[0002] There is a need in the art to discover new compounds useful
as antivirals.
[0003] It has now been discovered that certain
tetrahydroisoquinolines are surprisingly effective antivirals.
This, and other uses of these compounds are described herein.
SUMMARY OF THE INVENTION
[0004] This invention provides, among other things, novel compounds
useful for treating viral infections, pharmaceutical formulations
containing such compounds, as well as methods of inhibiting the
replication of a virus or treating a disease.
[0005] In an exemplary embodiment, the invention provides a
compound of the formula which is:
##STR00001##
in which
[0006] R.sup.1 is H or unsubstituted alkoxy or phenyl substituted
alkoxy,
[0007] R.sup.2 is H or CF.sub.3 or unsubstituted alkoxy or phenyl
substituted alkoxy,
[0008] R.sup.3 is H or --C(O)OR.sup.4 or --C(O)R.sup.4 or
--C(O)NR.sup.4R.sup.5, wherein [0009] R.sup.4 and R.sup.5 are
independently selected from unsubstituted alkyl, unsubstituted
phenyl, or unsubstituted pyridinyl;
[0010] A is substituted or unsubstituted phenyl.
Also provided are hydrates, salts and solvates of these
compounds.
[0011] In an exemplary embodiment, there is provided a
pharmaceutical formulation comprising a compound of the invention
and a pharmaceutically acceptable diluent or carrier.
[0012] Also provided is a method of treating a subject infected
with a lentivirus, e.g., human immunodeficiency virus (HIV). The
method comprises, administering to the subject a therapeutically
effective amount of a compound of the invention.
[0013] Other embodiments, objects and advantages of the invention
are apparent from the detailed description that follows.
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions and Abbreviations
[0014] As used herein, the singular forms "a," "an", and "the"
include plural references unless the context clearly dictates
otherwise. For example, reference to "an active agent" includes a
single active agent as well as two or more different active agents
in combination. It is to be understood that present teaching is not
limited to the specific dosage forms, carriers, or the like,
disclosed herein and as such may vary.
[0015] The abbreviations used herein generally have their
conventional meaning within the chemical and biological arts.
[0016] The following abbreviations have been used: Ac is acetyl;
AcOH is acetic acid; ACTBr is cetyltrimethylammonium bromide; AIBN
is azobisisobutyronitrile or 2,2 azobisisobutyronitrile; aq. is
aqueous; Ar is aryl; B.sub.2pin.sub.2 is bis(pinacolato)diboron; Bn
is, in general, benzyl [see Cbz for one example of an exception];
(BnS).sub.2 is benzyl disulfide; BnSH is benzyl thiol or benzyl
mercaptan; BnBr is benzyl bromide; Boc is tert-butoxy carbonyl;
Boc.sub.2O is di-tert-butyl dicarbonate; Bz is, in general,
benzoyl; BzOOH is benzoyl peroxide; Cbz or Z is benzyloxycarbonyl
or carboxybenzyl; Cs.sub.2CO.sub.3 is cesium carbonate; CSA is
camphor sulfonic acid; CTAB is cetyltrimethylammonium bromide; Cy
is cyclohexyl; DABCO is 1,4-diazabicyclo[2.2.2]octane; DCM is
dichloromethane or methylene chloride; DHP is dihydropyran; DIAD is
diisopropyl azodicarboxylate; DIEA or DIPEA is
N,N-diisopropylethylamine; DMAP is 4-(dimethylamino)pyridine; DME
is 1,2-dimethoxyethane; DMF is N,N-dimethylformamide; DMSO is
dimethylsulfoxide; equiv or eq. is equivalent; EtOAc is ethyl
acetate; EtOH is ethanol; Et.sub.2O is diethyl ether; EDCI is
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; ELS
is evaporative light scattering; equiv or eq is equivalent; h is
hours; HATU is
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate; HOBt is N-hydroxybenzotriazole; HCl is
hydrochloric acid; HPLC is high pressure liquid chromatography;
ISCO Companion is automated flash chromatography equipment with
fraction analysis by UV absorption available from Presearch; KOAc
or AcOK is potassium acetate; K.sub.2CO.sub.3 is potassium
carbonate; LiAlH.sub.4 or LAH is lithium aluminum hydride; LDA is
lithium diisopropylamide; LHMDS is lithium bis(trimethylsilyl)
amide; KHMDS is potassium bis(trimethylsilyl) amide; LiOH is
lithium hydroxide; m-CPBA is 3-chloroperoxybenzoic acid; MeCN or
ACN is methyl cyanide or cyanomethane or ethanenitrile or
acetonitrile which are all names for the same compound; MeOH is
methanol; MgSO.sub.4 is magnesium sulfate; mins or min is minutes;
Mp or MP is melting point; NaCNBH.sub.3 is sodium cyanoborohydride;
NaOH is sodium hydroxide; Na.sub.2SO.sub.4 is sodium sulfate; NBS
is N-bromosuccinimide; NH.sub.4Cl is ammonium chloride; NIS is
N-iodosuccinimide; N.sub.2 is nitrogen; NMM is N-methylmorpholine;
n-BuLi is n-butyllithium; overnight is O/N; PdCl.sub.2(pddf) is
1,1'-Bis(diphenylphosphino) ferrocene]dichloropalladium(II); Pd/C
is the catalyst known as palladium on carbon; Pd.sub.2(dba).sub.3
is an organometallic catalyst known as tris(dibenzylideneacetone)
dipalladium(0); Ra Ni or Raney Ni is Raney nickel; Ph is phenyl;
PMB is p-methoxybenzyl; PrOH is 1-propanol; iPrOH is 2-propanol;
POCl.sub.3 is phosphorus chloride oxide; PTSA is para-toluene
sulfonic acid; Pyr. or Pyr or Py as used herein means Pyridine; RT
or rt or r.t. is room temperature; sat. is saturated; Si-amine or
Si--NH.sub.2 is amino-functionalized silica, available from
SiliCycle; Si-pyr is pyridyl-functionalized silica, available from
SiliCycle; TEA or Et.sub.3N is triethylamine; TFA is
trifluoroacetic acid; Tf.sub.2O is trifluoromethanesulfonic
anhydride; THF is tetrahydrofuran; TFAA is trifluoroacetic
anhydride; THP is tetrahydropyranyl; TMSI is trimethylsilyl iodide;
H.sub.2O is water; diNO.sub.2PhSO.sub.2Cl is dinitrophenyl sulfonyl
chloride; 3-F-4-NO.sub.2-PhSO.sub.2Cl is
3-fluoro-4-nitrophenylsulfonyl chloride;
2-MeO-4-NO.sub.2-PhSO.sub.2Cl is 2-methoxy-4-nitrophenylsulfonyl
chloride; and (EtO).sub.2POCH.sub.2COOEt is a triethylester of
phosphonoacetic acid known as triethyl phosphonoacetate.
[0017] "Compound of the invention," as used herein refers to the
compounds discussed herein, salts (e.g. pharmaceutically acceptable
salts), prodrugs, solvates and hydrates of these compounds.
[0018] Where substituent groups are specified by their conventional
chemical formulae, written from left to right, they equally
encompass the chemically identical substituents, which would result
from writing the structure from right to left, e.g., --CH.sub.2O--
is intended to also recite --OCH.sub.2--.
[0019] The term "poly" as used herein means at least 2. For
example, a polyvalent metal ion is a metal ion having a valency of
at least 2.
[0020] "Moiety" refers to a radical of a molecule that is attached
to the remainder of the molecule.
[0021] The symbol , whether utilized as a bond or displayed
perpendicular to a bond, indicates the point at which the displayed
moiety is attached to the remainder of the molecule.
[0022] The term "alkyl," by itself or as part of another
substituent, means, unless otherwise stated, a straight or branched
chain, or cyclic hydrocarbon radical, or combination thereof, which
may be fully saturated, mono- or polyunsaturated and can include
di- and multivalent radicals, having the number of carbon atoms
designated (i.e. C.sub.1-C.sub.10 means one to ten carbons). In
some embodiments, the term "alkyl" means a straight or branched
chain, or combinations thereof, which may be fully saturated, mono-
or polyunsaturated and can include di- and multivalent radicals.
Examples of saturated hydrocarbon radicals include, but are not
limited to, groups such as methyl, ethyl, n-propyl, isopropyl,
n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl,
(cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for
example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An
unsaturated alkyl group is one having one or more double bonds or
triple bonds. Examples of unsaturated alkyl groups include, but are
not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl,
2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1-
and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
[0023] The term "alkenylene" by itself or as part of another
substituent means a divalent radical derived from an alkene.
[0024] The term "cycloalkylene" by itself or as part of another
substituent means a divalent radical derived from a
cycloalkane.
[0025] The term "heteroalkylene" by itself or as part of another
substituent means a divalent radical derived from an
heteroalkane.
[0026] The term "heterocycloalkylene" by itself or as part of
another substituent means a divalent radical derived from an
heterocycloalkane.
[0027] The term "arylene" by itself or as part of another
substituent means a divalent radical derived from an aryl.
[0028] The term "heteroarylene" by itself or as part of another
substituent means a divalent radical derived from heteroaryl.
[0029] The terms "alkoxy," "alkylamino" and "alkylthio" (or
thioalkoxy) are used in their conventional sense, and refer to
those alkyl groups attached to the remainder of the molecule via an
oxygen atom, an amino group, or a sulfur atom, respectively.
[0030] The term "heteroalkyl," by itself or in combination with
another term, means, unless otherwise stated, a stable straight or
branched chain, or cyclic hydrocarbon radical, or combinations
thereof, consisting of the stated number of carbon atoms and at
least one heteroatom. In some embodiments, the term "heteroalkyl,"
by itself or in combination with another term, means a stable
straight or branched chain, or combinations thereof, consisting of
the stated number of carbon atoms and at least one heteroatom. In
an exemplary embodiment, the heteroatoms can be selected from the
group consisting of O, N and S, and wherein the nitrogen and sulfur
atoms may optionally be oxidized and the nitrogen heteroatom may
optionally be quaternized. The heteroatom(s) O, N and S may be
placed at any interior position of the heteroalkyl group or at the
position at which the alkyl group is attached to the remainder of
the molecule. Examples include, but are not limited to,
--CH.sub.2--CH.sub.2--O--CH.sub.3,
--CH.sub.2--CH.sub.2--NH--CH.sub.3,
--CH.sub.2--CH.sub.2--N(CH.sub.3)--CH.sub.3,
--CH.sub.2--S--CH.sub.2--CH.sub.3, --CH.sub.2--CH.sub.2,
--S(O)--CH.sub.3, --CH.sub.2--CH.sub.2--S(O).sub.2--CH.sub.3,
--CH.dbd.CH--O--CH.sub.3, --CH.sub.2--CH.dbd.N--OCH.sub.3, and
--CH.dbd.CH--N(CH.sub.3)--CH.sub.3. Up to two heteroatoms may be
consecutive, such as, for example, --CH.sub.2--NH--OCH.sub.3.
Similarly, the term "heteroalkylene" by itself or as part of
another substituent means a divalent radical derived from
heteroalkyl, as exemplified, but not limited by,
--CH.sub.2--CH.sub.2--S--CH.sub.2--CH.sub.2-- and
--CH.sub.2--S--CH.sub.2--CH.sub.2--NH--CH.sub.2--. For
heteroalkylene groups, heteroatoms can also occupy either or both
of the chain termini (e.g., alkyleneoxy, alkylenedioxy,
alkyleneamino, alkylenediamino, and the like). Still further, for
alkylene and heteroalkylene linking groups, no orientation of the
linking group is implied by the direction in which the formula of
the linking group is written. For example, the formula
--C(O).sub.2R'-- represents both --C(O).sub.2R'-- and --R'
C(O).sub.2--.
[0031] The terms "cycloalkyl" and "heterocycloalkyl", by themselves
or in combination with other terms, represent, unless otherwise
stated, cyclic versions of "alkyl" and "heteroalkyl", respectively.
Additionally, for heterocycloalkyl, a heteroatom can occupy the
position at which the heterocycle is attached to the remainder of
the molecule. Examples of cycloalkyl include, but are not limited
to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl,
cycloheptyl, and the like. Examples of heterocycloalkyl include,
but are not limited to, 1-(1,2,5,6-tetrahydropyridyl),
1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl,
3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl,
tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl,
2-piperazinyl, and the like.
[0032] The terms "halo" or "halogen," by themselves or as part of
another substituent, mean, unless otherwise stated, a fluorine,
chlorine, bromine, or iodine atom. Additionally, terms such as
"haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl.
For example, the term "halo(C.sub.1-C.sub.4)alkyl" is mean to
include, but not be limited to, trifluoromethyl,
2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the
like.
[0033] The term "aryl" means, unless otherwise stated, a
polyunsaturated, aromatic, substituent that can be a single ring or
multiple rings (preferably from 1 or 2 or 3 rings), which are fused
together or linked covalently. The term "heteroaryl" refers to aryl
groups (or rings) that contain from one to four heteroatoms. In an
exemplary embodiment, the heteroatom is selected from B, N, O, and
S, wherein the nitrogen and sulfur atoms are optionally oxidized,
and the nitrogen atom(s) are optionally quaternized. A heteroaryl
group can be attached to the remainder of the molecule through a
heteroatom. Non-limiting examples of aryl and heteroaryl groups
include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl,
2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl,
pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl,
3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl,
5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl,
3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl,
purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl,
2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl.
Substituents for each of the above noted aryl and heteroaryl ring
systems are selected from the group of acceptable substituents
described below.
[0034] For brevity, the term "aryl" when used in combination with
other terms (e.g., aryloxy, arylthioxy, arylalkyl) includes both
aryl and heteroaryl rings as defined above. Thus, the term
"arylalkyl" is meant to include those radicals in which an aryl
group is attached to an alkyl group (e.g., benzyl, phenethyl,
pyridylmethyl and the like) including those alkyl groups in which a
carbon atom (e.g., a methylene group) has been replaced by, for
example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl,
3-(1-naphthyloxy)propyl, and the like).
[0035] Each of the above terms (e.g., "alkyl," "heteroalkyl,"
"aryl" and "heteroaryl") are meant to include both substituted and
unsubstituted forms of the indicated radical. Preferred
substituents for each type of radical are provided below.
[0036] Substituents for the alkyl and heteroalkyl radicals
(including those groups often referred to as alkylene, alkenyl,
heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) are
generically referred to as "alkyl group substituents," and they can
be one or more of a variety of groups selected from, but not
limited to: --R', --OR', .dbd.O, .dbd.NR', .dbd.N--OR', --NR'R'',
--SR', -halogen, --SiR'R''R''', --OC(O)R', --C(O)R', --CO.sub.2R',
--CONR'R'', --OC(O)NR'R'', --NR''C(O)R', --NR'--C(O)NR''R''',
--NR''C(O).sub.2R', --NR'''''-C(NR'R''R''').dbd.NR'''',
--NR''''--C(NR'R'').dbd.NR''', --S(O)R', --S(O).sub.2R',
--S(O).sub.2NR'R'', --NR''SO.sub.2R', --CN, --NO.sub.2, --N.sub.3,
--CH(Ph).sub.2, fluoro(C.sub.1-C.sub.4)alkoxy, and
fluoro(C.sub.1-C.sub.4)alkyl, in a number ranging from zero to
(2m'+1), where m' is the total number of carbon atoms in such
radical. R', R'', R''', R'''' and R''''' each preferably
independently refer to hydrogen, substituted or unsubstituted
heteroalkyl, substituted or unsubstituted aryl, e.g., aryl
substituted with 1-3 halogens, substituted or unsubstituted alkyl,
alkoxy or thioalkoxy groups, or arylalkyl groups. When a compound
of the invention includes more than one R group, for example, each
of the R groups is independently selected as are each R', R'',
R''', R'''' and R''''' groups when more than one of these groups is
present. When R' and R'' are attached to the same nitrogen atom,
they can be combined with the nitrogen atom to form a 5-, 6-, or
7-membered ring. For example, --NR'R'' is meant to include, but not
be limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above
discussion of substituents, one of skill in the art will understand
that the term "alkyl" is meant to include groups including carbon
atoms bound to groups other than hydrogen groups, such as haloalkyl
(e.g., --CF.sub.3 and --CH.sub.2CF.sub.3) and acyl (e.g.,
--C(O)CH.sub.3, --C(O)CF.sub.3, --C(O)CH.sub.2OCH.sub.3, and the
like).
[0037] Similar to the substituents described for the alkyl radical,
substituents for the aryl and heteroaryl groups are generically
referred to as "aryl group substituents." The substituents are
selected from, for example: --R', --OR', .dbd.O, .dbd.NR',
.dbd.N--OR', --NR'R'', --SR', -halogen, --SiR'R''R''', --OC(O)R',
--C(O)R', --CO.sub.2R', --CONR'R'', --OC(O)NR'R'', --NR''C(O)R',
--NR'--C(O)NR''R''', --NR''C(O).sub.2R',
--NR'''''-C(NR'R''R''').dbd.NR'''', --NR''''--C(NR'R'').dbd.NR''',
--S(O)R', --S(O).sub.2R', --S(O).sub.2NR'R'', --NR''SO.sub.2R',
--CN, --NO.sub.2, --N.sub.3, --CH(Ph).sub.2,
fluoro(C.sub.1-C.sub.4)alkoxy, and fluoro(C.sub.1-C.sub.4)alkyl, in
a number ranging from zero to the total number of open valences on
the aromatic ring system; and where R', R'', R''', R'''' and R'''''
are preferably independently selected from hydrogen, substituted or
unsubstituted alkyl, substituted or unsubstituted heteroalkyl,
substituted or unsubstituted aryl and substituted or unsubstituted
heteroaryl. When a compound of the invention includes more than one
R group, for example, each of the R groups is independently
selected as are each R', R'', R''', R'''' and R''''' groups when
more than one of these groups is present.
[0038] Two of the substituents on adjacent atoms of the aryl or
heteroaryl ring may optionally be replaced with a substituent of
the formula -T-C(O)--(CRR').sub.q--U--, wherein T and U are
independently --NR--, --O--, --CRR'-- or a single bond, and q is an
integer of from 0 to 3. Alternatively, two of the substituents on
adjacent atoms of the aryl or heteroaryl ring may optionally be
replaced with a substituent of the formula
-A-(CH.sub.2).sub.r--B--, wherein A and B are independently
--CRR'--, --O--, --NR--, --S--, --S(O)--, --S(O).sub.2--,
--S(O).sub.2NR'-- or a single bond, and r is an integer of from 1
to 4. One of the single bonds of the new ring so formed may
optionally be replaced with a double bond. Alternatively, two of
the substituents on adjacent atoms of the aryl or heteroaryl ring
may optionally be replaced with a substituent of the formula
(CRR').sub.s--X--(CR''R''').sub.d--, where s and d are
independently integers of from 0 to 3, and X is --O--, --NR'--,
--S--, --S(O)--, --S(O).sub.2--, or --S(O).sub.2NR'--. The
substituents R, R', R'' and R''' are preferably independently
selected from hydrogen or substituted or unsubstituted C.sub.1 or
C.sub.2 or C.sub.3 or C.sub.4 or C.sub.5 or C.sub.6 alkyl.
[0039] "Ring" as used herein, means a substituted or unsubstituted
cycloalkyl, substituted or unsubstituted heterocycloalkyl,
substituted or unsubstituted aryl, or substituted or unsubstituted
heteroaryl. A ring includes fused ring moieties. The number of
atoms in a ring is typically defined by the number of members in
the ring. For example, a "5- to 7-membered ring" means there are 5
or 6 or 7 atoms in the encircling arrangement. Unless otherwise
specified, the ring optionally includes a heteroatom. Thus, the
term "5- to 7-membered ring" includes, for example phenyl,
pyridinyl and piperidinyl. The term "5- to 7-membered
heterocycloalkyl ring", on the other hand, would include pyridinyl
and piperidinyl, but not phenyl. The term "ring" further includes a
ring system comprising more than one "ring", wherein each "ring" is
independently defined as above.
[0040] As used herein, the term "heteroatom" includes atoms other
than carbon (C) and hydrogen (H). Examples include oxygen (O),
nitrogen (N) sulfur (S), silicon (Si), germanium (Ge), aluminum
(Al).
[0041] The term "leaving group" means a functional group or atom
which can be displaced by another functional group or atom in a
substitution reaction, such as a nucleophilic substitution
reaction. By way of example, representative leaving groups include
triflate, chloro, bromo and iodo groups; sulfonic ester groups,
such as mesylate, tosylate, brosylate, nosylate and the like; and
acyloxy groups, such as acetoxy, trifluoroacetoxy and the like.
[0042] The symbol "R" is a general abbreviation that represents a
substituent group that is selected from substituted or
unsubstituted alkyl, substituted or unsubstituted heteroalkyl,
substituted or unsubstituted aryl, substituted or unsubstituted
heteroaryl, substituted or unsubstituted cycloalkyl and substituted
or unsubstituted heterocycloalkyl groups.
[0043] By "effective" amount of a drug, formulation, or permeant is
meant a sufficient amount of an active agent to provide the desired
local or systemic effect. A "pharmaceutically effective," or
"therapeutically effective" amount refers to the amount of drug
needed to effect the desired therapeutic result.
[0044] The term "pharmaceutically acceptable salt" is meant to
include a salt of a compound of the invention which is prepared
with relatively nontoxic acids or bases, depending on the
particular substituents found on the compounds described herein.
When compounds of the invention contain relatively acidic
functionalities, base addition salts can be obtained by contacting
the neutral form of such compounds with a sufficient amount of the
desired base, either neat or in a suitable inert solvent. Examples
of pharmaceutically acceptable base addition salts include sodium,
potassium, calcium, ammonium, organic amino (such as choline or
diethylamine or amino acids such as d-arginine, l-arginine,
d-lysine, l-lysine), or magnesium salt, or a similar salt. When
compounds of the invention contain relatively basic
functionalities, acid addition salts can be obtained by contacting
the neutral form of such compounds with a sufficient amount of the
desired acid, either neat or in a suitable inert solvent. Examples
of pharmaceutically acceptable acid addition salts include those
derived from inorganic acids like hydrochloric, hydrobromic,
nitric, carbonic, monohydrogencarbonic, phosphoric,
monohydrogenphosphoric, dihydrogenphosphoric, sulfuric,
monohydrogensulfuric, hydriodic, or phosphorous acids and the like,
as well as the salts derived from relatively nontoxic organic acids
like acetic, propionic, isobutyric, maleic, malonic, benzoic,
succinic, suberic, fumaric, lactic, mandelic, phthalic,
benzenesulfonic, p-tolylsulfonic, citric, tartaric,
methanesulfonic, and the like. Also included are salts of amino
acids such as arginate and the like, and salts of organic acids
like glucuronic or galactunoric acids and the like (see, for
example, Berge et al., "Pharmaceutical Salts", Journal of
Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds
of the invention contain both basic and acidic functionalities that
allow the compounds to be converted into either base or acid
addition salts.
[0045] The neutral forms of the compounds are preferably
regenerated by contacting the salt with a base or acid and
isolating the parent compounds in the conventional manner. The
parent form of the compound differs from the various salt forms in
certain physical properties, such as solubility in polar
solvents.
[0046] In addition to salt forms, the invention provides compounds
which are in a prodrug form. Prodrugs of the compounds described
herein readily undergo chemical changes under physiological
conditions to provide the compounds of the invention. Additionally,
prodrugs can be converted to the compounds of the invention by
chemical or biochemical methods in an ex vivo environment.
[0047] Certain compounds of the invention can exist in unsolvated
forms as well as solvated forms, including hydrated forms. In
general, the solvated forms are equivalent to unsolvated forms and
are encompassed within the scope of the invention. Certain
compounds of the invention may exist in multiple crystalline or
amorphous forms.
[0048] Certain compounds of the invention possess asymmetric carbon
atoms (optical centers) or double bonds; the racemates,
diastereomers, geometric isomers and individual isomers are
encompassed within the scope of the invention. The graphic
representations of racemic, ambiscalemic and scalemic or
enantiomerically pure compounds used herein are taken from Maehr,
J. Chem. Ed. 1985, 62: 114-120. Solid and broken wedges are used to
denote the absolute configuration of a stereocenter unless
otherwise noted. When the compounds described herein contain
olefinic double bonds or other centers of geometric asymmetry, and
unless specified otherwise, it is intended that the compounds
include both E and Z geometric isomers. Likewise, all tautomeric
forms are included.
[0049] Compounds of the invention can exist in particular geometric
or stereoisomeric forms. The invention contemplates all such
compounds, including cis- and trans-isomers, (-)- and
(+)-enantiomers, (R)- and (S)-enantiomers, diastereomers,
(D)-isomers, (L)-isomers, the racemic mixtures thereof, and other
mixtures thereof, such as enantiomerically or diastereomerically
enriched mixtures, as falling within the scope of the invention.
Additional asymmetric carbon atoms can be present in a substituent
such as an alkyl group. All such isomers, as well as mixtures
thereof, are intended to be included in this invention.
[0050] Optically active (R)- and (S)-isomers and d and l isomers
can be prepared using chiral synthons or chiral reagents, or
resolved using conventional techniques. If, for instance, a
particular enantiomer of a compound of the invention is desired, it
can be prepared by asymmetric synthesis, or by derivatization with
a chiral auxiliary, where the resulting diastereomeric mixture is
separated and the auxiliary group cleaved to provide the pure
desired enantiomers. Alternatively, where the molecule contains a
basic functional group, such as an amino group, or an acidic
functional group, such as a carboxyl group, diastereomeric salts
can be formed with an appropriate optically active acid or base,
followed by resolution of the diastereomers thus formed by
fractional crystallization or chromatographic means known in the
art, and subsequent recovery of the pure enantiomers. In addition,
separation of enantiomers and diastereomers is frequently
accomplished using chromatography employing chiral, stationary
phases, optionally in combination with chemical derivatization
(e.g., formation of carbamates from amines).
[0051] The compounds of the invention may also contain unnatural
proportions of atomic isotopes at one or more of the atoms that
constitute such compounds. For example, the compounds may be
radiolabeled with radioactive isotopes, such as for example tritium
(.sup.3H), iodine-125 (.sup.125I) or carbon-14 (.sup.14C). The
compounds may also be labeled with stable isotopes such as
deuterium. All isotopic variations of the compounds of the
invention, whether radioactive or not, are intended to be
encompassed within the scope of the invention.
[0052] The term "pharmaceutically acceptable carrier" or
"pharmaceutically acceptable vehicle" refers to any formulation or
carrier medium that provides the appropriate delivery of an
effective amount of an active agent as defined herein, does not
interfere with the effectiveness of the biological activity of the
active agent, and that is sufficiently non-toxic to the animal.
Representative carriers include water, oils, both vegetable and
mineral, cream bases, lotion bases, ointment bases and the like.
These bases include suspending agents, thickeners, penetration
enhancers, and the like. Their formulation is well known to those
in the pharmaceutical arts. Additional information concerning
carriers can be found in Remington: The Science and Practice of
Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005) which
is incorporated herein by reference.
[0053] The term "pharmaceutically acceptable additive" refers to
preservatives, antioxidants, fragrances, emulsifiers, dyes and
excipients known or used in the field of drug formulation and that
do not unduly interfere with the effectiveness of the biological
activity of the active agent, and that is sufficiently non-toxic to
the animal. Additives for topical formulations are well-known in
the art, and may be added to the topical composition, as long as
they are pharmaceutically acceptable and not deleterious to the
epithelial cells or their function. Further, they should not cause
deterioration in the stability of the composition. For example,
inert fillers, anti-irritants, tackifiers, excipients, fragrances,
opacifiers, antioxidants, gelling agents, stabilizers, surfactant,
emollients, coloring agents, preservatives, buffering agents, other
permeation enhancers, and other conventional components of topical
or transdermal delivery formulations as are known in the art.
[0054] The terms "enhancement," "penetration enhancement" or
"permeation enhancement" relate to an increase in the permeability
of the skin, nail, hair, claw or hoof to a drug, so as to increase
the rate at which the drug permeates through the skin, nail, hair,
claw or hoof. The enhanced permeation effected through the use of
such enhancers can be observed, for example, by measuring the rate
of diffusion of the drug through animal skin, nail, hair, claw or
hoof using a diffusion cell apparatus. A diffusion cell is
described by Merritt et al. Diffusion Apparatus for Skin
Penetration, J of Controlled Release, 1 (1984) pp. 161-162. The
term "permeation enhancer" or "penetration enhancer" intends an
agent or a mixture of agents, which, alone or in combination, act
to increase the permeability of the skin, nail, hair or hoof to a
drug.
[0055] The term "excipients" is conventionally known to mean
carriers, diluents and/or vehicles used in formulating drug
compositions effective for the desired use.
[0056] The terms "effective amount" or a "therapeutically effective
amount" of a drug or pharmacologically active agent refers to a
nontoxic but sufficient amount of the drug or agent to provide the
desired effect. In the oral dosage forms of the present disclosure,
an "effective amount" of one active of the combination is the
amount of that active that is effective to provide the desired
effect when used in combination with the other active of the
combination. The amount that is "effective" will vary from subject
to subject, depending on the age and general condition of the
individual, the particular active agent or agents, and the
appropriate "effective" amount in any individual case may be
determined by one of ordinary skill in the art using routine
experimentation.
[0057] The phrases "active ingredient", "therapeutic agent",
"active", or "active agent" mean a chemical entity which can be
effective in treating a targeted disorder, disease or
condition.
[0058] The phrase "pharmaceutically acceptable" means moieties or
compounds that are, within the scope of medical judgment, suitable
for use in humans without causing undesirable biological effects
such as undue toxicity, irritation, allergic response, and the
like, for example.
[0059] The phrase "unit", as used herein, refers to the number of
discrete objects to be administered which comprise the dosage form.
In some embodiments, the dosage form includes a compound of the
invention in one capsule. This is a single unit. In some
embodiments, the dosage form includes a compound of the invention
as part of a therapeutically effective dosage of a cream or
ointment. This is also a single unit. In some embodiments, the
dosage form includes a compound of the invention and another active
ingredient contained within one capsule, or as part of a
therapeutically effective dosage of a cream or ointment. This is a
single unit, whether or not the interior of the capsule includes
multiple discrete granules of the active ingredient. In some
embodiments, the dosage form includes a compound of the invention
in one capsule, and the active ingredient in a second capsule. This
is a two unit dosage form, such as two capsules or tablets, and so
such units are contained in a single package. Thus the term `unit`
refers to the object which is administered to the animal, not to
the interior components of the object.
[0060] "Biological medium," as used herein refers to both in vitro
and in vivo biological milieus. Exemplary in vitro "biological
media" include, but are not limited to, cell culture, tissue
culture, homogenates, plasma and blood. In vivo applications are
generally performed in mammals, preferably humans.
[0061] "Salt counterion", as used herein, refers to positively
charged ions that associate with a compound of the invention.
Examples of salt counterions include H.sup.+, H.sub.3O.sup.+,
ammonium, potassium, calcium, magnesium, organic amino (such as
choline or diethylamine or amino acids such as d-arginine,
l-arginine, d-lysine, l-lysine), and sodium.
II. Introduction
[0062] The invention provides tetrahydroisoquinolines, as well as
pharmaceutical formulations containing such compounds or
combinations of these compounds with at least one additional
therapeutically effective agent, can be used for, among other
things, treating viral infections.
III. The Compounds
III. a)
[0063] In one aspect, the invention provides a compound of the
invention. In an exemplary embodiment, the invention is a compound
described herein. In an exemplary embodiment, the invention is a
compound according to a formula described herein.
[0064] In an exemplary embodiment, the invention provides a
compound of the formula which is:
##STR00002##
in which [0065] R.sup.1 is H or unsubstituted alkoxy or phenyl
substituted alkoxy, [0066] R.sup.2 is H or CF.sub.3 or
unsubstituted alkoxy or phenyl substituted alkoxy, [0067] R.sup.3
is H or --C(O)OR.sup.4 or --C(O)R.sup.4 or --C(O)NR.sup.4R.sup.5,
wherein [0068] R.sup.4 and R.sup.5 are independently selected from
unsubstituted alkyl, unsubstituted phenyl, or unsubstituted
pyridinyl; [0069] A is substituted or unsubstituted phenyl or
substituted or unsubstituted pyrazole or substituted or
unsubstituted pyridinyl or substituted or unsubstituted thienyl or
substituted or unsubstituted pyrimidinyl or substituted or
unsubstituted pyrrole or substituted or unsubstituted thiazolyl
Also provided are hydrates, salts and solvates of these
compounds.
[0070] In an exemplary embodiment, A, R.sup.2 and R.sup.3 are as
described herein, and R.sup.1 is --CH.sub.3. In an exemplary
embodiment, A, R.sup.2 and R.sup.3 are as described herein, and
R.sup.1 is
##STR00003##
In an exemplary embodiment, A, R.sup.2 and R.sup.3 are as described
herein, and R.sup.1 is H.
[0071] In an exemplary embodiment, A, R.sup.1 and R.sup.3 are as
described herein, and R.sup.2 is --CH.sub.3. In an exemplary
embodiment, A, R.sup.1 and R.sup.3 are as described herein, and
R.sup.2 is
##STR00004##
In an exemplary embodiment, A, R.sup.1 and R.sup.3 are as described
herein, and R.sup.2 is H.
[0072] In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as
described herein, and R.sup.3 is H. In an exemplary embodiment, A,
R.sup.1 and R.sup.2 are as described herein, and R.sup.3 is
--C(O)OCH.sub.3. In an exemplary embodiment, A, R.sup.1 and R.sup.2
are as described herein, and R.sup.3 is --C(O)OC(CH.sub.3).sub.3.
In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is
##STR00005##
In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is
##STR00006##
In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is
##STR00007##
In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is
##STR00008##
In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is
##STR00009##
In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is
##STR00010##
In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is
##STR00011##
In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is
##STR00012##
In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is
##STR00013##
In an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is --C(O)NH.sub.2. In an exemplary embodiment,
A, R.sup.1 and R.sup.2 are as described herein, and R.sup.3 is
--C(O)NHC(CH.sub.3).sub.3. In an exemplary embodiment, A, R.sup.1
and R.sup.2 are as described herein, and R.sup.3 is
--(CH.sub.2).sub.nCH.sub.3, wherein n is an integer selected from 0
or 1 or 2 or 3 or 4 or 5. In an exemplary embodiment, A, R.sup.1
and R.sup.2 are as described herein, and R.sup.3 is
--(CH.sub.2).sub.nCH.sub.3, wherein n is an integer selected from 6
or 7 or 8 or 9 or 10. In an exemplary embodiment, A, R.sup.1 and
R.sup.2 are as described herein, and R.sup.3 is
--(CH.sub.2).sub.nCH.sub.3, wherein n is an integer selected from 2
or 3 or 4. In an exemplary embodiment, A, R.sup.1 and R.sup.2 are
as described herein, and R.sup.3 is --(CH.sub.2).sub.3CH.sub.3. In
an exemplary embodiment, A, R.sup.1 and R.sup.2 are as described
herein, and R.sup.3 is --CH.sub.3.
[0073] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00014##
wherein each R.sup.10, R.sup.11, and R.sup.12 is independently
selected from H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.11 and
R.sup.12 are as described herein, and R.sup.10 is --CH.sub.3. In an
exemplary embodiment, R.sup.11 and R.sup.12 are as described
herein, and R.sup.10 is --CH.sub.2CH.sub.3. In an exemplary
embodiment, R.sup.11 and R.sup.12 are as described herein, and
R.sup.10 is tert-butyl. In an exemplary embodiment, R.sup.11 and
R.sup.12 are as described herein, and R.sup.10 is --CF.sub.3. In an
exemplary embodiment, R.sup.11 and R.sup.12 are as described
herein, and R.sup.10 is --OBn. In an exemplary embodiment, R.sup.11
and R.sup.12 are as described herein, and R.sup.10 is halogen. In
an exemplary embodiment, R.sup.11 and R.sup.12 are as described
herein, and R.sup.10 is Cl. In an exemplary embodiment, R.sup.11
and R.sup.12 are as described herein, and R.sup.10 is H. In an
exemplary embodiment, R.sup.10 and R.sup.12 are as described
herein, and R.sup.11 is --OCH.sub.3. In an exemplary embodiment,
R.sup.10 and R.sup.12 are as described herein, and R.sup.11 is
--OBn. In an exemplary embodiment, R.sup.10 and R.sup.12 are as
described herein, and R.sup.11 is H. In an exemplary embodiment,
R.sup.10 and R.sup.11 are as described herein, and R.sup.12 is
--OCH.sub.3. In an exemplary embodiment, R.sup.10 and R.sup.11 are
as described herein, and R.sup.12 is --OBn. In an exemplary
embodiment, R.sup.10 and R.sup.11 are as described herein, and
R.sup.12 is halogen. In an exemplary embodiment, R.sup.10 and
R.sup.11 are as described herein, and R.sup.12 is H. In an
exemplary embodiment, R.sup.10 is unsubstituted C.sub.1-C.sub.6
alkoxy, R.sup.11 is H, and R.sup.12 is unsubstituted
C.sub.1-C.sub.6 alkoxy. In an exemplary embodiment, R.sup.10 is
methoxy, R.sup.11 is H, and R.sup.12 is unsubstituted
C.sub.1-C.sub.6 alkoxy. In an exemplary embodiment, R.sup.10 is
unsubstituted C.sub.1-C.sub.6 alkoxy, R.sup.11 is H, and R.sup.12
is methoxy. In an exemplary embodiment, R.sup.10 is methoxy,
R.sup.11 is H, and R.sup.12 is methoxy. In an exemplary embodiment,
R.sup.10 is H, R.sup.11 is unsubstituted C.sub.1-C.sub.6 alkoxy,
and R.sup.12 is unsubstituted C.sub.1-C.sub.6 alkoxy. In an
exemplary embodiment, R.sup.10 is H, R.sup.11 is methoxy, and
R.sup.12 is unsubstituted C.sub.1-C.sub.6 alkoxy. In an exemplary
embodiment, R.sup.10 is H, R.sup.11 is unsubstituted
C.sub.1-C.sub.6 alkoxy, and R.sup.12 is methoxy. In an exemplary
embodiment, R.sup.10 is H, R.sup.11 is methoxy, and R.sup.12 is
methoxy. In an exemplary embodiment, R.sup.10 is H, R.sup.11 is
unsubstituted C.sub.4-C.sub.6 alkoxy, and R.sup.12 is unsubstituted
C.sub.1-C.sub.6 alkoxy. In an exemplary embodiment, R.sup.10 is H,
R.sup.11 is methoxy, and R.sup.12 is unsubstituted C.sub.4-C.sub.6
alkoxy. In an exemplary embodiment, R.sup.10 is H, R.sup.11 is
butoxy, and R.sup.12 is methoxy. In an exemplary embodiment,
R.sup.10 is H, R.sup.11 is butoxy, and R.sup.12 is methoxy. In an
exemplary embodiment, R.sup.10 is H, R.sup.11 is halogen, and
R.sup.12 is unsubstituted C.sub.1-C.sub.6 alkoxy. In an exemplary
embodiment, R.sup.10 is H, R.sup.11 is unsubstituted
C.sub.1-C.sub.6 alkoxy, and R.sup.12 is halogen. In an exemplary
embodiment, R.sup.10 is H, R.sup.11 is methoxy, and R.sup.12 is
halogen. In an exemplary embodiment, R.sup.10 is H, R.sup.11 is
halogen, and R.sup.12 is methoxy. In an exemplary embodiment,
R.sup.10 is H, R.sup.11 is F, and R.sup.12 is unsubstituted
C.sub.1-C.sub.6 alkoxy. In an exemplary embodiment, R.sup.10 is H,
R.sup.11 is unsubstituted C.sub.1-C.sub.6 alkoxy, and R.sup.12 is
F. In an exemplary embodiment, R.sup.10 is unsubstituted
C.sub.1-C.sub.6 alkyl, R.sup.11 is unsubstituted C.sub.1-C.sub.6
alkoxy, and R.sup.12 is unsubstituted C.sub.1-C.sub.6 alkoxy. In an
exemplary embodiment, R.sup.10 is unsubstituted C.sub.1-C.sub.3
alkyl, R.sup.11 is unsubstituted C.sub.1-C.sub.3 alkoxy, and
R.sup.12 is unsubstituted C.sub.1-C.sub.3 alkoxy. In an exemplary
embodiment, R.sup.10 is methyl, R.sup.11 is unsubstituted
C.sub.1-C.sub.6 alkoxy, and R.sup.12 is unsubstituted
C.sub.1-C.sub.6 alkoxy. In an exemplary embodiment, R.sup.10 is
unsubstituted C.sub.1-C.sub.6 alkyl, R.sup.11 is unsubstituted
C.sub.3-C.sub.6 alkoxy, and R.sup.12 is unsubstituted
C.sub.1-C.sub.3 alkoxy.
[0074] In an exemplary embodiment, R.sup.10 is unsubstituted
C.sub.1-C.sub.6 alkyl, R.sup.11 is butoxy, and R.sup.12 is
unsubstituted C.sub.1-C.sub.3 alkoxy. In an exemplary embodiment,
R.sup.10 is unsubstituted C.sub.1-C.sub.6 alkyl, R.sup.11 is
unsubstituted C.sub.1-C.sub.6 alkoxy, and R.sup.12 is methoxy. In
an exemplary embodiment, R.sup.10 is methyl, R.sup.11 is
unsubstituted C.sub.1-C.sub.6 alkoxy, and R.sup.12 is methoxy. In
an exemplary embodiment, R.sup.10 is methyl, R.sup.11 is butoxy,
and R.sup.12 is methoxy. In an exemplary embodiment, R.sup.10 is H,
R.sup.11 is unsubstituted C.sub.1-C.sub.6 alkoxy, and R.sup.12 is
unsubstituted C.sub.1-C.sub.6 alkoxy. In an exemplary embodiment,
R.sup.10 is H, R.sup.11 is unsubstituted C.sub.1-C.sub.3 alkoxy,
and R.sup.12 is unsubstituted C.sub.1-C.sub.3 alkoxy. In an
exemplary embodiment, R.sup.10 is H, R.sup.11 is unsubstituted
C.sub.1-C.sub.3 alkoxy, and R.sup.12 is methoxy. In an exemplary
embodiment, R.sup.10 is H, R.sup.11 is methoxy, and R.sup.12 is
unsubstituted C.sub.1-C.sub.3 alkoxy. In an exemplary embodiment,
R.sup.10 is H, R.sup.11 is methoxy, and R.sup.12 is methoxy.
[0075] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00015##
wherein R.sup.10 is NR.sup.20R.sup.21, wherein R.sup.20 and
R.sup.21 are each independently selected from H or unsubstituted
alkyl, and wherein R.sup.11 and R.sup.12 are each independently
selected from H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.10 is
N(CH.sub.3).sub.2, wherein R.sup.20 and R.sup.21 are each
independently selected from H or unsubstituted alkyl, and wherein
R.sup.11 and R.sup.12 are each independently selected from H or
halogen or unsubstituted alkyl or halogen-substituted alkyl or
unsubstituted alkoxy or phenyl-substituted alkoxy. In an exemplary
embodiment, R.sup.10 is NH.sub.2, wherein R.sup.20 and R.sup.21 are
each independently selected from H or unsubstituted alkyl, and
wherein R.sup.11 and R.sup.12 are each independently selected from
H or halogen or unsubstituted alkyl or halogen-substituted alkyl or
unsubstituted alkoxy or phenyl-substituted alkoxy.
[0076] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00016##
wherein each R.sup.11, R.sup.12, and R.sup.13 is independently
selected from H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy, wherein at least one of said R.sup.11 or
R.sup.12 or R.sup.13 is unsubstituted alkoxy. In an exemplary
embodiment, R.sup.11 and R.sup.12 are as described herein, and
R.sup.13 is --CH.sub.3. In an exemplary embodiment, R.sup.11 and
R.sup.12 are as described herein, and R.sup.13 is
--CH.sub.2CH.sub.3. In an exemplary embodiment, R.sup.11 and
R.sup.12 are as described herein, and R.sup.13 is --OCH.sub.3. In
an exemplary embodiment, R.sup.11 and R.sup.12 are as described
herein, and R.sup.13 is --OCH.sub.2CH.sub.3. In an exemplary
embodiment, R.sup.11 is unsubstituted C.sub.1-C.sub.6 alkoxy,
R.sup.12 is unsubstituted C.sub.1-C.sub.6 alkoxy, and R.sup.13 is
unsubstituted C.sub.1-C.sub.6 alkoxy. In an exemplary embodiment,
R.sup.11 is methoxy, R.sup.12 is unsubstituted C.sub.1-C.sub.6
alkoxy, and R.sup.13 is unsubstituted C.sub.1-C.sub.6 alkoxy. In an
exemplary embodiment, R.sup.11 is unsubstituted C.sub.1-C.sub.3
alkoxy, R.sup.12 is methoxy, and R.sup.13 is unsubstituted
C.sub.1-C.sub.3 alkoxy. In an exemplary embodiment, R.sup.11 is
unsubstituted C.sub.1-C.sub.3 alkoxy, R.sup.12 is unsubstituted
C.sub.1-C.sub.3 alkoxy, and R.sup.13 is unsubstituted
C.sub.1-C.sub.3 alkoxy.
[0077] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00017##
wherein R.sup.12 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is
##STR00018##
wherein R.sup.12 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is
##STR00019##
wherein R.sup.12 is C.sub.1-C.sub.6 alkoxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00020##
wherein R.sup.12 is C.sub.1-C.sub.6 alkoxy.
[0078] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00021##
wherein R.sup.12 is unsubstituted C.sub.1-C.sub.6 alkoxy. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00022##
wherein R.sup.12 is unsubstituted C.sub.1-C.sub.3 alkoxy. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00023##
wherein R.sup.12 is methoxy.
[0079] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00024##
wherein R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy, R.sup.11 is unsubstituted
C.sub.1-C.sub.6 alkoxy and R.sup.12 is H or halogen or
unsubstituted alkyl or halogen-substituted alkyl or unsubstituted
alkoxy or phenyl-substituted alkoxy. In an exemplary embodiment,
R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy, R.sup.11 is unsubstituted ethoxy or
propoxy or isopropoxy or butoxy or isobutoxy or t-butoxy and
R.sup.12 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.10 is
H or halogen or unsubstituted alkyl or halogen-substituted alkyl or
unsubstituted alkoxy or phenyl-substituted alkoxy, R.sup.11 is
unsubstituted methoxy and R.sup.12 is H or halogen or unsubstituted
alkyl or halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.10 is
C.sub.1-C.sub.6 unsubstituted alkoxy, R.sup.11 is C.sub.1-C.sub.6
unsubstituted alkoxy and R.sup.12 is C.sub.1-C.sub.6 unsubstituted
alkoxy. In an exemplary embodiment, R.sup.10 is C.sub.1-C.sub.3
unsubstituted alkoxy, R.sup.11 is C.sub.1-C.sub.3 unsubstituted
alkoxy and R.sup.12 is C.sub.1-C.sub.3 unsubstituted alkoxy. In an
exemplary embodiment, R.sup.10 is H or halogen or unsubstituted
alkyl or halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy, R.sup.11 is methoxy and R.sup.12 is
methoxy. In an exemplary embodiment, R.sup.10 is C.sub.1-C.sub.6
unsubstituted alkoxy, R.sup.11 is methoxy and R.sup.12 is methoxy.
In an exemplary embodiment, R.sup.10 is C.sub.1-C.sub.3
unsubstituted alkoxy, R.sup.11 is methoxy and R.sup.12 is
methoxy.
[0080] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00025##
wherein R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy, R.sup.12 is unsubstituted
C.sub.1-C.sub.6 alkoxy and R.sup.11 is H or halogen or
unsubstituted alkyl or halogen-substituted alkyl or unsubstituted
alkoxy or phenyl-substituted alkoxy. In an exemplary embodiment,
R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy, R.sup.12 is unsubstituted ethoxy or
propoxy or isopropoxy or butoxy or isobutoxy or t-butoxy and
R.sup.11 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.10 is
H or halogen or unsubstituted alkyl or halogen-substituted alkyl or
unsubstituted alkoxy or phenyl-substituted alkoxy, R.sup.12 is
unsubstituted methoxy and R.sup.11 is H or halogen or unsubstituted
alkyl or halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy.
[0081] In an exemplary embodiment, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00026##
wherein R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy.
[0082] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00027##
wherein R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy.
[0083] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00028##
wherein R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is
##STR00029##
wherein R.sup.10 is unsubstituted C.sub.1-C.sub.6 alkyl or
unsubstituted C.sub.1-C.sub.6 alkoxy. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00030##
wherein R.sup.10 is unsubstituted C.sub.1-C.sub.3 alkyl or
unsubstituted C.sub.1-C.sub.3 alkoxy. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00031##
wherein R.sup.10 is methyl or methoxy.
[0084] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00032##
wherein R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy.
[0085] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00033##
wherein R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is
##STR00034##
wherein R.sup.10 is halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is
##STR00035##
wherein R.sup.10 is C.sub.1-C.sub.3 unsubstituted alkyl.
[0086] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00036##
wherein R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy.
[0087] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00037##
wherein R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is
##STR00038##
wherein R.sup.10 is unsubstituted C.sub.1-C.sub.6 alkyl or
unsubstituted C.sub.1-C.sub.6 alkoxy. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00039##
wherein R.sup.10 is unsubstituted C.sub.1-C.sub.3 alkyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00040##
wherein R.sup.10 is methyl or methoxy. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00041##
wherein R.sup.10 is unsubstituted C.sub.1-C.sub.3 alkoxy.
[0088] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00042##
wherein R.sup.10 is H or halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is
##STR00043##
wherein R.sup.10 is halogen or unsubstituted alkyl or
halogen-substituted alkyl or unsubstituted alkoxy or
phenyl-substituted alkoxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is
##STR00044##
wherein R.sup.10 is C.sub.1-C.sub.3 unsubstituted alkyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00045##
wherein R.sup.10 is unsubstituted C.sub.1-C.sub.6 alkyl or
unsubstituted C.sub.1-C.sub.6 alkoxy. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00046##
wherein R.sup.10 is unsubstituted C.sub.1-C.sub.3 alkyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00047##
wherein R.sup.10 is methyl or methoxy. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00048##
wherein R.sup.10 is unsubstituted C.sub.1-C.sub.3 alkoxy. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00049##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00050##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00051##
[0089] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00052##
wherein R.sup.12 is substituted or unsubstituted aryl or
substituted or unsubstituted heteroaryl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00053##
wherein R.sup.12 is substituted or unsubstituted aryl or
substituted or unsubstituted heteroaryl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00054##
wherein R.sup.12 is a substituted or unsubstituted
nitrogen-containing 4-8 membered ring. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00055##
wherein R.sup.12 is a substituted or unsubstituted
nitrogen-containing 5-6 membered ring. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00056##
wherein R.sup.12 is substituted or unsubstituted pyridinyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00057##
wherein R.sup.12 is substituted or unsubstituted pyridin-4-yl. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00058##
wherein R.sup.12 is substituted or unsubstituted pyridin-3-yl. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00059##
wherein R.sup.12 is substituted or unsubstituted pyridin-2-yl. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00060##
wherein R.sup.12 is unsubstituted pyridinyl.
[0090] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00061##
wherein R.sup.12 is substituted or unsubstituted pyrimidinyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00062##
wherein R.sup.12 is substituted or unsubstituted pyrimidin-5-yl. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00063##
wherein R.sup.12 is substituted or unsubstituted pyrimidin-2-yl. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00064##
wherein R.sup.12 is substituted or unsubstituted pyrimidin-4-yl. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00065##
wherein R.sup.12 is unsubstituted pyrimidin-5-yl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00066##
wherein R.sup.12 is unsubstituted pyrimidin-2-yl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00067##
wherein R.sup.12 is unsubstituted pyrimidin-4-yl.
[0091] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00068##
wherein R.sup.12 is substituted or unsubstituted imidazolyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00069##
wherein R.sup.12 is substituted or unsubstituted imidazol-1-yl.
[0092] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00070##
wherein R.sup.12 is substituted or unsubstituted indolyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00071##
wherein R.sup.12 is indolyl substituted with --C(O)OR.sup.22,
wherein R.sup.22 is C.sub.1-C.sub.6 alkyl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00072##
wherein R.sup.12 is indolyl substituted with --C(O)OR.sup.22,
wherein R.sup.22 is t-butyl. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is
##STR00073##
wherein R.sup.12 is indolyl substituted with C.sub.1-C.sub.6 alkyl.
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00074##
wherein R.sup.12 is indolyl substituted with methyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00075##
wherein R.sup.12 is substituted or unsubstituted indol-3-yl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00076##
wherein R.sup.12 is indol-3-yl substituted with C.sub.1-C.sub.6
alkyl. In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00077##
wherein R.sup.12 is indol-3-yl substituted with methyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00078##
wherein R.sup.12 is indol-3-yl substituted with --C(O)OR.sup.22,
wherein R.sup.22 is C.sub.1-C.sub.6 alkyl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00079##
wherein R.sup.12 is indol-3-yl substituted with --C(O)OR.sup.22,
wherein R.sup.22 is t-butyl.
[0093] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00080##
wherein R.sup.12 is substituted or unsubstituted pyrrolopyridinyl.
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00081##
wherein R.sup.12 is pyrrolopyridinyl substituted with
C.sub.1-C.sub.6 alkyl. In an exemplary embodiment, R.sup.1, R.sup.2
and R.sup.3 are as described herein, and A is
##STR00082##
wherein R.sup.12 is pyrrolopyridinyl substituted methyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00083##
wherein R.sup.12 is pyrrolopyridinyl substituted with
--C(O)OR.sup.22, wherein R.sup.22 is C.sub.1-C.sub.6 alkyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00084##
wherein R.sup.12 is pyrrolopyridinyl substituted with
--C(O)OR.sup.22, wherein R.sup.22 is t-butyl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00085##
wherein R.sup.12 is substituted or unsubstituted
pyrrolopyridin-3-yl. In an exemplary embodiment, R.sup.1, R.sup.2
and R.sup.3 are as described herein, and A is
##STR00086##
wherein R.sup.12 is pyrrolopyridin-3-yl substituted with
C.sub.1-C.sub.6 alkyl. In an exemplary embodiment, R.sup.1, R.sup.2
and R.sup.3 are as described herein, and A is
##STR00087##
wherein R.sup.12 is pyrrolopyridin-3-yl substituted with methyl. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00088##
wherein R.sup.12 is pyrrolopyridin-3-yl substituted with
--C(O)OR.sup.22, wherein R.sup.22 is C.sub.1-C.sub.6 alkyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00089##
wherein R.sup.12 is pyrrolopyridin-3-yl substituted with
--C(O)OR.sup.22, wherein R.sup.22 is t-butyl.
[0094] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00090##
wherein R.sup.12 is substituted or unsubstituted triazolyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00091##
wherein R.sup.12 is triazol-1-yl.
[0095] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00092##
wherein R.sup.11 is substituted or unsubstituted aryl or
substituted or unsubstituted heteroaryl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00093##
wherein R.sup.11 is substituted or unsubstituted aryl or
substituted or unsubstituted heteroaryl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00094##
wherein R.sup.11 is a substituted or unsubstituted
nitrogen-containing 4-8 membered ring. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00095##
wherein R.sup.11 is a substituted or unsubstituted
nitrogen-containing 5-6 membered ring. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00096##
wherein R.sup.11 is substituted or unsubstituted pyridinyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is
##STR00097##
wherein R.sup.11 is substituted or unsubstituted pyridin-4-yl. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00098##
wherein R.sup.11 is substituted or unsubstituted pyridin-3-yl. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00099##
wherein R.sup.11 is substituted or unsubstituted pyridin-2-yl. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00100##
wherein R.sup.11 is unsubstituted pyridinyl.
[0096] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is
##STR00101##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00102##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00103##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00104##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00105##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00106##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00107##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00108##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00109##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00110##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00111##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00112##
[0097] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is unsubstituted pyrazolyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is substituted pyrazolyl. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
pyrazolyl substituted with C.sub.1-C.sub.3 alkyl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is pyrazolyl substituted with methyl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00113##
[0098] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is unsubstituted pyridinyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is unsubstituted pyridin-3-yl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is unsubstituted pyridin-4-yl. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
substituted pyridinyl. In an exemplary embodiment, R.sup.1, R.sup.2
and R.sup.3 are as described herein, and A is substituted
pyridin-4-yl. In an exemplary embodiment, R.sup.1, R.sup.2 and
R.sup.3 are as described herein, and A is substituted pyridin-3-yl.
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is pyridinyl substituted with
C.sub.1-C.sub.3 alkyloxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is pyridinyl
substituted with two C.sub.1-C.sub.3 alkyloxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is pyridinyl substituted with methoxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is pyridin-3-yl substituted with methoxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is pyridin-4-yl substituted with methoxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is pyridin-3-yl substituted with two methoxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is pyridin-4-yl substituted with two methoxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00114##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00115##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00116##
[0099] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is pyridinyl substituted with
NR.sup.10R.sup.11, wherein R.sup.10 and R.sup.11 are each
independently selected from H or unsubstituted C.sub.1-C.sub.3
alkyl. In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is pyridinyl substituted with two
NR.sup.10R.sup.11, wherein R.sup.10 and R.sup.11 are each
independently selected from H or unsubstituted C.sub.1-C.sub.3
alkyl. In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is pyridinyl substituted with
N(CH.sub.3).sub.2. In an exemplary embodiment, R.sup.1, R.sup.2 and
R.sup.3 are as described herein, and A is pyridinyl substituted
with NH.sub.2. In an exemplary embodiment, R.sup.1, R.sup.2 and
R.sup.3 are as described herein, and A is pyridin-3-yl substituted
with N(CH.sub.3).sub.2. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is pyridin-4-yl
substituted with N(CH.sub.3).sub.2. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
pyridin-3-yl substituted with NH.sub.2. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
pyridin-4-yl substituted with NH.sub.2. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
##STR00117##
[0100] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is unsubstituted pyrimidinyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is unsubstituted pyrimidin-5-yl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is unsubstituted pyrimidin-4-yl. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
substituted pyrimidinyl. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is substituted
pyrimidin-5-yl. In an exemplary embodiment, R.sup.1, R.sup.2 and
R.sup.3 are as described herein, and A is substituted
pyrimidin-4-yl. In an exemplary embodiment, R.sup.1, R.sup.2 and
R.sup.3 are as described herein, and A is pyrimidinyl substituted
with C.sub.1-C.sub.3 alkyloxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is pyrimidinyl
substituted with two C.sub.1-C.sub.3 alkyloxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is pyrimidinyl substituted with methoxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is pyrimidin-5-yl substituted with methoxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is pyrimidin-4-yl substituted with methoxy. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is
##STR00118##
In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is pyrimidinyl substituted with substituted
phenyl. In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3
are as described herein, and A is pyrimidinyl substituted with
unsubstituted phenyl. In an exemplary embodiment, R.sup.1, R.sup.2
and R.sup.3 are as described herein, and A is pyrimidinyl
substituted with unsubstituted phenyl substituted with
C.sub.1-C.sub.3 alkyloxy. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is pyrimidinyl
substituted with unsubstituted phenyl substituted with methoxy. In
an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as
described herein, and A is
##STR00119##
[0101] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is unsubstituted thienyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is unsubstituted thien-2-yl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is unsubstituted thien-3-yl. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
thienyl substituted with C.sub.1-C.sub.3 alkyl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is thien-2-yl substituted with C.sub.1-C.sub.3 alkyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is thien-3-yl substituted with C.sub.1-C.sub.3
alkyl.
[0102] In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is unsubstituted thiazolyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is unsubstituted thiazol-4-yl. In an exemplary
embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described herein,
and A is unsubstituted thiazol-5-yl. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
unsubstituted thiazol-2-yl. In an exemplary embodiment, R.sup.1,
R.sup.2 and R.sup.3 are as described herein, and A is thiazolyl
substituted with C.sub.1-C.sub.3 alkyl. In an exemplary embodiment,
R.sup.1, R.sup.2 and R.sup.3 are as described herein, and A is
thiazol-4-yl substituted with C.sub.1-C.sub.3 alkyl. In an
exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are as described
herein, and A is thiazol-5-yl substituted with C.sub.1-C.sub.3
alkyl. In an exemplary embodiment, R.sup.1, R.sup.2 and R.sup.3 are
as described herein, and A is thiazol-2-yl substituted with
C.sub.1-C.sub.3 alkyl.
[0103] In an exemplary embodiment, the compound has the formula
which is:
##STR00120##
wherein R.sup.2, R.sup.3 and A are as described herein, or a
hydrate, solvate, or salt thereof.
[0104] In an exemplary embodiment, the compound has the formula
which is:
##STR00121##
wherein R.sup.1, R.sup.3 and A are as described herein, or a
hydrate, solvate, or salt thereof.
[0105] In an exemplary embodiment, the compound has the formula
which is:
##STR00122##
wherein R.sup.1, R.sup.2 and A are as described herein, or a
hydrate, solvate, or salt thereof.
[0106] In an exemplary embodiment, the compound has the formula
which is:
##STR00123##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.10, R.sup.11, and R.sup.12
are as described herein, or a hydrate, solvate, or salt
thereof.
[0107] In an exemplary embodiment, the compound has the formula
which is:
##STR00124##
wherein R.sup.3 and A are as described herein, or a hydrate,
solvate, or salt thereof.
[0108] In an exemplary embodiment, the compound has the formula
which is:
##STR00125##
wherein R.sup.2 and A are as described herein, or a hydrate,
solvate, or salt thereof.
[0109] In an exemplary embodiment, the compound has the formula
which is:
##STR00126##
wherein R.sup.1 and A are as described herein, or a hydrate,
solvate, or salt thereof.
[0110] In an exemplary embodiment, the compound has the formula
which is:
##STR00127##
wherein A is as described herein, or a hydrate, solvate, or salt
thereof.
[0111] In an exemplary embodiment, the compound has the formula
which is:
##STR00128##
or a hydrate, solvate, or salt thereof.
[0112] In an exemplary embodiment, the compound has the formula
which is:
##STR00129##
or a hydrate, solvate, or salt thereof.
[0113] In an exemplary embodiment, the compound has the formula
which is:
##STR00130##
or a hydrate, solvate, or salt thereof.
[0114] In an exemplary embodiment, the invention provides a
compound described herein, or a salt, hydrate or solvate thereof,
or a combination thereof. In an exemplary embodiment, the invention
provides a compound described in a FIGURE provided herein, or a
salt, hydrate or solvate thereof, or a combination thereof. In an
exemplary embodiment, the invention provides a compound described
herein, or a salt, hydrate or solvate thereof. In an exemplary
embodiment, the invention provides a compound described herein, or
a salt thereof. In an exemplary embodiment, the salt is a
pharmaceutically acceptable salt. In an exemplary embodiment, the
invention provides a compound described herein, or a hydrate
thereof. In an exemplary embodiment, the invention provides a
compound described herein, or a solvate thereof. In an exemplary
embodiment, the invention provides a compound described herein, or
a prodrug thereof. In an exemplary embodiment, the invention
provides a salt of a compound described herein. In an exemplary
embodiment, the invention provides a pharmaceutically acceptable
salt of a compound described herein. In an exemplary embodiment,
the invention provides a hydrate of a compound described herein. In
an exemplary embodiment, the invention provides a solvate of a
compound described herein. In an exemplary embodiment, the
invention provides a prodrug of a compound described herein.
[0115] In an exemplary embodiment, alkyl is linear alkyl. In
another exemplary embodiment, alkyl is branched alkyl.
[0116] In an exemplary embodiment, heteroalkyl is linear
heteroalkyl. In another exemplary embodiment, heteroalkyl is
branched heteroalkyl.
III.b) Preparation of Compounds
[0117] Compounds of use in the invention can be prepared using
commercially available starting materials, known intermediates, or
by using the synthetic methods described herein, or published in
references described and incorporated by reference herein.
A General Procedure to Make Compounds of the Invention
General Procedure for the Synthesis of Substituted Phenethyl
Amines.sup.a
##STR00131##
[0119] A solution of the Benzaldehyde 1 (0.1 mol), Nitromethane (50
ml, 0.93 mmol) and Ammonium acetate (0.26 mol) in Acetic acid (200
ml) was refluxed for 1 h. Upon cooling the product crystallized out
of solution. The crystals were filtered out and washed with a small
amount of ether to give a bright yellow nitrostyrene.
[0120] To a stirred solution of Lithium aluminum hydride (0.21 mol)
in Tetrahydrofuran (270 ml) was added dropwise a solution of the
above nitrostyrene (0.11 mol) in Tetrahydrofuran (200 ml). Upon
completion the reaction mixture was refluxed with stirring for 16
h, cooled to room temperature and the excess hydride decomposed by
the addition of aq. sat. Na.sub.2SO.sub.4. The mixture was filtered
and the filtrate rotary evaporated to an amber-brown oil (the title
compound) 2 which was used without further purification.
General Procedure for the Synthesis of Substituted Cinammic
Acids.sup.b
##STR00132##
[0122] A mixture of the Benzaldehyde 3 (30 mmol), Malonic acid (60
mmol), Pyridine (20 mL) and Piperidine (5 mmol) was stirred at
80.degree. C. for 1 h followed by refluxing at 110-115.degree. C.
for an additional 3 h. The cooled reaction mixture was poured into
water (250 mL) and acidified with conc. HCl. The resulting
precipitate was filtered off and washed several times with water.
It was redissolved in 2M NaOH, diluted with water, acidified with
conc. HCl. The solid precipitate was filtered washed several times
with water, dried under high vacuum over P.sub.2O.sub.5 to afford
the titled compound 4.
Alternate Synthesis of Cinnamic Acids
##STR00133##
[0124] The ethyl-2-(diethoxyphosphino)acetate was dissolved in THF
and cooled to 0.degree. C. To this mixture was added 1 equivalent
of NaH (60% in mineral oil) in portions. The mixture immediately
evolved of H.sub.2 gas. After the addition was complete, the
mixture was stirred at room temperature for 1 hour. To this mixture
at 0.degree. C. was added one equivalent of the benzaldehyde. The
mixture was stirred at 0.degree. C. for 1 hour, then allowed to
warm up to room temperature overnight. The mixture was pored over
ice water and extracted with EtOAc. The combined organic layers
were dried over MgSO.sub.4, filtered and evaporated to give a
residue, which was purified by flash chromatography. The correct
product was confirmed by LC-MS.
[0125] The resulting cinnamoyl ester was dissolved in a 1/1 mixture
of EtOH and 1M KOH solution and heated at 75.degree. C. overnight.
When all of the starting material was consumed, the reaction was
allowed to cool to room temperature and the EtOH was removed by
evaporation. The resulting residue was acidified with 2N
H.sub.3PO.sub.4 and the product was either filtered off to dry
under vacuum or extracted with EtOAc, followed by drying over
MgSO.sub.4, filtration and evaporation. The correct product was
confirmed by LC-MS.
General Procedure for the Synthesis of Substituted
Cinnamides.sup.c
##STR00134##
[0127] To a stirred mixture of the substituted Phenethylamine 2
(0.48 mmol), substituted Cinnamic acid 4 (0.72 mmol), DIEA [420 uL
(2.4 mmol)] & 10 ml of DMF was added HATU (1 mmol). The
reaction was stirred at rt for 1 h and then diluted with 20 ml of
EtOAc and washed 2.times. with sat NaCl. The EtOAc layer was dried
(Na.sub.2SO.sub.4) and the solvent removed yielding the title
compound 6.
General Procedure for the Cyclization and Reduction of the
Substituted Cinnamides: Synthesis of Substituted
Tetrahydroisoquinolines.sup.d
##STR00135##
[0129] To the substituted Cinnamide 6 (0.563 mmol) in ACN (13 ml)
was added, under reflux, POCl.sub.3 (3.9 mmol). The reaction was
stirred at reflux for 30 min and then rotary evaporated to dryness.
The residue was taken up into 10 ml of chloroform and was then
treated with 20 ml of 2N KOH and 50 mL of Et.sub.2O. This mixture
was rapidly stirred for 30 min at room temperature and the upper
organic layer removed, washed with water, dried (Na.sub.2SO.sub.4)
and the solvent removed. The resulting dark oil (Substituted
Dihydroisoquinoline) was then dissolved into 8 ml of dry EtOH and
then treated with NaBH.sub.4 (0.395 mmol). The mixture was stirred
for 1 h at room temperature and the resulting solid was carefully
filtered off and dried. The solid was triturated with 50/50
ACN/water, filtered and vacuum dried yielding the title compound
7.
General Synthesis of Dihydroisoquinolines.sup.e--
##STR00136##
[0131] The phenethylamine 2 was combined with ethyl formate (20 mL)
and heated at reflux overnight. The reaction was checked by TLC and
LC-MS for the consumption of starting material. The reaction was
allowed to cool to room temperature and the organic solvents were
evaporated to five a residue, which solidified on standing at room
temperature. The correct product 8 was confirmed by LC-MS and was
used in the next step without purification.
[0132] The formamide was cyclized to the dihydroisoquinoline 9 by
either of two methods: [0133] a. The phenethylformamide was
combined with polyphosphoric acid (PPA) and heated at 160.degree.
C. for 12 hours. The mixture was allowed to cool to room
temperature and poured over ice. The mixture was made basic with
NaOH solution and extracted with EtOAc. The combined organic layers
were dried over MgSO.sub.4, filtered and evaporated to give a
residue. The residue was purified by flash chromatography. The
correct product 9 was confirmed by LC-MS. [0134] b. To a solution
of the phenethylformamide in CH.sub.2Cl.sub.2 cooled to 0.degree.
C. was added 1 equivalent of POCl.sub.3 dropwise. After the
addition, the reaction was stirred from 2 hrs to 18 hrs. The
reaction mixture was evaporated to dryness and the pH was adjusted
to 10 with NH.sub.4OH solution. The mixture was extracted with
EtOAc and the combined organic layers were dried over MgSO.sub.4,
filtered and evaporated. The residue was either recrystallized or
purified by flash chromatography. The correct product 9 was
confirmed by LC-MS.
Alternate Synthesis of Dihydoisoquinolines.sup.f
##STR00137##
[0136] Acetic acid/trifluoroacetic acid (4/1) was added to a
mixture of the phenylethylamine 2 and 2 equivalents of
hexamethylenetetramine. The resulting solution was heated at reflux
for 8 hours. The reaction was allowed to cool to room temperature
and water was added to the solution, which was extracted with
dichloromethane. The combined organic layers were washed with
saturated NaHCO.sub.3, and brine before drying over MgSO.sub.4. The
organic layer was filtered and evaporated to dryness. The residue
was purified by flash chromatography to give the desired product.
The correct product 9 was confirmed by LC-MS.
Synthesis of Cinnamoyl Bromide.sup.g
##STR00138##
[0138] A catalytic amount of triethylamine (5 mol %) was added to a
solution of the acrylic acid in CH.sub.2Cl.sub.2. The mixture was
stirred for 5 minutes before NBS (120 mol %) was added in portions.
Within 5 minutes of the first addition, CO.sub.2 gas evolved. After
all of the NBS was added, the mixture was allowed to stir overnight
at room temperature. The organic solvent was evaporated and the
residue was purified by flash chromatography to give very good
yields of the desired cinnamoyl bromide.
General Method for Synthesis of Styrl-Tetrahydroisoquinoline
Derivatives.sup.h
##STR00139##
[0140] The bromovinylbenzene was dissolved in Et.sub.2O and cooled
to -78.degree. C. under argon. To this mixture was added 2.2
equivalents of t-BuLi dropwise. The resulting solution was stirred
for 1 hour at -78.degree. C. To this mixture was added a solution
of 1 equivalent of the dihydroisoquinoline in THF. At the end of
the addition, the mixture was allowed to stir at -78.degree. C. for
1 to 2 hours. The mixture was quenched by the direct addition of a
saturated solution of NH.sub.4Cl. The mixture was extracted with
EtOAc and the combined organic layers were dried over MgSO.sub.4,
filtered and evaporated to dryness. The residue was purified by
flash chromatography (and Prep HPLC). The correct product was
confirmed by LC-MS and/or H.sup.1 NMR.
##STR00140##
[0141] Typical Julia-Kocienski Reaction Conditions:
[0142] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and the
aldehyde (0.84 mmol) in THF (10 mL) was cooled to -35.degree. C.
with stirring under argon. To this mixture was added a solution of
lithium bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF)
and the reaction mixture was stirred for 1 hour at -35.degree. C.
The reaction was allowed to warm up to room temperature and the
organic solvent was evaporated to give a residue. The residue was
dissolved (or suspended) in 4M HCl dioxane (5 mL) and stirred at
room temperature until the reaction was completed. The organic
layer was evaporated to leave a residue, which was purified by
flash or reverse phase preparatory chromatography.
Synthesis of Key Intermediate tert-butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate.sup.i
##STR00141##
[0143] a. Ethyl
6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylate.sup.f
[0144] tert-Butyl
N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]carbamate (8.9 g, 24.89
mmol) was dissolved in CH.sub.2Cl.sub.2 (250 mL) and cooled to
0.degree. C. with stirring under argon. To this solution was added
ethyl 2-oxoacetate (9.86 mL, 49.84 mmol, 50% in Toluene), followed
by the dropwise addition of BF.sub.3-Et.sub.2O (7.7 mL, 62.21 mmol)
over 30 minutes. The mixture was stirred for 1 hour at 0.degree.
C., then allowed to warm to room temperature overnight. The organic
layer was evaporated to give a residue, which was purified by flash
chromatography. The correct product was confirmed by LC-MS;
M+1=342.
b. O2-tert-Butyl O1-ethyl
6-benzyloxy-7-methoxy-3,4-dihydro-1H-isoquinoline-1,2-dicarboxylate
[0145] Ethyl
6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylate
(9.0 g, 26.63 mmol) was dissolved in CH.sub.2Cl.sub.2 (200 mL),
followed by Et.sub.3N (4.0 mL, 28.8 mmol) and Boc.sub.2O (6.3 g,
28.8 mmol). The mixture was stirred overnight at room temperature.
The mixture was washed with 1M H.sub.3PO.sub.4 and brine. The
organic layer was dried over MgSO4, filtered and evaporated to give
the crude product, which was used without further purification.
LC-MS; M+1=442.
c.
6-Benzyloxy-2-tert-butoxycarbonyl-7-methoxy-3,4-dihydro-1H-isoquinoline-
-1-carboxylic Acid
[0146] O2-tert-Butyl O1-ethyl
6-benzyloxy-7-methoxy-3,4-dihydro-1H-isoquinoline-1,2-dicarboxylate
(11.0 g, 24.9 mmol) was dissolved in THF (50 mL), EtOH (50 mL) and
H.sub.2O (50 mL). To this solution was added solid KOH (3.8 g, 67.8
mmol) and the mixture was stirred at room temperature for 24 hours.
The organic solvents were evaporated and the resulting residue was
cooled in an ice bath and acidified with 2M H.sub.3PO.sub.4. The
mixture was extracted with EtOAc and the combined organic layers
were dried over MgSO4, filtered and evaporated to give the crude
product, which was used without further purification. LC-MS;
M+1=414.
d. tert-Butyl
6-benzyloxy-1-(hydroxymethyl)-7-methoxy-3,4-dihydro-1H-isoquinoline-2-car-
boxylate
[0147] To a solution of
6-benzyloxy-2-tert-butoxycarbonyl-7-methoxy-3,4-dihydro-1H-isoquinoline-1-
-carboxylic acid (4.0 g, 9.67 mmol) in THF (10 mL) at 0.degree. C.
was added Borane-THF complex (19.2 mL, 19.2 mmol, 1M). The reaction
mixture was stirred at rt for 4 h. The reaction was quenched with
water, extracted with EtOAc. The combined organic layer was washed
with brine, dried (MgSO.sub.4), and concentrated. The crude product
was obtained as colorless oil and used in the next step without
further purification. LC-MS; M+1=400.
e. tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfanylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate.sup.g
[0148] To a stirred solution of tert-butyl
6-benzyloxy-1-(hydroxymethyl)-7-methoxy-3,4-dihydro-1H-isoquinoline-2-car-
boxylate (3.0 g, 7.5 mmol), phenyl-1H-tetrazole-5-thiol (1.6 g, 9.0
mmol), and triphenylphosphine (2.36 g, 9.0 mmol) in THF (30 mL) was
added diisopropyl azodicarboxylate (1.7 mL, 9.0 mol, 2.2 M solution
in hexane) dropwise at 0.degree. C. The solution was allowed to
stir at 0.degree. C. for an additional 30 min and allowed to warm
to room temperature overnight. The reaction mixture was
concentrated in vacuo to give a residue which was purified by flash
column chromatography (20%-30% EtOAc in hexane) to give the correct
product. LC-MS; M+1=560.
f. tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate
[0149] tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfanylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (14.0 g, 25.03 mmol) was dissolved
in a mixture of THF EtOH (100 mL) and DMF (50 mL) and cooled to
0.degree. C. A solution of ammonium paramolybdate tetrahydrate
(12.6 g, 10.2 mmol) and 30% hydrogen peroxide (28 mL, 302.4 mmol)
at 0.degree. C. was added dropwise over 30 minutes. The reaction
mixture was allowed to warm to room temperature overnight, poured
into saturated aqueous sodium thiosulfate, and extracted with ethyl
acetate three times. The combined organic layers were washed with
water and brine and dried over MgSO.sub.4. The solvent was removed
in vacuo and the residual product was purified by flash
chromatography (30% EtOAc in hexane) to give the correct product.
LC-MS; M+1=592.
REFERENCES
[0150] .sup.a Cava, M. P.; Buck, K. T. Tetrahedron 1969, 25,
2795-2805 [0151] .sup.b Nag, Ahindra et al Journal of Molecular
Catalysis B: Enzymatic 2012, 82, 92-95; Heo, J. N., et al., Bull.
Korean Chem. Soc., 32 (12), 4431, 2011; Srikrishna, A. et al,
Synthetic Communications, 37(6), 965-976; 2007. [0152] .sup.c
Patent reference: WO2010001169, Astrazeneca. [0153] .sup.d Herbert,
Richard B. et al Tetrahedron 1990, 46, 7119-7138. [0154] .sup.e
Chen, T., et al., Bioorganic and Medicinal Chemistry, 17, 2351,
2009; Elliott, M. C., et al., Org. Biomol. Chem., 1, 3038, 2003;
Bohme, T., et al. J. Med Chem., 45, 3094, 2002. [0155] .sup.f
Miyazaki, M., et al, Journal of Organic Chemistry, 76(2), 534-542;
2011. [0156] .sup.g Muller, D, et al., Chem. Eur. J., 19. 15226,
2013. [0157] .sup.h Curtin, D. Y., et. al., JACS, 73, 2716, 1951;
Chrzanowska, M., et al., Tetrahedron: Asymmetry, 12, 1435, 2001;
Kawate, T. et al., Chem. Pharm. Bull. 41, (2), 287, 1993; Nakagawa,
M., J. Chem. Soc., Chem Commun., 991, 1990. [0158] .sup.i Reddy, R.
J. et al., J. Org. Chem., 2012, 77, 11101.
IV. Methods of Inhibiting the Replication of a Virus
[0159] The compounds of the invention exhibit potency against
viruses, and therefore have the potential to inhibit the
replication of viruses.
[0160] In a further aspect, the invention provides a method of
inhibiting the replication of a virus in an animal, comprising
administering a compound or a pharmaceutical formulation described
herein to the animal, wherein the animal is in need of treatment
thereof, thereby inhibiting the replication of the virus in an
animal. In an exemplary embodiment, the virus is a member of the
retroviridae family. In an exemplary embodiment, the virus is a
member of the orthoretroviridae subfamily. In an exemplary
embodiment, the virus is a lentivirus. In an exemplary embodiment,
the virus is human immunodeficiency virus (HIV). In an exemplary
embodiment, the virus is HIV-1. In an exemplary embodiment, the
virus is HIV-2. In an exemplary embodiment, the compound is
described herein, or a salt, prodrug, hydrate or solvate thereof,
or a combination thereof. In an exemplary embodiment, the invention
provides a compound described herein, or a salt, hydrate or solvate
thereof. In an exemplary embodiment, the invention provides a
compound described herein, or a prodrug thereof. In an exemplary
embodiment, the invention provides a compound described herein, or
a salt thereof. In another exemplary embodiment, the compound of
the invention is a compound described herein, or a pharmaceutically
acceptable salt thereof. In another exemplary embodiment, the
compound is described by a formula listed herein, or a
pharmaceutically acceptable salt thereof. In an exemplary
embodiment, the compound is part of a pharmaceutical formulation
described herein. In another exemplary embodiment, the contacting
occurs under conditions which permit entry of the compound into the
organism. Such conditions are known to one skilled in the art and
specific conditions are set forth in the Examples appended
hereto.
[0161] In another aspect, the microorganism is inside, or on the
surface of an animal. In an exemplary embodiment, the animal is
selected from the group consisting of human, cattle, deer,
reindeer, goat, honey bee, pig, sheep, horse, cow, bull, dog,
guinea pig, gerbil, rabbit, cat, camel, yak, elephant, ostrich,
otter, chicken, duck, goose, guinea fowl, pigeon, swan, and turkey.
In another exemplary embodiment, the animal is a human.
[0162] In an exemplary embodiment, the viral replication is
inhibited through oral administration of the compound of the
invention. In an exemplary embodiment, the viral replication is
inhibited through intravenous administration of the compound of the
invention. In an exemplary embodiment, the viral replication is
inhibited through topical administration of the compound of the
invention. In an exemplary embodiment, the viral replication is
inhibited through intraperitoneal administration of the compound of
the invention. In an exemplary embodiment, the compound is
administered in a topically effective amount. In an exemplary
embodiment, the pharmaceutical formulation is administered in an
orally effective amount.
V. Methods of Treating and/or Preventing Disease
[0163] The compounds of the invention exhibit potency against a
virus, and therefore have the potential to achieve therapeutic
efficacy in the animals described herein.
[0164] In another aspect, the invention provides a method of
treating a disease. The method includes administering to the animal
a therapeutically effective amount of the compound of the
invention, sufficient to treat and/or prevent the disease. In an
exemplary embodiment, the compound of the invention can be used in
human or veterinary medical therapy, particularly in the treatment
of viral-associated disease. In an exemplary embodiment, the
compound of the invention can be used in human or veterinary
medical therapy, particularly in the treatment or prophylaxis of
lentivirus-associated disease. In an exemplary embodiment, the
disease is associated with a human immunodeficiency virus. In an
exemplary embodiment, the disease is associated with HIV-1. In an
exemplary embodiment, the disease is associated with HIV-2. In an
exemplary embodiment, the disease is AIDS. In an exemplary
embodiment, the compound is described herein, or a salt, prodrug,
hydrate or solvate thereof, or a combination thereof. In an
exemplary embodiment, the invention provides a compound described
herein, or a salt, hydrate or solvate thereof. In an exemplary
embodiment, the invention provides a compound described herein, or
a prodrug thereof. In an exemplary embodiment, the invention
provides a compound described herein, or a salt thereof. In another
exemplary embodiment, the compound of the invention is a compound
described herein, or a pharmaceutically acceptable salt thereof. In
another exemplary embodiment, the compound is described by a
formula listed herein, or a pharmaceutically acceptable salt
thereof. In an exemplary embodiment, the compound is part of a
pharmaceutical formulation described herein. In another exemplary
embodiment, the contacting occurs under conditions which permit
entry of the compound into the organism. Such conditions are known
to one skilled in the art and specific conditions are set forth in
the Examples appended hereto.
[0165] In another exemplary embodiment, the animal is selected from
the group consisting of human, cattle, deer, reindeer, goat, honey
bee, pig, sheep, horse, cow, bull, dog, guinea pig, gerbil, rabbit,
cat, camel, yak, elephant, ostrich, otter, chicken, duck, goose,
guinea fowl, pigeon, swan, and turkey. In another exemplary
embodiment, the animal is a human. In another exemplary embodiment,
the animal is a mouse. In another exemplary embodiment, the animal
is selected from the group consisting of a human, cattle, goat,
pig, sheep, horse, cow, bull, dog, guinea pig, gerbil, rabbit, cat,
chicken and turkey. In another exemplary embodiment, the animal is
a human. In another exemplary embodiment, the animal is cattle. In
another exemplary embodiment, the animal is a cow. In another
exemplary embodiment, the animal is a bull.
[0166] In an exemplary embodiment, the disease is treated through
oral administration of the compound of the invention. In an
exemplary embodiment, the disease is treated through intravenous
administration of the compound of the invention. In an exemplary
embodiment, the disease is treated through topical administration
of the compound of the invention. In an exemplary embodiment, the
disease is treated through intraperitoneal administration of the
compound of the invention. In an exemplary embodiment, the compound
is administered in a topically effective amount. In an exemplary
embodiment, the pharmaceutical formulation is administered in an
orally effective amount.
[0167] In an exemplary embodiment, the invention provides a method
of treating AIDS by administering a therapeutically effective
amount of a compound of the invention.
VI. Pharmaceutical Formulations
[0168] In another aspect, the invention is a pharmaceutical
formulation which includes: (a) a pharmaceutically acceptable
excipient; and (b) a compound of the invention. In another aspect,
the pharmaceutical formulation includes: (a) a pharmaceutically
acceptable excipient; and (b) a compound according to a formula
described herein. In another aspect, the pharmaceutical formulation
includes: (a) a pharmaceutically acceptable excipient; and (b) a
compound described herein, or a salt, prodrug, hydrate or solvate
thereof, or a combination thereof. In another aspect, the
pharmaceutical formulation includes: (a) a pharmaceutically
acceptable excipient; and (b) a compound described herein, or a
salt, hydrate or solvate thereof, or a combination thereof. In
another aspect, the pharmaceutical formulation includes: (a) a
pharmaceutically acceptable excipient; and (b) a compound described
herein, or a salt, hydrate or solvate thereof. In another aspect,
the pharmaceutical formulation includes: (a) a pharmaceutically
acceptable excipient; and (b) a salt of a compound described
herein. In an exemplary embodiment, the salt is a pharmaceutically
acceptable salt. In another aspect, the pharmaceutical formulation
includes: (a) a pharmaceutically acceptable excipient; and (b) a
prodrug of a compound described herein. In another aspect, the
pharmaceutical formulation includes: (a) a pharmaceutically
acceptable excipient; and (b) a compound described herein. In an
exemplary embodiment, the pharmaceutical formulation is a unit
dosage form. In an exemplary embodiment, the pharmaceutical
formulation is a single unit dosage form.
[0169] The pharmaceutical formulations of the invention can take a
variety of forms adapted to the chosen route of administration.
Those skilled in the art will recognize various synthetic
methodologies that may be employed to prepare non-toxic
pharmaceutical formulations incorporating the compounds described
herein. Those skilled in the art will recognize a wide variety of
non-toxic pharmaceutically acceptable solvents that may be used to
prepare solvates of the compounds of the invention, such as water,
ethanol, propylene glycol, mineral oil, vegetable oil and
dimethylsulfoxide (DMSO).
[0170] The pharmaceutical formulation of the invention may be
administered orally, topically, intraperitoneally, parenterally, by
inhalation or spray or rectally in unit dosage forms containing
conventional non-toxic pharmaceutically acceptable carriers,
adjuvants and vehicles. It is further understood that the best
method of administration may be a combination of methods. Oral
administration in the form of a pill, capsule, elixir, syrup,
lozenge, troche, or the like is particularly preferred. The term
parenteral as used herein includes subcutaneous injections,
intradermal, intravascular (e.g., intravenous), intramuscular,
spinal, intrathecal injection or like injection or infusion
techniques. In an exemplary embodiment, the pharmaceutical
formulation is administered orally. In an exemplary embodiment, the
pharmaceutical formulation is administered intravenously. In an
exemplary embodiment, the pharmaceutical formulation is
administered intramuscularly. In an exemplary embodiment, the
pharmaceutical formulation is administered subcutaneously. In an
exemplary embodiment, the pharmaceutical formulation is
administered in an orally effective dose.
[0171] The pharmaceutical formulations containing compounds of the
invention are preferably in a form suitable for oral use, for
example, as tablets, troches, lozenges, aqueous or oily
suspensions, dispersible powders or granules, emulsion, hard or
soft capsules, or syrups or elixirs.
[0172] Compositions intended for oral use may be prepared according
to any method known in the art for the manufacture of
pharmaceutical formulations, and such compositions may contain one
or more agents selected from the group consisting of sweetening
agents, flavoring agents, coloring agents and preserving agents in
order to provide pharmaceutically elegant and palatable
preparations. Tablets may contain the active ingredient in
admixture with non-toxic pharmaceutically acceptable excipients
that are suitable for the manufacture of tablets. These excipients
may be for example, inert diluents, such as calcium carbonate,
sodium carbonate, lactose, calcium phosphate or sodium phosphate;
granulating and disintegrating agents, for example, corn starch, or
alginic acid; binding agents, for example starch, gelatin or
acacia; and lubricating agents, for example magnesium stearate,
stearic acid or talc. The tablets may be uncoated or they may be
coated by known techniques to delay disintegration and absorption
in the gastrointestinal tract and thereby provide a sustained
action over a longer period. For example, a time delay material
such as glyceryl monostearate or glyceryl distearate may be
employed.
[0173] Formulations for oral use may also be presented as hard
gelatin capsules wherein the active ingredient is mixed with an
inert solid diluent, for example, calcium carbonate, calcium
phosphate or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with water or an oil medium, for example peanut
oil, liquid paraffin or olive oil.
[0174] Aqueous suspensions contain the active materials in
admixture with excipients suitable for the manufacture of aqueous
suspensions. Such excipients are suspending agents, for example
sodium carboxymethylcellulose, methylcellulose,
hydroxypropylmethylcellulose, sodium alginate,
polyvinylpyrrolidone, gum tragacanth and gum acacia; and dispersing
or wetting agents, which may be a naturally-occurring phosphatide,
for example, lecithin, or condensation products of an alkylene
oxide with fatty acids, for example polyoxyethylene stearate, or
condensation products of ethylene oxide with long chain aliphatic
alcohols, for example heptadecaethyleneoxycetanol, or condensation
products of ethylene oxide with partial esters derived from fatty
acids and a hexitol such as polyoxyethylene sorbitol monooleate, or
condensation products of ethylene oxide with partial esters derived
from fatty acids and hexitol anhydrides, for example polyethylene
sorbitan monooleate. The aqueous suspensions may also contain one
or more preservatives, for example ethyl, or n-propyl
p-hydroxybenzoate, one or more coloring agents, one or more
flavoring agents, and one or more sweetening agents, such as
sucrose or saccharin.
[0175] Oily suspensions may be formulated by suspending the active
ingredients in a vegetable oil, for example arachis oil, olive oil,
sesame oil or coconut oil, or in a mineral oil such as liquid
paraffin. The oily suspensions may contain a thickening agent, for
example beeswax, hard paraffin or cetyl alcohol. Sweetening agents
such as those set forth above, and flavoring agents may be added to
provide palatable oral preparations. These compositions may be
preserved by the addition of an anti-oxidant such as ascorbic
acid.
[0176] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water provide the active
ingredient in admixture with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents and suspending agents are exemplified by those
already mentioned above. Additional excipients, for example
sweetening, flavoring and coloring agents, may also be present.
[0177] Pharmaceutical formulations of the invention may also be in
the form of oil-in-water emulsions and water-in-oil emulsions. The
oily phase may be a vegetable oil, for example olive oil or arachis
oil, or a mineral oil, for example liquid paraffin or mixtures of
these. Suitable emulsifying agents may be naturally-occurring gums,
for example gum acacia or gum tragacanth; naturally-occurring
phosphatides, for example soy bean, lecithin, and esters or partial
esters derived from fatty acids and hexitol; anhydrides, for
example sorbitan monooleate; and condensation products of the said
partial esters with ethylene oxide, for example polyoxyethylene
sorbitan monooleate. The emulsions may also contain sweetening and
flavoring agents.
[0178] Syrups and elixirs may be formulated with sweetening agents,
for example glycerol, propylene glycol, sorbitol or sucrose. Such
formulations may also contain a demulcent, a preservative, and
flavoring and coloring agents. The pharmaceutical formulations may
be in the form of a sterile injectable aqueous or oleaginous
suspension. This suspension may be formulated according to the
known art using those suitable dispersing or wetting agents and
suspending agents, which have been mentioned above. The sterile
injectable preparation may also be a sterile injectable solution or
suspension in a non-toxic parenterally acceptable diluent or
solvent, for example as a solution in 1,3-butanediol. Among the
acceptable vehicles and solvents that may be employed are water,
Ringer's solution and isotonic sodium chloride solution. In
addition, sterile, fixed oils are conventionally employed as a
solvent or suspending medium. For this purpose any bland fixed oil
may be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid find use in the
preparation of injectables.
[0179] The composition of the invention may also be administered in
the form of suppositories, e.g., for rectal administration of the
drug. These compositions can be prepared by mixing the drug with a
suitable non-irritating excipient that is solid at ordinary
temperatures but liquid at the rectal temperature and will
therefore melt in the rectum to release the drug. Such materials
are cocoa butter and polyethylene glycols.
[0180] Alternatively, the compositions can be administered
parenterally in a sterile medium. The drug, depending on the
vehicle and concentration used, can either be suspended or
dissolved in the vehicle. Advantageously, adjuvants such as local
anesthetics, preservatives and buffering agents can be dissolved in
the vehicle.
[0181] For administration to non-human animals, the composition
containing the therapeutic compound may be added to the animal's
feed or drinking water. Also, it will be convenient to formulate
animal feed and drinking water products so that the animal takes in
an appropriate quantity of the compound in its diet. It will
further be convenient to present the compound in a composition as a
premix for addition to the feed or drinking water. The composition
can also be added as a food or drink supplement for humans.
[0182] Dosage levels of the order of from about 1 mg to about 250
mg per kilogram of body weight per day and more preferably from
about 5 mg to about 150 mg per kilogram of body weight per day, and
more preferably from about 25 mg to about 150 mg per kilogram of
body weight per day, are useful in the treatment of the
above-indicated conditions. The amount of active ingredient that
may be combined with the carrier materials to produce a unit dosage
form will vary depending upon the condition being treated and the
particular mode of administration. Unit dosage forms will generally
contain between from about 1 mg to about 5000 mg of an active
ingredient.
[0183] Frequency of dosage may also vary depending on the compound
used and the particular disease treated. However, for treatment of
most disorders, a dosage regimen of 4 times daily or less is
preferred. It will be understood, however, that the specific dose
level for any particular animal (such as a human) will depend upon
a variety of factors including the activity of the specific
compound employed, the age, body weight, general health, sex, diet,
time of administration, route of administration and rate of
excretion, drug combination and the severity of the particular
disease undergoing therapy.
[0184] In an exemplary embodiment, the unit dosage form contains
from about 1 mg to about 7000 mg of a compound of the invention. In
an exemplary embodiment, the unit dosage form contains from about 1
mg to about 5000 mg of an active ingredient. In an exemplary
embodiment, the unit dosage form contains from about 100 mg to
about 2000 mg of a compound of the invention. In an exemplary
embodiment, the unit dosage form contains from about 200 mg to
about 1000 mg of a compound of the invention. In an exemplary
embodiment, the unit dosage form contains from about 500 mg to
about 800 mg of a compound of the invention. In an exemplary
embodiment, the unit dosage form contains from about 1 mg to about
100 mg of a compound of the invention. In an exemplary embodiment,
the unit dosage form contains from about 10 mg to about 100 mg of a
compound of the invention. In an exemplary embodiment, the unit
dosage form contains from about 50 mg to about 100 mg of a compound
of the invention. In an exemplary embodiment, the unit dosage form
contains from about 25 mg to about 75 mg of a compound of the
invention. In an exemplary embodiment, the unit dosage form
contains from about 40 mg to about 60 mg of a compound of the
invention. In an exemplary embodiment, the unit dosage form
contains from about 75 mg to about 200 mg of a compound of the
invention. In an exemplary embodiment, the unit dosage form
contains from about 1 mg to about 5 mg of a compound of the
invention. In an exemplary embodiment, the unit dosage form
contains from about 10 mg to about 25 mg of a compound of the
invention. In an exemplary embodiment, the unit dosage form
contains from about 50 mg to about 350 mg of a compound of the
invention. In an exemplary embodiment, the unit dosage form
contains from about 200 mg to about 400 mg of a compound of the
invention.
[0185] In an exemplary embodiment, the daily dosage contains from
about 1 mg to about 800 mg of a compound of the invention. In an
exemplary embodiment, the daily dosage contains from about 1 mg to
about 500 mg of an active ingredient. In an exemplary embodiment,
the daily dosage contains from about 100 mg to about 800 mg of a
compound of the invention. In an exemplary embodiment, the daily
dosage contains from about 200 mg to about 500 mg of a compound of
the invention. In an exemplary embodiment, the daily dosage
contains from about 500 mg to about 800 mg of a compound of the
invention. In an exemplary embodiment, the daily dosage contains
from about 1 mg to about 100 mg of a compound of the invention. In
an exemplary embodiment, the daily dosage contains from about 10 mg
to about 100 mg of a compound of the invention. In an exemplary
embodiment, the daily dosage contains from about 50 mg to about 100
mg of a compound of the invention. In an exemplary embodiment, the
daily dosage contains from about 75 mg to about 200 mg of a
compound of the invention. In an exemplary embodiment, the daily
dosage contains from about 1 mg to about 5 mg of a compound of the
invention. In an exemplary embodiment, the daily dosage contains
from about 10 mg to about 25 mg of a compound of the invention. In
an exemplary embodiment, the daily dosage contains from about 50 mg
to about 350 mg of a compound of the invention. In an exemplary
embodiment, the daily dosage contains from about 200 mg to about
400 mg of a compound of the invention.
[0186] Preferred compounds of the invention will have desirable
pharmacological properties that include, but are not limited to,
bioavailability, low toxicity, low serum protein binding and
desirable in vitro and in vivo half-lives. Penetration of the blood
brain barrier for compounds used to treat CNS disorders is
necessary, while low brain levels of compounds used to treat
peripheral disorders are often preferred.
[0187] Assays may be used to predict these desirable
pharmacological properties. Assays used to predict bioavailability
include transport across human intestinal cell monolayers,
including Caco-2 cell monolayers. Toxicity to cultured hepatocyctes
may be used to predict compound toxicity. Penetration of the blood
brain barrier of a compound in humans may be predicted from the
brain levels of laboratory animals that receive the compound
intravenously.
[0188] Serum protein binding may be predicted from albumin binding
assays. Such assays are described in a review by Oravcova, et al.
(Journal of Chromatography B (1996) volume 677, pages 1-27).
[0189] Compound half-life is inversely proportional to the
frequency of dosage of a compound. In vitro half-lives of compounds
may be predicted from assays of microsomal half-life as described
by Kuhnz and Gieschen (Drug Metabolism and Disposition, (1998)
volume 26, pages 1120-1127).
[0190] The amount of the composition required for use in treatment
will vary not only with the particular compound selected but also
with the route of administration, the nature of the condition being
treated and the age and condition of the animal (such as a human)
and will ultimately be at the discretion of the attendant physician
or clinician.
VI. a) Testing
[0191] Preferred compounds for use in the pharmaceutical
formulations described herein will have certain pharmacological
properties. Such properties include, but are not limited to, low
toxicity, low serum protein binding and desirable in vitro and in
vivo half-lives. Assays may be used to predict these desirable
pharmacological properties. Assays used to predict bioavailability
include transport across human intestinal cell monolayers,
including Caco-2 cell monolayers. Serum protein binding may be
predicted from albumin binding assays. Such assays are described in
a review by Oravcova et al. (1996, J. Chromat. B677: 1-27).
Compound half-life is inversely proportional to the frequency of
dosage of a compound. In vitro half-lives of compounds may be
predicted from assays of microsomal half-life as described by Kuhnz
and Gleschen (Drug Metabolism and Disposition, (1998) volume 26,
pages 1120-1127).
[0192] Toxicity and therapeutic efficacy of such compounds can be
determined by standard pharmaceutical procedures in cell cultures
or experimental animals, e.g., for determining the LD50 (the dose
lethal to 50% of the population) and the ED.sub.50 (the dose
therapeutically effective in 50% of the population). The dose ratio
between toxic and therapeutic effects is the therapeutic index and
it can be expressed as the ratio between LD.sub.50 and ED.sub.50.
Compounds that exhibit high therapeutic indices are preferred. The
data obtained from these cell culture assays and animal studies can
be used in formulating a range of dosages for use in humans or
animals. The dosage of such compounds lies preferably within a
range of circulating concentrations that include the ED.sub.50 with
little or no toxicity. The dosage can vary within this range
depending upon the unit dosage form employed and the route of
administration utilized. The exact formulation, route of
administration and dosage can be chosen by the individual physician
in view of the human's condition. (See, e.g. Fingl et al., 1975, in
"The Pharmacological Basis of Therapeutics", Ch. 1, p. 1).
VI. b) Administration
[0193] For any compound used in the method of the invention, the
therapeutically effective dose can be estimated initially from cell
culture assays, as disclosed herein. For example, a dose can be
formulated in animal models to achieve a circulating concentration
range that includes the EC.sub.50 (effective dose for 50% increase)
as determined in cell culture, i.e., the concentration of the test
compound which achieves a half-maximal inhibition of viral cell
growth. Such information can be used to more accurately determine
useful doses in humans or animals.
[0194] In general, the compounds prepared by the methods, and from
the intermediates, described herein will be administered in a
therapeutically effective amount by any of the accepted modes of
administration for agents that serve similar utilities. It will be
understood, however, that the specific dose level for any
particular animal (such as a human) will depend upon a variety of
factors including the activity of the specific compound employed,
the age, body weight, general health, sex, diet, time of
administration, route of administration, and rate of excretion,
drug combination, the severity of the particular disease undergoing
therapy and the judgment of the prescribing physician. The drug can
be administered from once or twice a day, or up to 3 or 4 times a
day.
[0195] Dosage amount and interval can be adjusted individually to
provide plasma levels of the active moiety that are sufficient to
maintain viral growth inhibitory effects. Usual animal (such as a
human) dosages for systemic administration range from 0.1 to 1000
mg/day, preferably, 1-500 mg/day, more preferably 10-200 mg/day,
even more preferably 100-200 mg/day. Stated in terms of animal
(such as a human) body surface areas, usual dosages range from
50-91 mg/m.sup.2/day.
[0196] The amount of the compound in a formulation can vary within
the full range employed by those skilled in the art. Typically, the
formulation will contain, on a weight percent (wt %) basis, from
about 0.01-10 wt % of the drug based on the total formulation, with
the balance being one or more suitable pharmaceutical excipients.
Preferably, the compound is present at a level of about 0.1-3.0 wt
%, more preferably, about 1.0 wt %.
[0197] Exemplary embodiments are summarized herein below.
[0198] In an exemplary embodiment, the invention provides a
pharmaceutical formulation comprising: a) the compound according to
any of the above paragraphs, or a pharmaceutically acceptable salt
thereof; and b) a pharmaceutically acceptable excipient.
[0199] In an exemplary embodiment, the invention provides a method
of inhibiting the replication of a virus in an animal, comprising:
administering a compound or a pharmaceutical formulation of a
preceding claim to the animal, wherein the animal is in need of
treatment thereof, thereby inhibiting the replication of the virus
in an animal.
[0200] In an exemplary embodiment, according to any of the above
paragraphs, wherein the virus is a member of the Orthoretroviridae
family.
[0201] In an exemplary embodiment, according to any of the above
paragraphs, wherein the virus is HIV.
[0202] In an exemplary embodiment, the invention provides a method
of treating a disease in an animal, comprising: a) administering a
compound or a pharmaceutical formulation described herein to the
animal, wherein the animal is in need of treatment thereof, thereby
treating the disease in the animal.
[0203] In an exemplary embodiment, according to any of the above
paragraphs, the disease is AIDS.
[0204] In an exemplary embodiment, according to any of the above
paragraphs, the animal is a human.
[0205] In an exemplary embodiment, according to any of the above
paragraphs, the invention is a use of a compound of the invention
or a pharmaceutical formulation of the invention in the manufacture
of a medicament for the treatment of a viral infection.
[0206] The invention is further illustrated by the Examples that
follow. The Examples are not intended to define or limit the scope
of the invention.
EXAMPLES
[0207] The following Examples illustrate the synthesis of
representative compounds used in the invention and the following
Reference Examples illustrate the synthesis of intermediates in
their preparation. These examples are not intended, nor are they to
be construed, as limiting the scope of the invention. It will be
clear that the invention may be practiced otherwise than as
particularly described herein. Numerous modifications and
variations of the invention are possible in view of the teachings
herein and, therefore, are within the scope of the invention.
[0208] All temperatures are given in degrees Centigrade. Room
temperature means 20 to 25.degree. C. Reagents were purchased from
commercial sources or prepared following standard literature
procedures. Unless otherwise noted, reactions were carried out
under a positive pressure of nitrogen. Reaction vessels were sealed
with either rubber septa or Teflon screw caps. Nitrogen was
introduced through Tygon tubing, fitted with a large bore syringe
needle. Concentration under vacuum refers to the removal of solvent
on a Buchi Rotary Evaporator.
[0209] Analytical HPLC was performed using a Supelco discovery
C.sub.18 15 cm.times.4.6 mm/5 .mu.m column coupled with an Agilent
1050 series VWD UV detector at 210 nm. Conditions: Solvent A:
H.sub.2O/1% acetonitrile/0.1% HCO.sub.2H; Solvent B: methanol.
[0210] Proton magnetic resonance (.sup.1H NMR) spectra were
recorded on a Varian INOVA NMR spectrometer [400 MHz (.sup.1H) or
500 MHz (.sup.1H)] or Varian 400-MR [400 MHz (1H)]. All spectra
were determined in the solvents indicated. Although chemical shifts
are reported in ppm downfield of tetramethylsilane, they are
referenced to the residual proton peak of the respective solvent
peak for .sup.1H NMR. Interproton coupling constants are reported
in Hertz (Hz).
[0211] LCMS spectra were obtained using a ThermoFinnigan AQA MS ESI
instrument utilizing a Phenomenex Aqua 5 micron C.sub.18 125 .ANG.
50.times.4.60 mm column. The spray setting for the MS probe was at
350 .mu.L/min with a cone voltage at 25 mV and a probe temperature
at 450.degree. C. The spectra were recorded using ELS and UV (254
nm) detection. Alternatively, LCMS spectra were obtained using an
Agilent 1200SL HPLC equipped with a 6130 mass spectrometer or
Agilent 1200 series with a 6140 mass spectrometer operating with
electrospray ionization.
[0212] Silica gel chromatography was carried out on either a
Teledyne ISCO CombiFlash Companion or Companion Rf Flash
Chromatography System with a variable flow rate from 5-100 mL/min.
The columns used were Teledyne ISCO RediSep Disposable Flash
Columns (4, 12, 40, 80, or 120 g prepacked silica gel), which were
run with a maximum capacity of 1 g crude sample per 10 g silica
gel. Samples were preloaded on Celite in Analogix Sample Loading
Cartridges with frits (1/in, 1/out). The eluent was 0-100% EtOAc in
heptane or 0-10% MeOH in CH.sub.2Cl.sub.2 as a linear gradient over
the length of the run (14-20 minutes). Peaks were detected by
variable wavelength UV absorption (200-360 nm). The resulting
fractions were analyzed, combined as appropriate, and evaporated
under reduced pressure to provide purified material.
EXAMPLES
Example A:
1-[2-(3,4-Dimethoxyphenyl)ethyl]-6,7-dimethoxy-1,2,3,4-tetrahyd-
roisoquinoline
##STR00142##
[0214] To the solution of 3,4-dimethoxyphenethyl bromide (1.78 g,
7.28 mmol) in anhydrous THF (30 mL), under argon, at -78.degree. C.
was added MeLi (6 mL, 1.6M in diethyl ether, 9.6 mmol), the
resulting mixture was stirred for 1 hr. A solution of t-BuLi (9 mL,
1.7M in pentane, 15.30 mmol), stirred at -78.degree. C. for another
1 hr, then the solution of commercially available
6,7-dimethoxy-3,4-dihydroisoquinoline (1.67 g, 8.73 mmol) in THF
(20 mL) was added with the aid of a syringe. After all the
addition, the resulting mixture was stirred at -78.degree. C. for 3
hrs, quenched with satd. aqueous NH.sub.4Cl solution and gradually
allowed to warm to room temperature and extracted with EtOAc. The
organic layer was washed with brine, dried (Na.sub.2SO.sub.4),
filtered, concentrated and purified with flash chromatography using
MeOH (NH.sub.3)/CHCl.sub.3 gradient to afford the titled compound.
M+H=358.
Example B:
[6-Benzyloxy-1-[(E)-2-(3-benzyloxy-4-methoxy-phenyl)vinyl]-7-me-
thoxy-3,4-dihydro-1H-isoquinolin-2-yl]-pyrazin-2-yl-methanone
##STR00143##
[0216] To the solution of
(E)-6-(benzyloxy)-1-(3-(benzyloxy)-4-methoxystyryl)-7-methoxy-1,2,3,4-tet-
rahydroisoquinoline (81.4 mg, 0.13 mmol) in anhydrous DMF (2 mL),
was added pyrazine-2-carboxylic acid (81 mg, 0.65 mmol), HATU (250
mg, 0.66 mmol) and DIPEA (1 mL). The resulting solution was stirred
at room temperature overnight. After the usual workup, the crude
obtained was purified on the Shimadzu HPLC system to afford the TFA
salt. M+H (Neutral)=614.
Example C:
1-[(E)-2-(5-Benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-6,7-dime-
thoxy-1,2,3,4-tetrahydroisoquinoline
##STR00144##
[0218] (E)-1-(Benzyloxy)-5-(2-bromovinyl)-2-methoxy-4-methylbenzene
(334 mg, 1.0 mmol) was dissolved in dry Et.sub.2O (15 mL) and
cooled to -78.degree. C. A solution of t-BuLi (1.3 mL, 2.2 mmol,
1.7M in pentane) was added dropwise and the resulting solution was
stirred at -78.degree. C. for 1 hour before a solution of
6,7-dimethoxy-3,4-dihydroisoquinoline (191 mg, 1.0 mmol), in THF (3
mL) was added dropwise. The resulting mixture was stirred for 2
hours at -78.degree. C. and then quenched with sat. aqueous
NH.sub.4Cl solution. The mixture was extracted with EtOAc and the
combined organic layers were dried over MgSO.sub.4, filtered and
evaporated to dryness. The residue obtained was purified by flash
silica gel chromatography to afford the titled compound. LCMS:
M+1=425.6.
Example D:
7-Benzyloxy-1-[(E)-2-(4-benzyloxy-3-methoxy-phenyl)vinyl]-2-but-
yl-6-methoxy-3,4-dihydro-1H-isoquinoline
##STR00145##
[0220] To the solution of
(E)-7-(benzyloxy)-1-(4-(benzyloxy)-3-methoxystyryl)-6-methoxy-1,2,3,4-tet-
rahydroisoquinoline (86 mg, 0.17 mmol) in DMF (3 mL) was added KH
(15 mg, 0.37 mmol), followed by 1-iodobutane (0.100 mL, 0.88 mmol).
The resulting solution was stirred at room temperature overnight.
The reaction mixture was diluted with EtOAc, washed with brine,
dried (Na.sub.2SO.sub.4), filtered, concentrated and purified with
flash chromatography using hexanes/EtOAc gradient to afford the
titled compound. M+H=564.
Example E:
6-Benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vin-
yl]-7-methoxy-2-methyl-3,4-dihydro-1H-isoquinoline
##STR00146##
[0222] A mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [50 mg (0.1 mmol)] and 50 .mu.l
of 38% formalin with 500 .mu.l of MeOH was stirred at room
temperature for 1 h then treated with 40 mg of NaBH.sub.4. After
stirring 12 h at room temperature the mixture was diluted with 10
mL of DCM and washed with water. The DCM layer was dried
(Na.sub.2SO.sub.4) then filtered and the filtrate rotary evaporated
to dryness. Yield=13.4 mg (25% yield) via prep chrom. MS (m/z): 536
[M+H]
Example F:
(6-Amino-2-pyridyl)-[6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methox-
y-2-methyl-phenyl)vinyl]-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]methano-
ne
##STR00147##
[0224] To a mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [50 mg (0.097 mmol)],
6-aminopyridine-2-carboxylic acid [13.8 mg (0.1 mmol)], DIEA [50 uL
(0.3 mmol)] and 1 mL of DMF was added HATU [47.5 mg (0.125 mmol)].
The reaction was stirred at rt for 1 h and then diluted with 20 mL
of EtOAc and washed 2.times. with sat NaCl. The EtOAc layer was
dried (Na.sub.2SO.sub.4) and the solvent removed. Yield=35 mg (57%)
via prep. chrom. MS (m/z): 642 [M+H]
Example G:
6-Benzyloxy-1-[(E)-2-(3-benzyloxy-4-methoxy-phenyl)vinyl]-2-but-
yl-7-methoxy-3,4-dihydro-1H-isoquinoline
##STR00148##
[0226] To the solution of
(E)-6-(benzyloxy)-1-(3-(benzyloxy)-4-methoxystyryl)-7-methoxy-1,2,3,4-tet-
rahydroisoquinoline (0.2841 g, 0.56 mmol), in DMF (5 mL) was added
KH (25 mg, 0.62 mmol), followed by 1-iodobutane (0.32 mL, 2.81
mmol). The resulting mixture was stirred at room temperature
overnight, After workup, the crude obtained was purified on the
Shimadzu HPLC system to afford the TFA salt. M+H (Neutral)=564.
Example H:
[6-Benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vi-
nyl]-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-pyrazin-2-yl-methanone
##STR00149##
[0228] To a mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [50 mg (0.097 mmol)], Pyrazine
carboxylic acid [12.4 mg (0.1 mmol)], DIEA [50 ul (0.3 mmol)] and 1
mL of DMF was added HATU [47.5 mg (0.125 mmol)]. The reaction was
stirred at rt for 1 h and then diluted with 20 mL of EtOAc and
washed 2.times. with sat NaCl. The EtOAc layer was dried
(Na.sub.2SO.sub.4) and the solvent removed. Yield=51.2 mg (84%) via
prep chrom. MS (m/z): 628 [M+H]
Example I: Methyl
6-benzyloxy-1-[(E)-2-(4,5-dimethoxy-2-methyl-phenyl)vinyl]-7-methoxy-3,4--
dihydro-1H-isoquinoline-2-carboxylate
##STR00150##
[0230] A mixture of
6-benzyloxy-1-[(E)-2-(4,5-dimethoxy-2-methyl-phenyl)vinyl]-7-methoxy-1,2,-
3,4-tetrahydroisoquinoline [44.5 mg (0.1 mmol)] and 2 mL of DCM
with DIEA [26 uL (0.15 mmol)] was treated with Methyl chloroformate
[14 ul (0.12 mmol)] and stirred at room temperature for 1 h. The
mixture was diluted with 10 mL of DCM and washed with water. The
DCM layer was dried (Na.sub.2SO.sub.4) then filtered and the
filtrate rotary evaporated to dryness. Yield=50 mg (99% yield) MS
(m/z): 504 [M+H]
Example J:
6-Benzyloxy-1-[(E)-2-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl-
)vinyl]-7-methoxy-1,2,3,4-tetrahydroisoquinoline
##STR00151##
[0231] 4-tert-Butyl-2-methoxy-phenol.sup.a
[0232] A mixture of 4-t-butyl-2-bromophenol [5. g (0.0218 mol)],
Copper(II) chloride [1.5 g (0.0112 mol)], NaOMe [12 g (0.218 mol)]
in 150 mL of DMF was refluxed for 4.5 h, filtered and the solvent
removed via rotary evaporation. The residue was diluted with water
and treated with conc. HCl until neutral. The mixture was then
extracted with DCM, dried (Na.sub.2SO.sub.4) and the solvent
removed affording the desired 4-tert-butyl-2-methoxy-phenol.
Yield=3.1 g (79% after flash chromatography with DCM) MS (m/z): 181
[M+H]
##STR00152##
Synthesis of 5-bromo-4-tert-butyl-2-methoxy-phenol.sup.b
[0233] To a solution of 4-tert-butyl-2-methoxy-phenol [3.1 g
(0.0172 mol)] in CCl.sub.4 (62 mL) was added drop wise a solution
of Br.sub.2 [0.9 mL (0.0174 mol)] in CCl.sub.4 (31 mL) at
100.degree. C. Upon completion the reaction was washed with water,
dried (Na.sub.2SO.sub.4) and the solvent removed affording
5-bromo-4-tert-butyl-2-methoxy-phenol. Yield=4 g (90% used without
further purification) MS (m/z): 259 [M+H].
##STR00153##
1-Benzyloxy-5-bromo-4-tert-butyl-2-methoxy-benzene.sup.c
[0234] A mixture of 5-bromo-4-tert-butyl-2-methoxy-phenol [4 g
(0.01555 mol)], Benzyl bromide [5.3 g (0.031 mol)], K.sub.2CO.sub.3
[4.28 g (0.031 mol) in ACN (31 mL) was refluxed for 18 h, cooled
and the solvent removed via rotary evaporation. The residue was
diluted with water and extracted with EtOAc. The extract was then
dried (MgSO.sub.4) and the solvent removed affording the desired
1-benzyloxy-5-bromo-4-tert-butyl-2-methoxy-benzene. Yield=4.5 g
(83% after flash chromatography with 10% EtOAc/Hexane) MS (m/z):
349 [M+H]
##STR00154##
5-(Benzyloxy)-2-tert-butyl-4-methoxybenzaldehyde
[0235] To a solution of
1-benzyloxy-5-bromo-4-tert-butyl-2-methoxy-benzene [4.5 g (0.0129
mol)] in THF (15 mL) was added, at -78.degree. C., 1.7M t-Butyl
lithium [8.8 mL (0.014 mol)]. The reaction mixture was then stirred
at -78.degree. C. for 40 min and then treated with DMF [5 mL
(0.0645 mol)]. The mixture was then allowed to slowly come to room
temperature overnight and was then quenched with sat NH.sub.4Cl,
extracted with Et.sub.2O. The extract was dried (MgSO.sub.4) and
the solvent removed affording
5-benzyloxy-2-tert-butyl-4-methoxy-benzaldehyde. Yield=0.52 g (13%
used without further purification) MS (m/z): 299 [M+H]
##STR00155##
(E)-3-(5-Benzyloxy-2-tert-butyl-4-methoxy-phenyl)prop-2-enoic
Acid
[0236] A mixture of 5-benzyloxy-2-tert-butyl-4-methoxy-benzaldehyde
[0.520 g (0.0017 mol)], malonic acid [0.354 g (0.0034 mol)],
pyridine (3 mL) and piperidine (0.1 mL) was stirred at 80.degree.
C. for 1 h followed by stirring for 3 h at 115.degree. C. The
reaction was then poured into water (20 mL) and acidified with
conc. HCl. The resulting white ppt. was filtered and vacuum dried
affording the desired
(E)-3-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)prop-2-enoic acid.
Yield=0.6 g (quant) MS (m/z): 341 [M+H]
##STR00156##
(E)-3-(5-Benzyloxy-2-tert-butyl-4-methoxy-phenyl)-N-[2-(3-benzyloxy-4-met-
hoxy-phenyl)ethyl]prop-2-enamide
[0237] To a mixture of
(E)-3-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)prop-2-enoic acid
[163 mg (0.5 mmol)], 2-(3-benzyloxy-4-methoxy-phenyl)ethanamine
[129 mg (0.5 mmol)], DMF (2 mL) and DIEA [0.250 mL (1.4 mmol)] was
added HATU [238 mg (0.62 mmol)]. The reaction mix was stirred at
room temperature 2 h then diluted with 20 mL of EtOAc and washed
2.times. with sat. NaCl aq. The EtOAc layer was dried (MgSO.sub.4)
and the solvent removed affording
(E)-3-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)-N-[2-(3-benzyloxy-4-met-
hoxy-phenyl) ethyl] prop-2-enamide. Yield=225 mg (78% after flash
with 10% MeOH/DCM) MS (m/z): 580 [M+H]
##STR00157##
6-Benzyloxy-1-[(E)-2-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)vinyl]-7--
methoxy-3,4-dihydroisoquinoline
[0238] To a solution of
(E)-3-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)-N-[2-(3-benzyloxy-4-met-
hoxy-phenyl)ethyl]prop-2-enamide [225 mg (0.39 mmol)] in ACN (9 mL)
was added, under reflux, POCl.sub.3 [300 ul (3.21 mmol)]. The
reaction was stirred at reflux for 10 min and then rotary
evaporated to dryness. The residue was taken up into 10 mL of
chloroform and was then treated with 20 mL of 2N KOH and 50 mL of
Et.sub.2O. This mixture was rapidly stirred for 30 min at room
temperature and the upper organic layer removed, washed with water,
dried (Na.sub.2SO.sub.4) and the solvent removed. Yield=205 mg
crude: A 50 mg fraction was removed and purified via reverse phase
preparatory chromatography affording 15 mg (23% yield) MS (m/z):
562 [M+H]
##STR00158##
6-Benzyloxy-1-[(E)-2-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)vinyl]-7--
methoxy-1,2,3,4-tetrahydroisoquinoline
[0239] The crude
6-benzyloxy-1-[(E)-2-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)vinyl]-7--
methoxy-3,4-dihydroisoquinoline from the previous reaction (155 mg)
was the dissolved into 8 mL of dry EtOH and then treated with
NaBH.sub.4 [12 mg (0.32 mmol)]. The mixture was stirred for 1 h at
room temperature and the resulting solid was carefully filtered off
and dried. The solid was triturated with 50/50 ACN/water, filtered
and vacuum dried. Yield=50 mg (11% overall) MS (m/z): 564 [M+H]
Example K:
(2-Amino-3-pyridyl)-[6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methox-
y-2-methyl-phenyl)vinyl]-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]methano-
ne
##STR00159##
[0241] To a mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [50 mg (0.097 mmol)],
2-aminopyridine-3-carboxylic acid [13.8 mg (0.1 mmol)], DIEA [50 ul
(0.3 mmol)] and 1 mL of DMF was added HATU [47.5 mg (0.125 mmol)].
The reaction was stirred at rt for 1 h and then diluted with 20 mL
of EtOAc and washed 2.times. with sat NaCl. The EtOAc layer was
dried (Na.sub.2SO.sub.4) and the solvent removed. Yield=24 mg (39%)
via prep chrom MS (m/z): 642 [M+H]
Example L: Methyl
6-benzyloxy-1-[(E)-2-(3-benzyloxy-4-methoxy-phenyl)vinyl]-7-methoxy-3,4-d-
ihydro-1H-isoquinoline-2-carboxylate
##STR00160##
[0243] To the solution of
(E)-6-(benzyloxy)-1-(3-(benzyloxy)-4-methoxystyryl)-7-methoxy-1,2,3,4-tet-
rahydroisoquinoline (51.4 mg, 0.083 mmol) in anhydrous
1,2-dichloroethane (3 mL) was added DIPEA (0.5 mL) followed by
methyl chloroformate (33 micromL, 0.43 mmol). The resulting
solution was stirred at room temperature overnight. It was
concentrated to dryness and purified on the Shimadzu HPLC system to
afford the TFA salt. M+H (Neutral)=566.
Example M:
[6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vi-
nyl]-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-(2-pyridyl)methanone
##STR00161##
[0245] To a mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [50 mg (0.097 mmol)], Picolinic
acid [12.4 mg (0.1 mmol)], DIEA [50 ul (0.3 mmol)] & 1 mL of
DMF was added HATU [47.5 mg (0.125 mmol)]. The reaction was stirred
at rt for 1 h and then diluted with 20 mL of EtOAc and washed
2.times. with sat NaCl. The EtOAc layer was dried
(Na.sub.2SO.sub.4) and the solvent removed. Yield=42 mg (58%) via
prep chrom. MS (m/z): 627 [M+H]
Example N:
(2-amino-4-pyridyl)-[6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methox-
y-2-methyl-phenyl)vinyl]-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]methano-
ne
##STR00162##
[0247] To a mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [50 mg (0.097 mmol)],
2-aminopyridine-4-carboxylic acid[13.8 mg (0.1 mmol)], DIEA [50 ul
(0.3 mmol)] & 1 mL of DMF was added HATU [47.5 mg (0.125
mmol)]. The reaction was stirred at rt for 1 h and then diluted
with 20 mL of EtOAc and washed 2.times. with sat NaCl. The EtOAc
layer was dried (Na.sub.2SO.sub.4) and the solvent removed.
Yield=28 mg (46%) via prep chrom. MS (m/z): 642 [M+H]
Example O:
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vin-
yl]-N-tert-butyl-7-methoxy-3,4-dihydro-1H-isoquinoline-2-carboxamide
##STR00163##
[0249] A mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [50 mg (0.1 mmol)] and 2 mL of
DCM was treated with t-Butylisocyanate [14 .mu.l (0.12 mmol)] and
stirred at room temperature for 1 h. The mixture was diluted with
10 mL of DCM and washed with water. The DCM layer was dried
(Na.sub.2SO.sub.4) then filtered and the filtrate rotary evaporated
to dryness. Yield=13 mg (21% yield) via prep chrom. MS (m/z): 621
[M+H]
Example P:
(6-amino-3-pyridyl)-[6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methox-
y-2-methyl-phenyl)vinyl]-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]methano-
ne
##STR00164##
[0251] To a mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [50 mg (0.097 mmol)],
6-aminopyridine-3-carboxylic acid [13.8 mg (0.1 mmol)], DIEA [50 ul
(0.3 mmol)] and 1 mL of DMF was added HATU [47.5 mg (0.125 mmol)].
The reaction was stirred at rt for 1 h and then diluted with 20 mL
of EtOAc and washed 2.times. with sat NaCl. The EtOAc layer was
dried (Na.sub.2SO.sub.4) and the solvent removed. Yield=30 mg (49%)
via prep chrom. MS (m/z): 642 [M+H]
Example Q:
6-benzyloxy-1-[2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)ethyl]--
7-methoxy-1,2,3,4-tetrahydroisoquinoline
##STR00165##
[0253] A mixture of
6-benzyloxy-1-[(E)-2-(3-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [100 mg (0.1919 mmol)] and 10 mg
of PtO.sub.2 in 10 mL of 50/50 THF/EtOH was rapidly stirred,
evacuated and filled with H.sub.2 gas 3.times.. The reaction mix
was then stirred under positive H.sub.2 pressure using a balloon
for 2 h, then filtered and the filtrate rotary evaporated to
dryness.
[0254] Yield=44.6 mg (45% yield) via prep chrom. MS (m/z): 524
[M+H]
Example R:
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vin-
yl]-7-methoxy-3,4-dihydro-1H-isoquinoline-2-carboxamide
##STR00166##
[0256] A mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [50 mg (0.1 mmol)] and 2 mL of
DCM was treated with TMS-Isocyanate [13 mg (0.11 mmol)] and stirred
at room temperature for 1 h. The mixture was diluted with 10 mL of
DCM and washed with water. The DCM layer was dried
(Na.sub.2SO.sub.4) then filtered and the filtrate rotary evaporated
to dryness. Yield=38.1 mg (70% yield) Triturated from ACN/Water. MS
(m/z): 565 [M+H]
Example S:
7-benzyloxy-1-[(E)-2-(4-benzyloxy-3-methoxy-phenyl)vinyl]-6-met-
hoxy-1,2,3,4-tetrahydroisoquinoline
##STR00167##
[0257] (E)-1-(Benzyloxy)-2-methoxy-4-(2-nitrovinyl)benzene
[0258] 4-Benzyloxy-3-methoxyphenethylamine was prepared according
to Schrittweieser. J. H, et, J.O.C. 2011, 76, 6703-6714. A solution
of 4-(benzyloxy)-3-methoxybenzaldehyde (25 g, 103.2 mmol),
nitromethane (18 mL, 333.2 mmol) and NH.sub.4OAc (20.23 g, 262.5
mmol) in AcOH (220 mL) was refluxed for 5 hr. After cooling it was
poured into ice-water (300 mL), followed by addition
CH.sub.2Cl.sub.2 (200 mL) stirred at room temperature until the
phases were separated. The aqueous phase was extracted with the
CH.sub.2Cl.sub.2 (3.times.100 mL). The combined organics were
washed with water (200 mL), saturated NaHCO.sub.3 (200 mL), brine
(200 mL), dried (Na.sub.2SO.sub.4), filtered and concentrated to
afford a brownish solid which was recrystallized from ethanol to
afford the desired compound in 68% yield.
2-(4-(Benzyloxy)-3-methoxyphenyl)ethanamine
[0259] To a suspension of LiAlH.sub.4 (8 g, 210 mmol) in anhydrous
THF (120 mL) under argon was added dropwise a solution of the
4-benzyloxy-3-methoxy-beta-nitrostyrene (11.51 g, 40.34 mmol) in
THF (80 mL) over 1 hr. After the addition, the resulting mixture
was stirred and heated to reflux for 16 hr, then diluted with THF
(100 mL), cooled (0.degree. C.) ice-bath. To the vigorously stirred
mixture was added water (8 mL), 15% NaOH (8 mL) and water (24 mL).
The ice-bath was removed, the stirring was continued for 1 hr at
room temperature. The resulting suspension was filtered through a
celite pad washed with THF. The combined washings and filtrate were
concentrated to dryness. The residue obtained was dissolved in 10%
HCl (20 mL) washed with ether, basified and extracted with EtOAc
(3.times.100 mL). The combined organics were washed with water,
brine, dried (K.sub.2CO.sub.3), filtered and concentrated to
dryness to afford 8 g of 4-benzyloxy-3-methoxyphenethylamine as a
yellowish oil. M+H=258.
(E)-3-(4-(Benzyloxy)-3-methoxyphenyl)acrylic Acid
[0260] The (E)-3-(4-(benzyloxy)-3-methoxyphenyl)acrylic acid was
prepared by the Knoevenagel condensation reaction (Kaushik. M. et.
al. J. of Molecular Catalysis B; Enzymatic 82 (2912) 92-95. A
mixture of 4-(benzyloxy)-3-methoxybenzaldehyde (14.54 g, 60.02
mmol), malonic acid (12.5 g, 120 mmol), pyridine (40 mL) and
piperidine (1 mL, 10.12 mmol) was stirred and heated to 85.degree.
C. for 1 hr and refluxed 115.degree. C. for an additional 5 hr. The
mixture was poured into water and acidified with conc HCl. The
precipitate was collected washed with cold water. The white solid
residue was dissolved in NaOH, diluted with water, acidified again,
the white solid precipitate was collected washed several times with
water, and dried over P.sub.2O.sub.5 under high vacuum
overnight.
(E)-N-(4-(Benzyloxy)-3-methoxyphenethyl)-3-(4-(benzyloxy)-3-methoxyphenyl)-
acrylamide
[0261] To the mixture of
(E)-3-(4-benzyloxy)-3-methoxyphenyl)acrylic acid (5.16 g, 18.15
mmol), 2-(4-(benzyloxy-3-methoxyphenyl)ethanamine (5.6 g, 21.76
mmol), HATU (8.3 g, 21.83 mmol) in anhydrous DMF (100 mL) was added
DIPEA (16 mL, 91.85 mmol). The resulting mixture was stirred at
room temperature for 2 hr, diluted with EtOAc (500 mL), washed
sequentially with water, brine, dried (Na.sub.2SO.sub.4), filtered,
concentrated and purified by flash chromatography using
MeOH/CHCl.sub.3 gradient to afford the titled compound in 60%
yield. M+H=524.
##STR00168##
(E)-7-(Benzyloxy)-1-(4-(benzyloxy)-3-methoxystyryl)-6-methoxy-1,2,3,4-tet-
rahydroisoquinoline
[0262] The mixture of
(E)-N-(benzyloxy)-3-methoxyphenethyl)-3-(4-(benzyloxy)-3-methoxyphenyl)ac-
rylamide (1.7 g, 3.25 mmol) and anhydrous acetonitrile (60 mL) was
stirred and heated to reflux, POCl.sub.3 (2.2 mL, 23.60 mmol) was
added dropwise. After the addition, the resulting reddish solution
was stirred and heated to reflux for 1 hr, and concentrated to
dryness. The residue was taken up EtOAc (100 mL), treated with 2M
KOH solution (20 mL), stirred rapidly for 1 hr. The organic layer
was washed with water, brine, dried over Na.sub.2SO.sub.4, filtered
and concentrated to dryness. To the residue obtained was added
NaBH4 (100 mg, 2.63 mmol), EtOH (35 mL) and stirred at room
temperature for 1 hr. The excess reagent was destroyed by dropwise
addition of 2M HCl, basified with 2M KOH and evaporated to dryness
to remove EtOH. The residue obtained was partitioned between water
and CHCl.sub.3, the organic layer was washed with brine, dried
(K.sub.2CO.sub.3), filtered, concentrated and purified by flash
chromatography using MeOH (NH.sub.3)/CHCl.sub.3 gradient to afford
the titled compound. M+H=508.
Example T:
[6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vi-
nyl]-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-(3-pyridyl)methanone
##STR00169##
[0264] To a mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [50 mg (0.097 mmol)], Nicotinic
acid [12.4 mg (0.1 mmol)], DIEA [50 ul (0.3 mmol)] & 1 mL of
DMF was added HATU [47.5 mg (0.125 mmol)]. The reaction was stirred
at rt for 1 h and then diluted with 20 mL of EtOAc and washed
2.times. with sat NaCl. The EtOAc layer was dried
(Na.sub.2SO.sub.4) and the solvent removed. Yield=62 mg (86%) via
prep chrom. MS (m/z): 627 [M+H]
Example U:
[6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vi-
nyl]-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-(4-pyridyl)methanone
##STR00170##
[0266] To a mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline) [25 mg (0.048 mmol)],
Isonicotinic acid [9 mg (0.072 mmol)], DIEA [42 ul (0.24 mmol)]
& 1 mL of DMF was added HATU [38 mg (0.1 mmol)]. The reaction
was stirred at rt for 1 h and then diluted with 20 mL of EtOAc and
washed 2.times. with sat NaCl. The EtOAc layer was dried
(Na.sub.2SO.sub.4) and the solvent removed. Yield=11.5 mg (38%) via
prep chrom. MS (m/z): 627 [M+H]
Example V:
6-benzyloxy-1-[(E)-2-(3-benzyloxy-4-methoxy-phenyl)vinyl]-7-met-
hoxy-2-methyl-3,4-dihydro-1H-isoquinoline
##STR00171##
[0268] A mixture of
(E)-6-(benzyloxy)-1-(3-(benzyloxy)-4-methoxystyryl)-7-methoxy-1,2,3,4-tet-
rahydroisoquinoline (0.4697 g, 0.93 mmol) and (0.4844 mL) of 38%
formalin with EtOH (10 mL) was stirred at room temperature for 1 hr
then treated with NaBH.sub.4 (0.372 g, 9.83 mmol) and stirred
overnight. The mixture was diluted with DCM (50 mL), washed with
brine, dried (Na.sub.2SO.sub.4), filtered, concentrated and
purified on the Shimadzu HPLC system to afford the TFA salt. M+H
(Neutral)=522.
Example W:
6-benzyloxy-7-methoxy-1-[(E)-2-(o-tolyl)vinyl]-1,2,3,4-tetrahyd-
roisoquinoline
##STR00172##
[0269]
(E)-6-(Benzyloxy)-7-methoxy-1-(2-methylstyryl)-1,2,3,4-tetrahydrois-
oquinoline
[0270] Title compound was prepared analogously as Example X using
(E)-3-o-tolylacrylic acid (0.4235 g, 2.61 mmol) and
2-(3-(benzyloxy)-4-methoxyphenyl)ethanamine (0.7392 g, 2.87 mmol)
via the HATU coupling, the imine formation, and NaBH.sub.4
reduction in EtOH/DCM mixture. M+H=386.
Example X:
6-benzyloxy-1-[(E)-2-(4-fluoro-2-methyl-phenyl)vinyl]-7-methoxy-
-1,2,3,4-tetrahydroisoquinoline
##STR00173##
[0271]
(E)-N-(3-(Benzyloxy)-4-methoxyphenethyl)-3-(4-fluoro-2-methylphenyl-
)acrylamide
[0272] The amide was formed from the
(E)-3-(4-fluoro-2-methylphenyl)acrylic acid (0.8 g, 4.88 mmol) and
the amine (1.63 g, 6.33 mmol) by the HATU coupling procedure.
(E)-6-(Benzyloxy)-1-(4-fluoro-2-methylstyryl)-7-methoxy-3,4-dihydroisoquin-
oline
[0273] The mixture of the amide (1.04 g, 2.48 mmol) in acetonitrile
(30 mL) was stirred and heated to reflux, POCl.sub.3 (1.6 mL, 17.17
mmol) was added dropwise, stirred for 1 hr and worked up as
usual.
(E)-6-(Benzyloxy)-1-(4-fluoro-2-methylstyryl)-7-methoxy-1,2,3,4-tetrahydro-
isoquinoline
[0274] The crude imine obtained was treated with NaBH.sub.4 (60 mg,
1.59 mmol) in EtOH (5 mL)/DCM 2 (mL), stirred at room temperature
for 1 hr, the solid precipitate was filtered off washed with 50/50
ACN/water and dried under high vacuum to afford the titled
compound. M+H=404.
Example Y: tert-butyl
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-3,4-dihydro-1H-isoquinoline-2-carboxylate
##STR00174##
[0276] To a mixture of
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline [100 mg (0.1919 mmol)] and
Di-t-butyl dicarbonate [42 mg (0.1919 mmol)] in 5 mL of DCM was
stirred at room temperature for 1 h then rotary evaporated to
dryness. Yield=25 mg (21% yield) via prep chrom. MS (m/z): 622
[M+H].
Example Z:
6-benzyloxy-7-methoxy-1-[(E)-2-[4-methoxy-2-(trifluoromethyl)ph-
enyl]vinyl]-1,2,3,4-tetrahydroisoquinoline
##STR00175##
[0277]
(E)-6-(Benzyloxy)-7-methoxy-1-(4-methoxy-2-(trifluoromethyl)styryl)-
-3,4-dihydroisoquinoline
[0278] To the mixture of
(E)-3-(4-methoxy-2-(trifluoromethyl)phenyl)acrylic acid (1.36 g,
5.52 mmol) prepared from the aldehyde by the usual Knoevenagel
condensation reaction (1.56 g, 6.06 mmol), HATU (2.30 g, 6.06 mmol)
in DMF (25 mL) was added DIPEA (4.8 mL, 27.56 mmol) and stirred at
room temperature for 2 hr. After workup, the crude was purified
with flash chromatography using EtOAc/Hexanes gradient to afford
the amide. The mixture of the amide (1.04 g, 2.14 mmol) and
acetonitrile (25 mL) was stirred and heated to reflux, POCl.sub.3
(1.4 mL, 15.02 mmol) was added dropwise, stirred and heated to
reflux for 1 hr. After the usual workup, ca 200 mg of the desired
product was purified on the Shimadzu HPLC to afford the TFA
salt.
(E)-6-(Benzyloxy)-7-methoxy-1-(4-methoxy-2-(trifluoromethyl)styryl)-1,2,3,-
4-tetrahydroisoquinoline
[0279] The remaining crude was treated with NaBH.sub.4 (51 mg, 1.35
mmol) in EtOH (25 mL) for 1 hr. After the usual workup it was
purified with flash chromatography using MeOH (NH.sub.3)/CHCl.sub.3
gradient to afford the titled compound. M+H=470.
Example AA:
6-benzyloxy-1-[(E)-2-(5-benzyloxy-2-ethyl-4-methoxy-phenyl)vinyl]-7-metho-
xy-1,2,3,4-tetrahydroisoquinoline
##STR00176##
[0280] 1-Benzyloxy-4-ethyl-2-methoxy-benzene
[0281] A mixture of 4-ethyl-2-methoxy-phenol [5.5 g (0.036 mol)],
Benzyl bromide [12.3 g (0.072 mol)], K.sub.2CO.sub.3 [10 g (0.072
mol) in 73 mL of ACN was refluxed overnight. The reaction mixture
was then rotary evaporated and the residue treated with water then
extracted with EtOAc. The extract was washed with sat. NaCl, dried
(MgSO.sub.4) and the solvent removed.
[0282] Yield=8.7 g (quant) MS (m/z): 243 [M+H]
##STR00177##
(E)-3-(5-Benzyloxy-2-ethyl-4-methoxy-phenyl)prop-2-enoic Acid
[0283] The compound 1-benzyloxy-4-ethyl-2-methoxy-benzene [8.7 g
(0.036 mol)] was added to a mixture of POCl.sub.3 [20 mL (0.21
mol)] and DMF [17 g (0.22 mol)] with stirring at 0.degree. C. The
viscous mixture was then heated to 80.degree. C. and stirred there
for 4 h. The reaction mix was then poured onto ice and then
extracted with Et.sub.2O. The extract was dried (MgSO.sub.4) and
the solvent removed. Flash chrom. with 10% EtOAc/Hexane afforded
the desired aldehyde [3 g (0.011 mol)] 31% yield.
[0284] A mixture of the above aldehyde [3 g (0.011 mol)], malonic
acid [2.2 g (0.022 mol)], pyridine (7 mL) and piperidine (0.2 mL)
was stirred at 80.degree. C. for 1 h followed by stirring for 3 h
at 115.degree. C. The reaction was then poured into water (200 mL)
and acidified with conc. HCl. The resulting white ppt. was filtered
and vacuum dried. Yield=3.2 g (29% overall) MS (m/z): 313 [M+H]
##STR00178##
(E)-3-(5-Benzyloxy-2-ethyl-4-methoxy-phenyl)-N-[2-(3-benzyloxy-4-methoxy--
phenyl)ethyl]prop-2-enamide
[0285] To a mixture of
(E)-3-(4,5-dimethoxy-2-ethyl-phenyl)prop-2-enoic acid [393 mg (1.7
mmol)], 2-(3-benzyloxy-4-methoxy-phenyl)ethanamine[257 mg (1
mmol)], DMF (10 mL) and DIEA (1 mL (6 mmol) was added HATU [950 mg
(2.5 mmol)]. The reaction mix was stirred at room temperature 2 h
then diluted with 50 mL of EtOAc and washed 2.times. with sat. NaCl
aq. The EtOAc layer was dried (MgSO.sub.4) and the solvent removed.
Yield=310 mg (54% after flash with 10% MeOH/DCM) MS (m/z): 552
[M+H]
##STR00179##
6-Benzyloxy-1-[(E)-2-(5-benzyloxy-2-ethyl-4-methoxy-phenyl)vinyl]-7-metho-
xy-1,2,3,4-tetrahydroisoquinoline
[0286] To a solution of
(E)-3-(5-benzyloxy-2-ethyl-4-methoxy-phenyl)-N-[2-(3-benzyloxy-4-methoxy--
phenyl)ethyl]prop-2-enamide [310 mg (0.563 mmol)] in ACN (13 mL)
was added, under reflux, POCl.sub.3 [361 ul (3.9 mmol)]. The
reaction was stirred at reflux for 10 min and then rotary
evaporated to dryness. The residue was taken up into 10 mL of
chloroform and was then treated with 20 mL of 2N KOH and 50 mL of
Et.sub.2O. This mixture was rapidly stirred for 30 min at room
temperature and the upper organic layer removed, washed with water,
dried (Na.sub.2SO.sub.4) and the solvent removed. The dark oil was
the dissolved into 8 mL of dry EtOH and then treated with
NaBH.sub.4 [15 mg (0.395 mmol)]. The mixture was stirred for 1 h at
room temperature and the resulting solid was carefully filtered off
and dried. The solid was triturated with 50/50 ACN/water, filtered
and vacuum dried. Yield=150 mg (50% overall) MS (m/z): 536
[M+H]
Example AB:
6-benzyloxy-1-[(E)-2-(3-benzyloxy-4-methoxy-phenyl)vinyl]-7-methoxy-1,2,3-
,4-tetrahydroisoquinoline
##STR00180##
[0287] 2-(3-(Benzyloxy)-4-methoxyphenyl)ethanamine
[0288] were prepared as described in detail above.
(E)-3-(3-(Benzyloxy)-4-methoxyphenyl)acrylic acid
[0289] were prepared as described in detail above.
(E)-N-(3-(Benzyloxy)-4-methoxyphenethyl)-3-(3-(benzyloxy)-4-methoxyphenyl)-
acrylamide
[0290] To the mixture of
(E)-3-(3-(benzyloxy)-4-methoxyphenyl)acrylic acid (3.3 g, 11.61
mmol), 2-(3-(benzyloxy)-4-methoxyphenyl)ethanamine (4.45 g, 17.30
mmol) and HATU (6.58 g, 17.31 mmol) in DMF (100 mL) was added DIPEA
(10 mL, 57.41 mmol). The resulting solution was stirred at room
temperature for 2 hrs, diluted with EtOAc (300 mL), washed with
brine, dried (Na.sub.2SO.sub.4), filtered, concentrated and
purified by flash chromatography using MeOH (NH.sub.3)/CHCl.sub.3
gradient to afford 10 in 50% yield. M+H=524.
(E)-6-(Benzyloxy)-1-(3-(benzyloxy)-4-methoxystyryl)-7-methoxy-1,2,3,4-tetr-
ahydroisoquinoline
[0291] The mixture of
(E)-N-(3-(benzyloxy)-4-methoxyphenethyl)-3-(3-(benzyloxy)-4-methoxyphenyl-
)acrylamide (2.5 g, 4.77 mmol) and acetonitrile (90 mL) was stirred
and heated to reflux, POCl.sub.3 (3.3 mL, 35.40 mmol) was added
dropwise. The resulting reddish mixture was stirred and heated to
reflux for 1 hr and treated as described in detail for
(E)-7-(benzyloxy)-1-(4-(benzyloxy)-3-methoxystyryl)-6-methoxy-1,2,3,4-tet-
rahydroisoquinoline. The crude obtained was purified on the
Shimadzu HPLC system to afford the titled compound as the TFA salt.
M+H (Neutral)=508.
Example AC:
6-benzyloxy-1-[(E)-2-(5-benzyloxy-2-chloro-4-methoxy-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline
##STR00181##
[0292] 5-Benzyloxy-2-chloro-4-methoxy-benzaldehyde
[0293] A mixture of 3-benzyloxy-4-methoxy-benzaldehyde [5 g (0.021
mol)] and NCS [3.4 g (0.0252 mol)] in 50 mL of DMF was heated to
70.degree. C. and stirred there for 3 h. After cooling water was
added and the resulting ppt. was filtered off and dried under high
vacuum. Yield=2 g (34%) after flash chrom with DCM/Hexane MS (m/z):
277 [M+H]
##STR00182##
(E)-3-(5-Benzyloxy-2-chloro-4-methoxy-phenyl)prop-2-enoic Acid
[0294] A mixture of 5-benzyloxy-2-chloro-4-methoxy-benzaldehyde [2
g (0.072 mol)], malonic acid [1.5 g (0.014 mol)], pyridine (4 mL)
and piperidine (0.150 mL) was stirred at 80.degree. C. for 1 h
followed by stirring for 3 h at 115.degree. C. The reaction was
then poured into water (200 mL) and acidified with conc. HCl. The
resulting white ppt., product, was filtered and vacuum dried
Yield=2.2 g (96%) MS (m/z): 319 [M+H]
##STR00183##
(E)-3-(5-Benzyloxy-2-chloro-4-methoxy-phenyl)-N-[2-(3-benzyloxy-4-methoxy-
-phenyl)ethyl]prop-2-enamide
[0295] To a mixture of
(E)-3-(5-benzyloxy-2-chloro-4-methoxy-phenyl)prop-2-enoic acid [318
mg (1 mmol)], 2-(3-benzyloxy-4-methoxy-phenyl)ethanamine 150 mg
(0.6 mmol)], DMF (5 mL) and DIEA [0.5 mL (3 mmol)] was added HATU
[475 mg (1.25 mmol)]. The reaction mix was stirred at room
temperature 2 h then diluted with 50 mL of EtOAc and washed
2.times. with sat. NaCl aq. The EtOAc layer was dried (MgSO.sub.4)
and the solvent removed. Yield=256 mg (74% after flash with 10%
MeOH/DCM) MS (m/z): 558 [M+H]
##STR00184##
6-Benzyloxy-1-[(E)-2-(5-benzyloxy-2-chloro-4-methoxy-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline
[0296] To a solution of
(E)-3-(5-benzyloxy-2-chloro-4-methoxy-phenyl)-N-[2-(3-benzyloxy-4-methoxy-
-phenyl)ethyl]prop-2-enamide [256 mg (0.46 mmol)] in ACN (9 mL) was
added, under reflux, POCl.sub.3 [300 ul (3.21 mmol)]. The reaction
was stirred at reflux for 10 min and then rotary evaporated to
dryness. The residue was taken up into 10 mL of chloroform and was
then treated with 20 mL of 2N KOH and 50 mL of Et.sub.2O. This
mixture was rapidly stirred for 30 min at room temperature and the
upper organic layer removed, washed with water, dried
(Na.sub.2SO.sub.4) and the solvent removed. The dark oil was the
dissolved in 8 mL of dry EtOH and then treated with NaBH.sub.4 [12
mg (0.32 mmol)]. The mixture was stirred for 1 h at room
temperature and the resulting solid was carefully filtered off and
dried. The solid was triturated with 50/50 ACN/water, filtered and
vacuum dried. Yield=126 mg (51% overall) MS (m/z): 542 [M+H]
Example AD:
6-benzyloxy-1-[(E)-2-(5-benzyloxy-2-methyl-phenyl)vinyl]-7-methoxy-1,2,3,-
4-tetrahydroisoquinoline
##STR00185##
[0297] 5-(Benzyloxy)-2-methylbenzaldehyde
[0298] 5-Hydroxy-2-methylbenzaldehyde (2.07 g, 15.20 mmol) was
combined with benzylbromide (2.71 mL, 22.8 mmol) and
Cs.sub.2CO.sub.3 (9.91 g, 30.4 mmol) in DMF (100 mL). The resulting
mixture was stirred at 80.degree. C. overnight. Upon consumption of
the starting material by TLC analysis, the reaction was allowed to
cool to room temperature. The organic solvent was removed under
reduced pressure. The residue obtained was purified by flash
chromatography to afford the titled compound LCMS: M+1=227.3.
(E)-3-(5-(Benzyloxy)-2-methylphenyl)acrylic acid
[0299] 5-(Benzyloxy)-2-methylbenzaldehyde (3.00 g, 13.26 mmol) was
dissolved in pyridine (50 mL) along with malonic acid (2.78 g,
26.52 mmol) and a catalytic amount of piperidine (0.35 mL). The
resulting mixture was heated at reflux for 18 hours, then the
reaction mixture was allowed to cool to room temperature. The
reaction was poured into ice cold 1M H.sub.3PO.sub.4 (100 mL) and
the resulting mixture was stirred for 10 minutes, the solid
precipitate was filtered, washed with water and dried over
P.sub.2O.sub.5 overnight. LCMS: M+1=269.3.
(E)-4-(Benzyloxy)-2-(2-bromovinyl)-1-methylbenzene
[0300] The solution of (E)-3-(5-(benzyloxy)-2-methylphenyl)acrylic
acid (1.00 g, 3.73 mmol) in CH.sub.2Cl.sub.2 (20 mL) with Et.sub.3N
(0.025 mL, 0.184 mmol) was stirred for 5 minutes. To this solution
was added NBS (809 mg, 4.42 mmol) portionwise, as the reaction gave
off CO.sub.2 gas. After all the additions the reaction mixture was
stirred overnight. Additional NBS (809 mg, 4.42 mmol) was added and
the mixture stirred for another 18 hours. Upon complete reaction by
TLC indication, it was purified by flash silica gel chromatography
to furnish the tilted compound.
(E)-6-(Benzyloxy)-1-(5-(benzyloxy)-2-methylstyryl)-7-methoxy-1,2,3,4-tetra-
hydroisoquinoline
[0301] A solution of
(E)-4-(benzyloxy)-2-(2-bromovinyl)-1-methylbenzene (303 mg, 1 mmol)
was dissolved in dry Et.sub.2O (15 mL) and cooled to -78.degree. C.
A solution of t-BuLi (1.3 mL, 2.2 mmol, 1.7M in pentane) was added
dropwise and the resulting solution was stirred at -78.degree. C.
for 1 hour before a solution of
6-(benzyloxy)-7-methoxy-3,4-dihydroisoquinoline (134 mg, 0.5 mmol)
in THF (3 mL) was added dropwise. The resulting mixture was stirred
for 2 hours at -78.degree. C. and then quenched with sat. aqueous
NH.sub.4Cl solution. The mixture was extracted with EtOAc and the
combined organic layers were dried over MgSO.sub.4, filtered and
evaporated to dryness. The residue obtained was purified by flash
silica gel chromatography to afford the tiled compound. LCMS:
M+1=492.6.
Examples AE/AF:
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-3,4-dihydroisoquinoline and
6-benzyloxy-1-[(E)-2-(5-benzyloxy-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline
##STR00186##
[0302] O-Benzylisovanillin
[0303] A mixture of isovanillin (10.0 g, 66 mmol), benzyl chloride
(16.7 g, 15.2 mL, 131 mmol), and anhydrous K.sub.2CO.sub.3 (6.4 g,
46 mmol) in EtOH (100 mL) was refluxed for 5 h. After being
stirred, the reaction mixture was concentrated to dryness and
redissolved in 100 mL of CH.sub.2Cl.sub.2, and then 5% aqueous NaOH
(3.times.50 mL) was added. The organic layer was washed with brine
(2.times.50 mL) and H.sub.2O (2.times.50 mL), dried with anhydrous
Na.sub.2SO.sub.4, and evaporated to dryness. Needles were obtained
after crystallization from MeOH/CH.sub.2Cl.sub.2 corresponding to
O-benzylisovanillin (3-benzyloxy-4-methoxybenzaldehyde, 15 g,
94%).
3-Benzyloxy-4-methoxy-.beta.-nitrostyrene
[0304] A mixture of O-benzylisovanillin (15.0 g, 61.9 mmol),
nitromethane (11.34 g, 10.0 mL, 186 mmol), and NH.sub.4OAc (11.9 g,
155 mmol) in AcOH (100 mL) was refluxed for 4 h. After cooling, the
mixture was diluted with H.sub.2O (100 mL) and extracted with
CH.sub.2Cl.sub.2 (3.times.30 mL). The organic solution was washed
with brine (2.times.50 mL) and H.sub.2O (2.times.30 mL), dried with
anhydrous Na.sub.2SO.sub.4 and evaporated to dryness. Yellow
needles were obtained after recrystallization from EtOH affording
the 3-benzyloxy-4-methoxy-a-nitrostyrene (15.4 g, 87%).
.beta.-(3-Benzyloxy-4-methoxyphenyl)ethylamine
[0305] A solution of 3-benzyloxy-4-methoxy-.beta.-nitrostyrene
(11.1 g, 39 mmol) in 150 mL of anhydrous THF was added dropwise to
a vigorously stirred suspension of LiAlH.sub.4 (5.9 g, 156 mmol) in
120 mL of anhydrous Et.sub.2O under nitrogen atmosphere and was
refluxed for 16 h. After the solution was cooled, the excess
reagent was destroyed by dropwise addition of H.sub.2O and 15%
aqueous NaOH. After partial evaporation of the filtered portion,
the aqueous solution was extracted with CH.sub.2Cl.sub.2
(3.times.50 mL) and the organic layers were treated with 5% aqueous
HCl. The resulting aqueous acid layer was made basic (5% aqueous
NH.sub.4OH, pH 9) and extracted with CH.sub.2Cl.sub.2. The organic
solution was washed with brine (2.times.50 mL) and H.sub.2O
(2.times.50 mL), dried with anhydrous K.sub.2CO.sub.3, and
evaporated to dryness, to afford
.beta.-(3-benzyloxy-4-methoxyphenyl) ethylamine (6.8 g, 69%) as an
oil.
##STR00187##
1-(Benzyloxy)-2-methoxy-4-methylbenzene
[0306] To a solution of 2-methoxy-4-methylphenol (10.0 g, 72.4
mmol) in 145 mL of CH.sub.3CN was added K.sub.2CO.sub.3 (20.0 g,
145 mmol) and benzyl bromide (24.8 g, 145 mmol). The resulting
mixture was refluxed for 18 h and the solvent was removed with a
rotary evaporator. The residue was treated with H.sub.2O and
extracted with EtOAc (3.times.50 mL). The combined organic extracts
were washed with brine, dried over MgSO4, and concentrated in
vacuo. The residue was purified by silica gel flash column
chromatography (10% EtOAc/hexanes) to yield
1-(benzyloxy)-2-methoxy-4-methylbenzene (16.2 g, 98%).
5-Benzyloxy-4-methoxy-2-methylbenzaldehyde
[0307] To a mixture of POCl.sub.3 (60.9 g, 397 mmol) and DMF (29.0
g, 397 mmol) at 0.degree. C. was added
1-(benzyloxy)-2-methoxy-4-methylbenzene (15.1 g, 66 mmol). The
resulting solution was heated to 80.degree. C. and stirred for 4 h.
After being cooled to room temperature, the reaction mixture was
poured into ice and extracted with ether. The combined extracts
were concentrated in vacuo and purified by silica gel flash column
chromatography (10% EtOAc/hexanes) to afford benzaldehyde 10 (12.0
g, 71%) as a white solid.
2-Methyl-4-methoxy-5-benzyloxycinnamic Acid
[0308] 5-Benzyloxy-4-methoxy-2-methylbenzaldehyde (13.5 g, 52.7
mM), malonic acid (11.0 g, 105.4 mM), pyridine (30 mL), and
piperidine (0.9 g, 1.0 mL, 11 mmol) were mixed well, heated to
80-85.degree. C. for 1 h and finally refluxed (110-115.degree. C.)
for an additional 3 h. The reaction mixture was poured into water
and acidified with concentrated HCl. The precipitate obtained was
filtered, and washed with cold water repeatedly. The residue was
dissolved in NaOH, diluted, again acidified, the precipitate was
collected washed with cold water and dried under high vacuum over
P.sub.2O.sub.5 and used without further purifications.
##STR00188##
(E)-3-(5-(Benzyloxy)-4-methoxy-2-methylphenyl)-N-(3-(benzyloxy)-4-methoxy-
phenethyl)acrylamide
[0309] To the stirred solution of the
2-methyl-4-methoxy-5-benzyloxycinnamic acid (3.0 g, 10.0 mmol) and
.beta.-(3-benzyloxy-4-methoxyphenyl)ethylamine (2.6 g, 10.0 mmol)
in DMF (40 mL) was added HATU (5.7 g, 15 mmol) followed by
diisopropylethylamine (1.95 g, 2.6 mL, 15.0 mmol). The reaction
mixture was stirred at room temperature for 1 h. The solution was
diluted with EtOAc (50 mL), washed with 10% citric acid, saturated
aqueous solution of NaHCO.sub.3, dried (Na.sub.2SO.sub.4), filtered
and was purified by flash chromatography Yield 3.5 g (65%).
(E)-6-(benzyloxy)-1-(5-(benzyloxy)-4-methoxy-2-methylstyryl)-7-methoxy-3,4-
-dihydroisoquinoline and
(E)-6-(Benzyloxy)-1-(5-(benzyloxy)-4-methoxy-2-methylstyryl)-7-methoxy-1,-
2,3,4-tetrahydroisoquinoline
[0310] The amide (200 mg, 0.37 mmol) was suspended in dry
acetonitrile (10 mL). The stirred mixture was heated to reflux.
Then phosphorus oxychloride (400 mg, 0.24 mL, 2.6 mmol) was added
drop wise. The reflux was continued for a further 1 h. The solution
was evaporated thoroughly to dryness under high vacuum to remove
the excess of POCI.sub.3. The residue was dissolved in chloroform
(10 mL), shaken with 2M KOH (10 mL) and ether (20 mL). The
separated upper layer was washed with water (2.times.10 mL) and
evaporated in vacuo to give an oil. A portion of the material was
purified and isolated as Example AE. The remaining material was
dissolved in ethanol (8 mL) sodium borohydride (9.8 mg, 0.26 mmol)
was added. The mixture was stirred at room temperature for 30 min.
The excess reagent was destroyed by dropwise addition of 2M HCl.
The reaction mixture was basified with 2M NaOH. Most of the ethanol
was removed in vacuo. The residue was partitioned between water (10
mL) and chloroform (10 mL). The organic layer was washed with water
(2.times.10 mL). The solvent was removed in vacuo. The residue was
purified by column chromatography to afford the titled isoquinoline
(0.12 g, 62%).
Example AG:
6-benzyloxy-7-methoxy-1-[(E)-2-(4-methoxy-2-methyl-phenyl)vinyl]-1,2,3,4--
tetrahydroisoquinoline
##STR00189##
[0311] (E)-3-(4-Methoxy-2-methylphenyl)acrylic Acid
[0312] 4-Methoxy-2-methylbenzaldehyde (5.0 g, 33.3 mmol) was
dissolved in pyridine (14 mL) along with malonic acid (6.93 g,
66.58 mmol) and a catalytic amount of piperidine (0.5 mL). The
resulting mixture was heated at reflux for 18 hours. After the
starting material was consumed, the reaction mixture was allowed to
cool to room temperature. The reaction was poured into ice cold 1M
H.sub.3PO.sub.4 (100 mL) and the resulting mixture was stirred for
10 minutes and the solid was filtered off. The solid was washed
with water and dried over P.sub.2O.sub.5 overnight. LCMS:
M+1=193.2
(E)-1-(2-Bromovinyl)-4-methoxy-2-methylbenzene
[0313] The (E)-3-(4-methoxy-2-methylphenyl)acrylic acid (1.93 g,
10.06 mmol) was stirred in CH.sub.2Cl.sub.2 (30 mL) along with
Et.sub.3N (0.069 mL, 0.502 mmol) for 5 minutes. To this solution
was added NBS (2.14 g, 12.04 mmol) in portions, as the reaction
gave off CO.sub.2 gas. The reaction mixture was allowed to stir
overnight. After TLC analysis indicated complete reaction it was
purified by flash silica gel chromatography to afford (1.95 g) of a
solid.
(E)-6-(Benzyloxy)-7-methoxy-1-(4-methoxy-2-methylstyryl)-1,2,3,4-tetrahydr-
oisoquinoline
[0314] A solution of (E)-1-(2-bromovinyl)-4-methoxy-2-methylbenzene
(228 mg, 1 mmol) was dissolved in dry Et.sub.2O (15 mL) and cooled
to -78.degree. C. A solution of t-BuLi (1.3 mL, 2.2 mmol, 1.7M in
pentane) was added dropwise and the resulting solution was stirred
at -78.degree. C. for 1 hour before a solution of
6-(benzyloxy)-7-methoxy-3,4-dihydroisoquinoline (134 mg, 0.5 mmol)
in THF (3 mL) was added dropwise. The resulting mixture was stirred
for 2 hours at -78.degree. C. and then quenched with sat. aqueous
NH.sub.4Cl solution. The mixture was extracted with EtOAc and the
combined organic layers were dried over MgSO.sub.4, filtered and
evaporated to dryness. The residue obtained was purified by flash
silica gel chromatography to afford the titled compound. LCMS:
M+1=416.6.
Example AH:
6-benzyloxy-1-[(E)-2-(4,5-dimethoxy-2-methyl-phenyl)vinyl]-7-methoxy-1,2,-
3,4-tetrahydroisoquinoline
##STR00190##
[0315] (E)-3-(4,5-Dimethoxy-2-methyl-phenyl)prop-2-enoic Acid
[0316] The compound 1,2-dimethoxy-4-methyl-benzene [25 g (0.164
mol)] was added to a mixture of POCl.sub.3 [151 g (0.987 mol)] and
DMF [73 g (1 mol)] with stirring at 0.degree. C. The viscous
mixture was then heated to 80.degree. C. and stirred there for 4 h.
The reaction mix was then poured onto ice and then extracted with
Et.sub.2O. The extract was dried (MgSO.sub.4) and the solvent
removed. Flash chrom. with 10% EtOAc/Hexane afforded the desired
aldehyde [26 g (0.144 mol)] 88% yield.
[0317] A mixture of the above aldehyde [5.4 g (0.03 mol)], malonic
acid [6.24 g (0.06 mol)], pyridine (20 mL) and piperidine (0.5 mL)
was stirred at 80.degree. C. for 1 h followed by stirring for 3 h
at 115.degree. C. The reaction was then poured into water (200 mL)
and acidified with conc. HCl. The resulting white ppt. was filtered
and vacuum dried. Yield=4.8 g (63% overall) MS (m/z): 223 [M+H]
##STR00191##
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(4,5-dimethoxy-2-methyl-p-
henyl)prop-2-enamide
[0318] To a mixture of
(E)-3-(4,5-dimethoxy-2-methyl-phenyl)prop-2-enoic acid [444 mg (2
mmol)], 2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [300 mg (1.2
mmol)], DMF (10 mL) and DIEA (1 mL (6 mmol) was added HATU [950 mg
(2.5 mmol)]. The reaction mix was stirred at room temperature 2 h
then diluted with 50 mL of EtOAc and washed 2.times. with sat. NaCl
aq. The EtOAc layer was dried (MgSO.sub.4) and the solvent removed.
Yield=300 mg (54% after flash with 10% MeOH/DCM) MS (m/z): 462
[M+H]
##STR00192##
6-Benzyloxy-1-[(E)-2-(4,5-dimethoxy-2-methyl-phenyl)vinyl]-7-methoxy-1,2,-
3,4-tetrahydroisoquinoline
[0319] To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(4,5-dimethoxy-2-methyl-p-
henyl)prop-2-enamide [300 mg (0.651 mmol)] in ACN (13 mL) was
added, under reflux, POCl.sub.3 [417 ul (4.5 mmol)]. The reaction
was stirred at reflux for 10 min and then rotary evaporated to
dryness. The residue was taken up into 10 mL of chloroform and was
then treated with 20 mL of 2N KOH and 50 mL of Et.sub.2O. This
mixture was rapidly stirred for 30 min at room temperature and the
upper organic layer removed, washed with water, dried
(Na.sub.2SO.sub.4) and the solvent removed. The dark oil was the
dissolved into 8 mL of dry EtOH and then treated with NaBH.sub.4
[17 mg (0.447 mmol)]. The mixture was stirred for 1 h at room
temperature and the resulting solid was carefully filtered off and
dried. The solid was triturated with 50/50 ACN/water, filtered and
vacuum dried. Yield=124 mg (44% overall) MS (m/z): 446 [M+H]
Example AI:
(E)-6-(benzyloxy)-7-methoxy-1-(4-methoxy-2-(4-methoxybutoxy)styryl)-1,2,3-
,4-tetrahydroisoquinoline
##STR00193##
[0321] To the solution of 2-hydroxy-methoxybenzaldehyde 1 (1.0 g,
6.57 mmol) in anhydrous acetonitrile (20 ml) under argon was added
Cs.sub.2CO.sub.3 (2.14 g, 6.58 mmol), the resulting mixture was
stirred at room temperature for 30 mins, then
1-bromo-4-methoxybutane 2 (1.1 g, 6.58 mmol) was added. The
resulting mixture was stirred at room temperature overnight. The
volatiles were removed, partitioned between water and EtOAc. The
organic layer was washed with brine, dried (Na.sub.2SO.sub.4),
filtered, concentrated to dryness and purified on the ISCO using
EtOAc/Hexanes gradient to afford
4-methoxy-2-(4-methoxybutoxy)benzaldehyde 3. The
(E)-3-(4-methoxy-2-(4-methoxybutoxy)phenyl)acrylic acid 5 was
prepared by the Knoevenagel condensation reaction as described in
detail in the first patent writeup.
[0322] To the mixture of 5 (0.9542 g, 3.40 mmol),
2-(3-(benzyloxy)-4-methoxyphenyl)ethanamine hydrochloride 6 (1.2 g,
4.085 mmol), HATU (1.55 g, 4.085 mmol) in anhydrous DMF (25 ml) was
added DIEA (5 ml, 28.70 mmol). The resulting mixture was stirred at
room temperature for 2 hrs, diluted with EtOAc and washed with
brine. The organic layer was dried (Na.sub.2SO.sub.4), filtered,
concentrated and purified on the ISCO using EtOAc/Hexanes gradient
to furnish the acrylamide 7. To the mixture of the acrylamide in
anhydrous acetonitrile (60 ml) was added POCl.sub.3 (5 ml, 53.64
mmol), stirred and heated to reflux monitored by LCMS. Ca 1 hr, the
reaction was worked up as described in detail on the first patent
writeup. NaBH.sub.4 reduction of the imine in EtOH afforded the
titled compound. M+H=504.
Example AJ:
(E)-6-(benzyloxy)-7-methoxy-1-(2-methyl-4-(trifluoromethoxy)styryl)-1,2,3-
,4-tetrahydroisoquinoline
##STR00194##
[0324] To the mixture of the acrylamide 9 (1.0 g, 2.06 mmol)
obtained by the HATU coupling of 8 and 9 described in detail in
Example AI, in anhydrous acetonitrile (25 ml), was stirred and
heated to reflux, to the solution was added POCl.sub.3 (2 ml). The
reaction was carried out as described in details in the provisional
writeup. The imine obtained was subjected to the NaBH.sub.4
reduction in EtOH. After the usual workup, the crude obtained was
purified by HPLC to afford the titled compound as the TFA salt.
M+H=470, M+H+TFA=584.
Example AK:
6-benzyloxy-7-methoxy-1-[(E)-2-(2-methylpyrazol-3-yl)vinyl]-1,2,3,4-tetra-
hydroisoquinoline
##STR00195##
[0326] (E)-3-(2-Methylpyrazol-3-yl)prop-2-enoic acid: A mixture of
2-methylpyrazole-3-carbaldehyde [0.286 g (0.0026 mol)], malonic
acid [0.53 g (0.0052 mol)], pyridine (5 mL) and piperidine (0.050
mL) was stirred at 80.degree. C. for 1 h followed by stirring for 3
h at 115.degree. C. The reaction was then poured into water (100
mL) and acidified with conc. HCl. The resulting white ppt.,
product, was filtered and vacuum dried. Yield=395 mg (99%) MS
(m/z): 153 [M+H]
##STR00196##
[0327]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(2-methylpyrazol-3--
yl)prop-2-enamide: To a mixture of
(E)-3-(2-Methylpyrazol-3-yl)prop-2-enoic acid [304 mg (2 mmol)],
2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [514 mg (2 mmol)], DMF
(8 mL) and DIEA [1 mL (6 mmol)] was added HATU [950 mg (2.5 mmol)].
The reaction mix was stirred at room temperature 2 h then diluted
with 50 mL of EtOAc and washed 2.times. with sat. NaCl aq. The
EtOAc layer was dried (MgSO.sub.4) and the solvent removed.
Yield=800 mg (99% after flash with 10% MeOH/DCM) MS (m/z): 392
[M+H]
##STR00197##
[0328]
6-Benzyloxy-7-methoxy-1-[(E)-2-(2-methylpyrazol-3-yl)vinyl]-1,2,3,4-
-tetrahydroisoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(2-methylpyrazol-3-yl)pro-
p-2-enamide [800 mg (2 mmol)] in ACN (30 ml) was added, under
reflux, POCl.sub.3 [1000 ul (11 mmol)]. The reaction was stirred at
reflux for 10 min and then rotary evaporated to dryness. The
residue was taken up into 10 ml of chloroform and was then treated
with 20 ml of 2N KOH and 50 ml of Et.sub.2O. This mixture was
rapidly stirred for 30 min at room temperature and the upper
organic layer removed, washed with water, dried (Na2SO4) and the
solvent removed. The dark oil was the dissolved into 24 ml of dry
MeOH and then treated with NaBH.sub.4 [60 mg (1.65 mmol)]. The
mixture was stirred for 1 h at room temperature. A light yellow
solid ppt'd out of solution, was filtered off, triturated with 0.1%
TFA and then dried in vacuo. Yield=500 mg (64%) as TFA salt. MS
(m/z): 376 [M+H]
Example AL:
6-Benzyloxy-1-[(E)-2-(1-ethylpyrazol-4-yl)vinyl]-7-methoxy-1,2,3,4-tetrah-
ydroisoquinoline
##STR00198##
[0330] (E)-3-(1-Ethylpyrazol-4-yl)prop-2-enoic acid: A mixture of
1-ethylpyrazole-4-carbaldehyde [0.322 g (2.6 mmol)], malonic acid
[0.530 g (5.2 mmol)], pyridine (5 mL) and piperidine (0.050 mL) was
stirred at 80.degree. C. for 1 h followed by stirring for 3 h at
115.degree. C. The reaction was then poured into water (100 mL) and
acidified with conc. HCl. The resulting white ppt., product, was
filtered and vacuum dried. Yield=436 mg (99%) MS (m/z): 169
[M+H]
##STR00199##
[0331]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(1-ethylpyrazol-4-y-
l)prop-2-enamide: To a mixture of
(E)-3-(1-Ethylpyrazol-4-yl)prop-2-enoic acid [370 mg (2.2 mmol)],
2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [565 mg (2.2 mmol)], DMF
(8 mL) and DIEA [1 mL (6 mmol)] was added HATU [950 mg (2.5 mmol)].
The reaction mix was stirred at room temperature 2 h then diluted
with 50 mL of EtOAc and washed 2.times. with sat. NaCl aq. The
EtOAc layer was dried (MgSO.sub.4) and the solvent removed.
Yield=900 mg (99%) after flash with 10% MeOH/DCM) MS (m/z): 406
[M+H]
##STR00200##
[0332]
6-Benzyloxy-1-[(E)-2-(1-ethylpyrazol-4-yl)vinyl]-7-methoxy-1,2,3,4--
tetrahydroisoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(1-ethylpyrazol-4-yl)prop-
-2-enamide [900 mg (2.2 mmol)] in ACN (30 ml) was added, under
reflux, POCl.sub.3 [1000 ul (11 mmol)]. The reaction was stirred at
reflux for 10 min and then rotary evaporated to dryness. The
residue was taken up into 10 ml of chloroform and was then treated
with 20 ml of 2N KOH and 50 ml of Et.sub.2O. This mixture was
rapidly stirred for 30 min at room temperature and the upper
organic layer removed, washed with water, dried (Na.sub.2SO.sub.4)
and the solvent removed. The dark oil was the dissolved into 24 ml
of dry MeOH and then treated with NaBH.sub.4 [60 mg (1.65 mmol)].
The mixture was stirred for 1 h at room temperature. A light yellow
solid ppt'd out of solution, was filtered off, triturated with 0.1%
TFA and then dried in vacuo. Yield=600 mg (70%) as TFA salt. MS
(m/z): 390 [M+H]
Example AM:
6-Benzyloxy-7-methoxy-1-[(E)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2,3,4-tet-
rahydroisoquinoline
##STR00201##
[0334] (E)-3-(3,4,5-Trimethoxyphenyl)prop-2-enoic acid: A mixture
of 3,4,5-trimethoxybenzaldehyde [0.5 g (0.0026 mol)], malonic acid
[0.53 g (0.0052 mol)], pyridine (5 mL) and piperidine (0.050 mL)
was stirred at 80.degree. C. for 1 h followed by stirring for 3 h
at 115.degree. C. The reaction was then poured into water (100 mL)
and acidified with conc. HCl. The resulting white ppt., product,
was filtered and vacuum dried. Yield=530 mg (86%) MS (m/z): 239
[M+H]
##STR00202##
[0335]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(3,4,5-trimethoxyph-
enyl)prop-2-enamide: To a suspension of
(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoic acid [0.530 g (0.0022
mol)] in 20 ml of Dichloromethane was added 2 drops of DMF followed
by oxalyl chloride [271 ul (3.2 mol)]. After 1 h stirring at room
temperature the reaction was rotary evaporated to dryness and the
resulting yellow residue was dried in vacuo. To a solution of
2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [565 mg (2.2 mmol)] and
DIEA [1 mL (6 mmol)] in 20 ml of Dichloromethane was added
dropwise, at ice bath temperature, the crude yellow acyl chloride
dissolved in 4 ml of Dichloromethane. The reaction mix was then
stirred at room temperature 2 h then diluted with 50 mL of EtOAc
and washed 2.times. with sat. NaCl aq. The EtOAc layer was dried
(MgSO.sub.4) and the solvent removed. Yield=1 g (99%) after flash
with 10% MeOH/DCM) MS (m/z): 478 [M+H]
##STR00203##
[0336]
6-Benzyloxy-7-methoxy-1-[(E)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2,3-
,4-tetrahydroisoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(3,4,5-trimethoxyphenyl)p-
rop-2-enamide [1000 mg (2.2 mmol)] in ACN (45 ml) was added, under
reflux, POCl.sub.3 [1500 ul (16 mmol)]. The reaction was stirred at
reflux for 10 min and then rotary evaporated to dryness. The
residue was taken up into 10 ml of chloroform and was then treated
with 20 ml of 2N KOH and 50 ml of Et.sub.2O. This mixture was
rapidly stirred for 30 min at room temperature and the upper
organic layer removed, washed with water, dried (Na.sub.2SO.sub.4)
and the solvent removed. The dark oil was the dissolved into 24 ml
of dry MeOH and then treated with NaBH.sub.4 [60 mg (1.65 mmol)] at
00. The mixture was stirred for 1 h at room temperature. An off
white solid ppt'd out of solution, was filtered off, triturated
with 0.1% TFA and then dried in vacuo. Yield=605 mg (60%) as TFA
salt. MS (m/z): 462 [M+H]
Example AN:
6-Benzyloxy-7-methoxy-1-[(E)-2-(7-methoxybenzofuran-4-yl)vinyl]-1,2,3,4-t-
etrahydroisoquinoline
##STR00204##
[0338] 7-methoxybenzofuran-4-carbaldehyde: To a mixture of
POCl.sub.3 (0.65 ml, 0.04 mol) and DMF (2.1 ml, 0.04 mol) at
0.degree. C. was added 7-methoxybenzofuran (1 g, 0.0067 mol). The
resulting solution was heated to 80.degree. C. and stirred for 4 h.
After being cooled to room temperature, the reaction mixture was
poured into ice and extracted with ether. The combined extracts
were concentrated in vacuo and purified by silica gel flash column
chromatography (10% EtOAc/hexanes) to afford benzaldehyde (750 mg,
64%) as an off-white solid.
##STR00205##
[0339] (E)-3-(7-Methoxybenzofuran-4-yl)prop-2-enoic acid:
7-methoxybenzofuran-4-carbaldehyde (0.4 g, 0.0023 mol), malonic
acid (0.53 g, 0.0052 mol), pyridine (5 mL), and piperidine (50 ul,
0.5 mmol) were mixed well, heated to 80-85.degree. C. for 1 h and
finally refluxed (110-115.degree. C.) for an additional 3 h. The
reaction mixture was poured into water and acidified with
concentrated HCl. The precipitate obtained was filtered, and washed
with cold water repeatedly. The residue was dissolved in NaOH,
diluted, again acidified, the precipitate was collected washed with
cold water and dried under high vacuum over P.sub.2O.sub.5 and used
without further purifications. Yield=444 mg.
##STR00206##
[0340]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(7-methoxybenzofura-
n-4-yl)prop-2-enamide: To a suspension of
(E)-3-(7-methoxybenzofuran-4-yl)prop-2-enoic acid [444 mg (0.002
mol)] in 20 ml of Dichloromethane was added 2 drops of DMF followed
by oxalyl chloride [271 ul (3.2 mol)]. After 1 h stirring at room
temperature the reaction was rotary evaporated to dryness and the
resulting yellow residue was dried in vacuo. To a solution of
2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [565 mg (2.2 mmol)] and
DIEA [1 mL (6 mmol)] in 20 ml of Dichloromethane was added
dropwise, at ice bath temperature, the crude yellow acyl chloride
dissolved in 4 ml of Dichloromethane. The reaction mix was then
stirred at room temperature 2 h then diluted with 50 mL of EtOAc
and washed 2.times. with sat. NaCl aq. The EtOAc layer was dried
(MgSO.sub.4) and the solvent removed. Yield=0.850 g (93%) after
flash chromatography with 10% MeOH/DCM).
##STR00207##
[0341]
6-Benzyloxy-7-methoxy-1-[(E)-2-(7-methoxybenzofuran-4-yl)vinyl]-1,2-
,3,4-tetrahydroisoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(7-methoxybenzofuran-4-yl-
)prop-2-enamide [850 mg (1.85 mmol)] in ACN (30 ml) was added,
under reflux, POCl.sub.3 [1000 ul (11 mmol)]. The reaction was
stirred at reflux for 10 min and then rotary evaporated to dryness.
The residue was taken up into 10 ml of chloroform and was then
treated with 20 ml of 2N KOH and 50 ml of Et.sub.2O. This mixture
was rapidly stirred for 30 min at room temperature and the upper
organic layer removed, washed with water, dried (Na.sub.2SO.sub.4)
and the solvent removed. The dark oil was the dissolved into 24 ml
of dry MeOH and then treated with NaBH.sub.4 [60 mg (1.65 mmol)].
The mixture was stirred for 1 h at room temperature. A light yellow
solid ppt'd out of solution, was filtered off, triturated with 0.1%
TFA and then dried in vacuo. Yield=700 mg (84%) as TFA salt. MS
(m/z): 442 [M+H]
Example AO:
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-methoxybenzofuran-7-yl)vinyl]-1,2,3,4-t-
etrahydroisoquinoline
##STR00208##
[0343] 4-Methoxybenzofuran-7-carbaldehyde: To a solution of
7-bromo-4-methoxy-benzofuran (1.1 g (5 mmol) in THF (13 ml) at
-78.degree. C. was added 1.6M n-BuLi (3.4 ml, 5.5 mmol). The
resulting solution was stirred at -75.degree. C. for 40 min
followed by the addition of DMF (0.401 ml, 5.5 mmol). The mixture
was allowed to warm slowly to room temperature and stirred
overnight. The reaction was quenched with NH.sub.4Cl sat and
extracted with Et.sub.2O. The extracts were dried
(Na.sub.2SO.sub.4) and the solvent removed. Yield=528 mg after
trituration with hexane.
##STR00209##
[0344] (E)-3-(4-methoxybenzofuran-7-yl)prop-2-enoic acid:
4-methoxybenzofuran-7-carbaldehyde (0.4 g, 0.0023 mol), malonic
acid (0.53 g, 0.0052 mol), pyridine (5 mL), and piperidine (50 ul,
0.5 mmol) were mixed well, heated to 80-85.degree. C. for 1 h and
finally refluxed (110-115.degree. C.) for an additional 3 h. The
reaction mixture was poured into water and acidified with
concentrated HCl. The precipitate obtained was filtered, and washed
with cold water repeatedly. The residue was dissolved in NaOH,
diluted, again acidified, the precipitate was collected washed with
cold water and dried under high vacuum over P.sub.2O.sub.5 and used
without further purifications. Yield=444 mg.
##STR00210##
[0345]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(7-methoxybenzofura-
n-4-yl)prop-2-enamide: To a suspension of
(E)-3-(4-methoxybenzofuran-7-yl)prop-2-enoic acid [444 mg (0.002
mol)] in 20 ml of Dichloromethane was added 2 drops of DMF followed
by oxalyl chloride [271 ul (3.2 mol)]. After 1 h stirring at room
temperature the reaction was rotary evaporated to dryness and the
resulting yellow residue was dried in vacuo. To a solution of
2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [565 mg (2.2 mmol)] and
DIEA [1 mL (6 mmol)] in 20 ml of Dichloromethane was added
dropwise, at ice bath temperature, the crude yellow acyl chloride
dissolved in 4 ml of Dichloromethane. The reaction mix was then
stirred at room temperature 2 h then diluted with 50 mL of EtOAc
and washed 2.times. with sat. NaCl aq. The EtOAc layer was dried
(MgSO.sub.4) and the solvent removed. Yield=0.847 g (93%) after
flash chromatography with 10% MeOH/DCM)
##STR00211##
[0346]
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-methoxybenzofuran-7-yl)vinyl]-1,2-
,3,4-tetrahydroisoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(4-methoxybenzofuran-7-yl-
)prop-2-enamide [315 mg (0.69 mmol)] in ACN (13 ml) was added,
under reflux, POCl.sub.3 [400 ul (4.3 mmol)]. The reaction was
stirred at reflux for 10 min and then rotary evaporated to dryness.
The residue was taken up into 30 ml of chloroform and was then
treated with 30 ml of 2N KOH and 100 ml of Et.sub.2O. This mixture
was rapidly stirred for 30 min at room temperature and the upper
organic layer removed, washed with water, dried (Na.sub.2SO.sub.4)
and the solvent removed. The dark oil was the dissolved into 7 ml
of dry MeOH (with 1 ml of DCM) and then treated with NaBH.sub.4 [18
mg (0.47 mmol)]. The mixture was stirred for 1 h at room
temperature. A light yellow solid ppt'd out of solution, was
filtered off, triturated with 0.1% TFA and then dried in vacuo.
Yield=300 mg (99%) as TFA salt. MS (m/z): 442 [M+H]
Example AP:
6-Benzyloxy-1-[(E)-2-(4-benzyloxy-3,5-dimethoxy-phenyl)vinyl]-7-methoxy-1-
,2,3,4-tetrahydroisoquinoline
##STR00212##
[0348] (E)-3-(4-Benzyloxy-3,5-dimethoxy-phenyl)prop-2-enoic acid:
4-benzyloxy-3,5-dimethoxy-benzaldehyde (0.71 g (0.0026 mmol)),
malonic acid (0.53 g, 0.0052 mol), pyridine (5 mL), and piperidine
(50 ul, 0.5 mmol) were mixed well, heated to 80-85.degree. C. for 1
h and finally refluxed (110-115.degree. C.) for an additional 3 h.
The reaction mixture was poured into water and acidified with
concentrated HCl. The precipitate obtained was filtered, and washed
with cold water repeatedly. The residue was dissolved in NaOH,
diluted, again acidified, the precipitate was collected washed with
cold water and dried under high vacuum over P.sub.2O.sub.5 and used
without further purifications. Yield=769 mg.
##STR00213##
[0349]
(E)-3-(4-Benzyloxy-3,5-dimethoxy-phenyl)-N-[2-(3-benzyloxy-4-methox-
y-phenyl)ethyl]prop-2-enamide: To a suspension of
(E)-3-(4-benzyloxy-3,5-dimethoxy-phenyl)proEp-2-enoic acid [628 mg
(0.002 mol)] in 20 ml of Dichloromethane was added 2 drops of DMF
followed by oxalyl chloride [271 ul (3.2 mol)]. After 1 h stirring
at room temperature the reaction was rotary evaporated to dryness
and the resulting yellow residue was dried in vacuo. To a solution
of 2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [565 mg (2.2 mmol)]
and DIEA [1 mL (6 mmol)] in 20 ml of Dichloromethane was added
dropwise, at ice bath temperature, the crude yellow acyl chloride
dissolved in 4 ml of Dichloromethane. The reaction mix was then
stirred at room temperature 2 h then diluted with 50 mL of EtOAc
and washed 2.times. with sat. NaCl aq. The EtOAc layer was dried
(MgSO.sub.4) and the solvent removed. Yield=1.2 g (99%) after flash
chromatography with 10% MeOH/DCM)
##STR00214##
[0350]
6-Benzyloxy-1-[(E)-2-(4-benzyloxy-3,5-dimethoxy-phenyl)vinyl]-7-met-
hoxy-1,2,3,4-tetrahydroisoquinoline: To a solution of
(E)-3-(4-benzyloxy-3,5-dimethoxy-phenyl)-N-[2-(3-benzyloxy-4-methoxy-phen-
yl)ethyl]prop-2-enamide [1200 mg (2.2 mmol)] in ACN (45 ml) was
added, under reflux, POCl.sub.3 [1500 ul (16 mmol)]. The reaction
was stirred at reflux for 10 min and then rotary evaporated to
dryness. The residue was taken up into 10 ml of chloroform and was
then treated with 20 ml of 2N KOH and 50 ml of Et.sub.2O. This
mixture was rapidly stirred for 30 min at room temperature and the
upper organic layer removed, washed with water, dried
(Na.sub.2SO.sub.4) and the solvent removed. The dark oil was the
dissolved into 24 ml of dry MeOH and then treated with NaBH.sub.4
[60 mg (1.65 mmol)] at 00. The mixture was stirred for 1 h at room
temperature. A off white solid ppt'd out of solution, was filtered
off, triturated with 0.1% TFA and then dried in vacuo. Yield=571 mg
(48% overall) as TFA salt. MS (m/z): 538 [M+H]
Example AQ:
6-Benzyloxy-7-methoxy-1-[(E)-2-(2,4,5-trimethoxyphenyl)vinyl]-1,2,3,4-tet-
rahydroisoquinoline
##STR00215##
[0352] (E)-3-(2,4,5-Trimethoxyphenyl)prop-2-enoic acid:
2,4,5-trimethoxybenzaldehyde (0.5 g, 0.0026 mol), malonic acid
(0.53 g, 0.0052 mol), pyridine (5 mL), and piperidine (50 ul, 0.5
mmol) were mixed well, heated to 80-85.degree. C. for 1 h and
finally refluxed (110-115.degree. C.) for an additional 3 h. The
reaction mixture was poured into water and acidified with
concentrated HCl. The precipitate obtained was filtered, and washed
with cold water repeatedly. The residue was dissolved in NaOH,
diluted, again acidified, the precipitate was collected washed with
cold water and dried under high vacuum over P.sub.2O.sub.5 and used
without further purifications.
[0353] Yield=594 mg.
##STR00216##
[0354]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(2,4,5-trimethoxyph-
enyl)prop-2-enamide: To a solution of
(E)-3-(2,4,5-trimethoxyphenyl)prop-2-enoic acid [594 mg (0.0025
mol)], 2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [565 mg (2.2
mmol)] and DIEA [3 ml (0.0025 mol] in 9 ml of Dimethylforamide was
added HATU [1.3 g (0.0034 mol)]. After 1 h stirring at room
temperature the reaction mix was then diluted with 50 mL of EtOAc
and washed 2.times. with sat. NaCl aq. The EtOAc layer was dried
(MgSO.sub.4) and the solvent removed. Yield=1.2 g (99%) after flash
chromatography with 10% MeOH/DCM)
##STR00217##
[0355]
6-Benzyloxy-7-methoxy-1-[(E)-2-(2,4,5-trimethoxyphenyl)vinyl]-1,2,3-
,4-tetrahydroisoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(2,4,5-trimethoxyphenyl)p-
rop-2-enamide [1190 mg (2.5 mmol)] in ACN (45 ml) was added, under
reflux, POCl.sub.3 [1500 ul (16 mmol)]. The reaction was stirred at
reflux for 10 min and then rotary evaporated to dryness. The
residue was taken up into 10 ml of chloroform and was then treated
with 20 ml of 2N KOH and 50 ml of Et.sub.2O. This mixture was
rapidly stirred for 30 min at room temperature and the upper
organic layer removed, washed with water, dried (Na.sub.2SO.sub.4)
and the solvent removed. The dark oil was the dissolved into 24 ml
of dry MeOH and then treated with NaBH.sub.4 [60 mg (1.65 mmol)].
The mixture was stirred for 1 h at room temperature. A light yellow
solid ppt'd out of solution, was filtered off, triturated with 0.1%
TFA and then dried in vacuo. Yield=295 mg (26% overall) as TFA
salt. MS (m/z): 462 [M+H]
Example AR:
6-Benzyloxy-1-[(E)-2-(3-bromo-4-methoxy-phenyl)vinyl]-7-methoxy-1,2,3,4-t-
etrahydroisoquinoline
##STR00218##
[0357] (E)-3-(3-Bromo-4-methoxy-phenyl)prop-2-enoic acid:
3-bromo-4-methoxy-benzaldehyde (1 g (0.0046 mmol)), malonic acid
(0.93 g, 0.0092 mol), pyridine (9 mL), and piperidine (88 ul, 0.5
mmol) were mixed well, heated to 80-85.degree. C. for 1 h and
finally refluxed (110-115.degree. C.) for an additional 3 h. The
reaction mixture was poured into water and acidified with
concentrated HCl. The precipitate obtained was filtered, and washed
with cold water repeatedly. The residue was dissolved in NaOH,
diluted, again acidified, the precipitate was collected washed with
cold water and dried under high vacuum over P.sub.2O.sub.5 and used
without further purifications. Yield=1.2 g.
##STR00219##
[0358]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(3-bromo-4-methoxy--
phenyl)prop-2-enamide: To a suspension of
(E)-3-(3-bromo-4-methoxy-phenyl)prop-2-enoic acid [1.2 g (0.0046
mol)] in 20 ml of Dichloromethane was added 5 drops of DMF followed
by oxalyl chloride [613 ul (6.9 mol)]. After 1 h stirring at room
temperature the reaction was rotary evaporated to dryness and the
resulting yellow residue was dried in vacuo. To a solution of
2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [1.2 g (4.6 mmol)] and
DIEA [1 mL (6 mmol)] in 20 ml of Dichloromethane was added
dropwise, at ice bath temperature, the crude yellow acyl chloride
dissolved in 4 ml of Dichloromethane. The reaction mix was then
stirred at room temperature 2 h then diluted with 50 mL of EtOAc
and washed 2.times. with sat. NaCl aq. The EtOAc layer was dried
(MgSO.sub.4) and the solvent removed. Yield=2.3 g (99%) after flash
chromatography with 10% MeOH/DCM)
##STR00220##
[0359]
6-Benzyloxy-1-[(E)-2-(3-bromo-4-methoxy-phenyl)vinyl]-7-methoxy-1,2-
,3,4-tetrahydroisoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(3-bromo-4-methoxy-phenyl-
)prop-2-enamide [2.3 g (0.0046 mol)] in ACN (90 ml) was added,
under reflux, POCl.sub.3 [3000 ul (33 mmol)]. The reaction was
stirred at reflux for 10 min and then rotary evaporated to dryness.
The residue was taken up into 30 ml of chloroform and was then
treated with 30 ml of 2N KOH and 100 ml of Et.sub.2O. This mixture
was rapidly stirred for 30 min at room temperature and the upper
organic layer removed, washed with water, dried (Na.sub.2SO.sub.4)
and the solvent removed. The dark oil was the dissolved into 40 ml
of dry MeOH and then treated with NaBH.sub.4 [120 mg (3.3 mmol)].
The mixture was stirred for 1 h at room temperature. A light yellow
solid ppt'd out of solution, was filtered off, triturated with 0.1%
TFA and then dried in vacuo. Yield=2 g (91% overall) as TFA salt.
MS (m/z): 480 [M+H]
Example AS:
6-Benzyloxy-1-[(E)-2-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)vinyl]-7--
methoxy-1,2,3,4-tetrahydroisoquinoline
##STR00221##
[0361]
(E)-3-(5-Benzyloxy-2-tert-butyl-4-methoxy-phenyl)prop-2-enoic acid:
5-benzyloxy-2-tert-butyl-4-methoxy-benzaldehyde (0.116 g (0.39
mmol)), malonic acid (83 g, 0.8 mol), pyridine (5 mL), and
piperidine (88 ul, 0.5 mmol) were mixed well, heated to
80-85.degree. C. for 1 h and finally refluxed (110-115.degree. C.)
for an additional 3 h. The reaction mixture was poured into water
and acidified with concentrated HCl. The precipitate obtained was
filtered, and washed with cold water repeatedly. The residue was
dissolved in NaOH, diluted, again acidified, the precipitate was
collected washed with cold water and dried under high vacuum over
P.sub.2O.sub.5 and used without further purifications. Yield=133
mg.
##STR00222##
[0362]
(E)-3-(5-Benzyloxy-2-tert-butyl-4-methoxy-phenyl)-N-[2-(3-benzyloxy-
-4-methoxy-phenyl)ethyl]prop-2-enamide: To a suspension of
(E)-3-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)prop-2-enoic acid
[113 mg (0.39 mmol)] in 10 ml of Dichloromethane was added 2 drops
of DMF followed by oxalyl chloride [51 ul (0.6 mmol)]. After 1 h
stirring at room temperature the reaction was rotary evaporated to
dryness and the resulting yellow residue was dried in vacuo. To a
solution of 2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [103 mg (0.4
mmol)] and DIEA [100 uL (0.6 mmol)] in 10 ml of Dichloromethane was
added dropwise, at ice bath temperature, the crude yellow acyl
chloride dissolved in 4 ml of Dichloromethane. The reaction mix was
then stirred at room temperature 2 h then diluted with 50 mL of
EtOAc and washed 2.times. with sat. NaCl aq. The EtOAc layer was
dried (MgSO.sub.4) and the solvent removed. Yield=225 mg (99%)
after flash chromatography with 10% MeOH/DCM)
##STR00223##
[0363]
6-Benzyloxy-1-[(E)-2-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)vin-
yl]-7-methoxy-1,2,3,4-tetrahydroisoquinoline: To a solution of
(E)-3-(5-benzyloxy-2-tert-butyl-4-methoxy-phenyl)-N-[2-(3-benzyloxy-4-met-
hoxy-phenyl)ethyl]prop-2-enamide [225 mg (0.39 mmol)] in ACN (9 ml)
was added, under reflux, POCl.sub.3 [300 ul (3.21 mmol)]. The
reaction was stirred at reflux for 10 min and then rotary
evaporated to dryness. The residue was taken up into 10 ml of
chloroform and was then treated with 20 ml of 2N KOH and 50 ml of
Et.sub.2O. This mixture was rapidly stirred for 30 min at room
temperature and the upper organic layer removed, washed with water,
dried (Na.sub.2SO.sub.4) and the solvent removed. The dark oil was
the dissolved into 8 ml of dry EtOH and then treated with
NaBH.sub.4 [12 mg (0.32 mmol)]. The mixture was stirred for 1 h at
room temperature and the resulting solid was carefully filtered off
and dried. The solid was triturated with 50/50 ACN/water, filtered
and vacuum dried.
[0364] Yield=50 mg (11% overall) as TFA salt. MS (m/z): 564
[M+H]
Example AT:
6-Benzyloxy-1-[(E)-2-(3,5-dimethoxyphenyl)vinyl]-7-methoxy-1,2,3,4-tetrah-
ydroisoquinoline
##STR00224##
[0366] Using the same procedure outlined in Example AI at the same
scale with the aldehyde 3,5-dimethoxybenzaldehyde the reaction
afforded the desired adduct. Yield=30 mg (34%) as TFA salt via prep
chrom. MS (m/z): 432 [M+H]
Example AU:
6-benzyloxy-7-methoxy-1-[(E)-2-(2-methoxy-4-pyridyl)vinyl]-1,2,3,4-tetrah-
ydroisoquinoline
##STR00225##
[0368] (E)-3-(6-Methoxy-3-pyridyl)prop-2-enoic acid:
6-methoxypyridine-3-carbaldehyde (3 g (0.022 mol)), malonic acid
(4.35 g (0.042 mol)), pyridine (15 mL), and piperidine (400 ul, 4
mmol) were mixed well, heated to 80-85.degree. C. for 1 h and
finally refluxed (110-115.degree. C.) for an additional 3 h. The
reaction mixture was poured into water and acidified with
concentrated HCl. The precipitate obtained was filtered, and washed
with cold water repeatedly. The residue was dissolved in NaOH,
diluted, again acidified, the precipitate was collected washed with
cold water and dried under high vacuum over P.sub.2O.sub.5 and used
without further purifications. Yield=2.8 g.
##STR00226##
[0369]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(2-methoxy-4-pyridy-
l)prop-2-enamide: To a suspension of
(E)-3-(6-Methoxy-3-pyridyl)prop-2-enoic acid [179 mg (1 mmol)] in
10 ml of Dichloromethane was added 2 drops of DMF followed by
oxalyl chloride [300 ul (3 mmol)]. After 1 h stirring at room
temperature the reaction was rotary evaporated to dryness and the
resulting yellow residue was dried in vacuo. To a solution of
2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [257 mg (1 mmol)] and
DIEA [500 uL (3 mmol)] in 10 ml of Dichloromethane was added
dropwise, at ice bath temperature, the crude yellow acyl chloride
dissolved in 4 ml of Dichloromethane. The reaction mix was then
stirred at room temperature 2 h then diluted with 50 mL of EtOAc
and washed 2.times. with sat. NaCl aq. The EtOAc layer was dried
(MgSO.sub.4) and the solvent removed. Yield=286 mg (68%) after
flash chromatography with 10% MeOH/DCM)
##STR00227##
[0370]
6-Benzyloxy-7-methoxy-1-[(E)-2-(2-methoxy-4-pyridyl)vinyl]-1,2,3,4--
tetrahydroisoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(2-methoxy-4-pyridyl)prop-
-2-enamide [286 mg (0.68 mmol)] in ACN (9 ml) was added, under
reflux, POCl.sub.3 [600 ul (6.42 mmol)]. The reaction was stirred
at reflux for 10 min and then rotary evaporated to dryness. The
residue was taken up into 10 ml of chloroform and was then treated
with 20 ml of 2N KOH and 50 ml of Et.sub.2O. This mixture was
rapidly stirred for 30 min at room temperature and the upper
organic layer removed, washed with water, dried (Na.sub.2SO.sub.4)
and the solvent removed. The dark oil was the dissolved into 8 ml
of dry EtOH and then treated with NaBH4 [12 mg (0.32 mmol)]. The
mixture was stirred for 1 h at room temperature and the resulting
solid was carefully filtered off and dried. The solid was
triturated with 50/50 ACN/water, filtered and vacuum dried.
Yield=20 mg (8% overall) as TFA salt. MS (m/z): 403 [M+H]
Example AV:
6-Benzyloxy-1-[(E)-2-(2,4-dimethoxyphenyl)vinyl]-7-methoxy-1,2,3,4-tetrah-
ydroisoquinoline
##STR00228##
[0372] (E)-3-(2,4-Dimethoxyphenyl)prop-2-enoic acid: A mixture of
2,4-dimethoxybenzaldehyde [0.43 g (0.0026 mol)], malonic acid [0.53
g (0.0052 mol)], pyridine (5 mL) and piperidine (0.050 mL) was
stirred at 80.degree. C. for 1 h followed by stirring for 3 h at
115.degree. C. The reaction was then poured into water (100 mL) and
acidified with conc. HCl. The resulting white ppt., product, was
filtered and vacuum dried. Yield=577 mg (99%)]
##STR00229##
[0373]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(3,4,5-trimethoxyph-
enyl)prop-2-enamide: To a suspension of
(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoic acid [0.577 g (0.0026
mol)] in 20 ml of Dichloromethane was added 2 drops of DMF followed
by oxalyl chloride [271 ul (3.2 mol)]. After 1 h stirring at room
temperature the reaction was rotary evaporated to dryness and the
resulting yellow residue was dried in vacuo. To a solution of
2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [565 mg (2.2 mmol)] and
DIEA [1 mL (6 mmol)] in 20 ml of Dichloromethane was added
dropwise, at ice bath temperature, the crude yellow acyl chloride
dissolved in 4 ml of Dichloromethane. The reaction mix was then
stirred at room temperature 2 h then diluted with 50 mL of EtOAc
and washed 2.times. with sat. NaCl aq. The EtOAc layer was dried
(MgSO4) and the solvent removed. Yield=780 mg (67%) after flash
with 10% MeOH/DCM)
##STR00230##
[0374]
6-Benzyloxy-1-[(E)-2-(2,4-dimethoxyphenyl)vinyl]-7-methoxy-1,2,3,4--
tetrahydroisoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(2,4-dimethoxyphenyl)prop-
-2-enamide [780 mg (1.74 mmol)] in ACN (30 ml) was added, under
reflux, POCl.sub.3 [1000 ul (11 mmol)]. The reaction was stirred at
reflux for 10 min and then rotary evaporated to dryness. The
residue was taken up into 10 ml of chloroform and was then treated
with 20 ml of 2N KOH and 50 ml of Et2O. This mixture was rapidly
stirred for 30 min at room temperature and the upper organic layer
removed, washed with water, dried (Na2SO4) and the solvent removed.
The dark oil was the dissolved into 24 ml of dry MeOH and then
treated with NaBH.sub.4 [60 mg (1.65 mmol)]. The mixture was
stirred for 1 h at room temperature. A light yellow solid ppt'd out
of solution, was filtered off, triturated with 0.1% TFA and then
dried in vacuo. Yield=22 mg (3% overall) as TFA salt. MS (m/z): 432
[M+H]
Example AW:
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-pyridyl)vinyl]-1,2,3,4-tetrahydroisoqui-
noline
##STR00231##
[0376] (E)-3-(4-Pyridyl)prop-2-enoic acid: pyridine-4-carbaldehyde
(5 g, 0.047 mol), malonic acid (2.2 g (0.094 mol)), pyridine (30
mL), and piperidine (850 ul, 8.5 mmol) were mixed well, heated to
80-85.degree. C. for 1 h and finally refluxed (110-115.degree. C.)
for an additional 3 h. The reaction mixture was poured into water
and acidified with concentrated HCl. The precipitate obtained was
filtered, and washed with cold water repeatedly. The residue was
dissolved in NaOH, diluted, again acidified, the precipitate was
collected washed with cold water and dried under high vacuum over
P.sub.2O.sub.5 and used without further purifications. Yield=6.9
g.
##STR00232##
[0377]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(4-pyridyl)prop-2-e-
namide: To a suspension of (E)-3-(4-pyridyl)prop-2-enoic acid
[0.149 g (1 mmol)] in 10 ml of Dichloromethane was added 1 drop of
DMF followed by oxalyl chloride [300 ul (3 mmol)]. After 1 h
stirring at room temperature the reaction was rotary evaporated to
dryness and the resulting yellow residue was dried in vacuo. To a
solution of 2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [257 mg (1
mmol)] and DIEA [1 mL (6 mmol)] in 20 ml of Dichloromethane was
added dropwise, at ice bath temperature, the crude yellow acyl
chloride dissolved in 4 ml of Dichloromethane. The reaction mix was
then stirred at room temperature 2 h then diluted with 50 mL of
EtOAc and washed 2.times. with sat. NaCl aq. The EtOAc layer was
dried (MgSO4) and the solvent removed. Yield=234 mg (60%) after
flash with 10% MeOH/DCM)
##STR00233##
[0378]
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-pyridyl)vinyl]-1,2,3,4-tetrahydro-
isoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(4-pyridyl)prop-2-enamide
[234 mg (0.6 mmol)] in ACN (15 ml) was added, under reflux,
POCl.sub.3 [500 ul (5.2 mmol)]. The reaction was stirred at reflux
for 10 min and then rotary evaporated to dryness. The residue was
taken up into 10 ml of chloroform and was then treated with 20 ml
of 2N KOH and 50 ml of Et2O. This mixture was rapidly stirred for
30 min at room temperature and the upper organic layer removed,
washed with water, dried (Na2SO4) and the solvent removed. The dark
oil was the dissolved into 24 ml of dry MeOH and then treated with
NaBH.sub.4 [5 mg (0.13 mmol)]. The mixture was stirred for 1 h at
room temperature. A light yellow solid ppt'd out of solution, was
filtered off, triturated with 0.1% TFA and then dried in vacuo.
Yield=130 mg (58% overall) as TFA salt. MS (m/z): 371 [M+H]
Example AX:
6-Benzyloxy-7-methoxy-1-[(E)-2-(6-methoxy-3-pyridyl)vinyl]-1,2,3,4-tetrah-
ydroisoquinoline
##STR00234##
[0380] (E)-3-(6-Methoxy-3-pyridyl)prop-2-enoic acid:
6-methoxypyridine-3-carbaldehyde (1 g (0.007 mol)), malonic acid
(1.45 g (0.014 mol)), pyridine (5 mL), and piperidine (100 ul, 1
mmol) were mixed well, heated to 80-85.degree. C. for 1 h and
finally refluxed (110-115.degree. C.) for an additional 3 h. The
reaction mixture was poured into water and acidified with
concentrated HCl. The precipitate obtained was filtered, and washed
with cold water repeatedly. The residue was dissolved in NaOH,
diluted, again acidified, the precipitate was collected washed with
cold water and dried under high vacuum over P.sub.2O.sub.5 and used
without further purifications. Yield=950 mg.
##STR00235##
[0381]
(E)-N-[2-(3-Benzyloxy-4-methoxy-phenyl)ethyl]-3-(6-methoxy-3-pyridy-
l)prop-2-enamide: To a suspension of
(E)-3-(6-methoxy-3-pyridyl)prop-2-enoic acid [0.179 g (1 mmol)] in
10 ml of Dichloromethane was added 1 drop of DMF followed by oxalyl
chloride [300 ul (3 mmol)]. After 1 h stirring at room temperature
the reaction was rotary evaporated to dryness and the resulting
yellow residue was dried in vacuo. To a solution of
2-(3-benzyloxy-4-methoxy-phenyl)ethanamine [257 mg (1 mmol)] and
DIEA [1 mL (6 mmol)] in 20 ml of Dichloromethane was added
dropwise, at ice bath temperature, the crude yellow acyl chloride
dissolved in 4 ml of Dichloromethane. The reaction mix was then
stirred at room temperature 2 h then diluted with 50 mL of EtOAc
and washed 2.times. with sat. NaCl aq. The EtOAc layer was dried
(MgSO4) and the solvent removed. Yield=395 mg (94%) after flash
chromatography with 10% MeOH/DCM)
##STR00236##
[0382]
6-Benzyloxy-7-methoxy-1-[(E)-2-(6-methoxy-3-pyridyl)vinyl]-1,2,3,4--
tetrahydroisoquinoline: To a solution of
(E)-N-[2-(3-benzyloxy-4-methoxy-phenyl)ethyl]-3-(6-methoxy-3-pyridyl)prop-
-2-enamide [395 mg (0.94 mmol)] in ACN (45 ml) was added, under
reflux, POCl.sub.3 [1500 ul (16 mmol)]. The reaction was stirred at
reflux for 10 min and then rotary evaporated to dryness. The
residue was taken up into 10 ml of chloroform and was then treated
with 20 ml of 2N KOH and 50 ml of Et2O. This mixture was rapidly
stirred for 30 min at room temperature and the upper organic layer
removed, washed with water, dried (Na2SO4) and the solvent removed.
The dark oil was the dissolved into 15 ml of dry MeOH and then
treated with NaBH4 [5 mg (0.14 mmol)]. The mixture was stirred for
1 h at room temperature. A light yellow solid ppt'd out of
solution, was filtered off, triturated with 0.1% TFA and then dried
in vacuo. Yield=226 mg (60% overall) as TFA salt. MS (m/z): 403
[M+H]
Example AY:
6-(Benzyloxy)-1-(5-(benzyloxy)-4-methoxy-2-methylphenyl)-7-methoxy-1,2,3,-
4-tetrahydroisoquinoline
##STR00237##
[0384] 1-(Benzyloxy)-2-methoxy-4-methylbenzene:
2-Methoxy-4-methylphenol (14.9 g, 107.8 mmol) was combined with
benzylbromide (37.2 g, 217.5 mmol), K.sub.2CO.sub.3 (30 g, 217.5
mmol), in acetonitrile (220 mL) and heated at reflux for 18 hours.
After TLC analysis showed complete reaction, it was allowed to cool
to room temperature. The organic solvent was evaporated to dryness,
the residue obtained was extracted with EtOAc and water. The
combined organic layers were dried over MgSO.sub.4, filtered and
evaporated to dryness the crude product obtained was used in the
next step without further purification. LCMS: M+1=229.3.
[0385] 1-(Benzyloxy)-5-bromo-2-methoxy-4-methylbenzene: The
1-(Benzyloxy)-2-methoxy-4-methylbenzene (3.00 g, 13.14 mmol) was
dissolved in dry DMF (25 mL) and NBS (2.34 g, 13.14 mmol) was added
in portions. The resulting reaction mixture was stirred at room
temperature for 18 hours. The reaction was monitored by TLC
analysis, upon completion the organic solvent was removed under
high vacuum to dryness. The residue obtained was purified by flash
chromatography to afford the desired product as a solid. LCMS:
M+1=308.2.
[0386]
6-(Benzyloxy)-1-(5-(benzyloxy)-4-methoxy-2-methylphenyl)-7-methoxy--
1,2,3,4-tetrahydroisoquinoline: The
1-(Benzyloxy)-5-bromo-2-methoxy-4-methylbenzene (307 mg, 1.0 mmol)
was dissolved in dry THF (10 mL) and cooled to -78.degree. C.,
under argon. To this solution was added t-BuLi (1.3 mL, 2.2 mmol,
1.7M in pentane) dropwise, as the solution turned light yellow.
After the addition, the reaction mixture was stirred for an hour at
-78.degree. C. before a solution of
6-(benzyloxy)-7-methoxy-3,4-dihydroisoquinoline (268 mg, 1.0 mmol)
in THF (3 mL) was added drop-wise. The mixture was allowed to stir
at -78.degree. C. for 2 hours, and then immediately quenched with
sat. aqueous NH.sub.4Cl solution. The reaction mixture was
extracted with EtOAc, and the combined organic layers were dried
over MgSO.sub.4, filtered and evaporated to dryness. The residue
obtained was purified by flash chromatography to afford the titled
compound. LCMS: M+1=496.
Example AZ: tert-Butyl
N-[[2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl]me-
thyl]carbamate
##STR00238##
[0388] The title compound was obtained from tert-Butyl
N-[(2-bromophenyl)methyl]carbamate using the same protocol as
described in Example AY above. LC-MS; M+1=475.
Example BA:
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-methoxy-2,6-dimethyl-phenyl)vinyl]-1,2,-
3,4-tetrahydroisoquinoline
##STR00239##
[0390] 2-[(E)-2-bromovinyl]-5-methoxy-1,3-dimethyl-benzene: This
intermediate was obtain first through the alternate cinnamic acid
approach protocol (which utilizes ethyl
2-diethoxyphosphanylacetate) to obtain the corresponding cinnamic
acid in 2 steps. The conversion to the vinyl bromide followed the
same protocol as Example AD.
[0391]
6-benzyloxy-7-methoxy-1-[(E)-2-(4-methoxy-2,6-dimethyl-phenyl)vinyl-
]-1,2,3,4-tetrahydroisoquinoline: The title compound was obtained
through the same protocol as shown in Example AD above. LC-MS;
M+1=430.
Example BB:
6-Benzyloxy-7-methoxy-1-[(E)-2-(6-methyl-1,3-benzodioxol-5-yl)vinyl]-1,2,-
3,4-tetrahydroisoquinoline
##STR00240##
[0393] 5-[(E)-2-bromovinyl]-6-methyl-1,3-benzodioxole was obtained
from 6-methyl-1,3-benzodioxole-5-carbaldehyde through the two step
protocol as shown in Example AD.
[0394]
6-Benzyloxy-7-methoxy-1-[(E)-2-(6-methyl-1,3-benzodioxol-5-yl)vinyl-
]-1,2,3,4-tetrahydroisoquinoline was obtained using the same
conditions as in Example AD above. LC-MS; M+1=430.
Example BC:
6-Benzyloxy-7-methoxy-1-[(E)-2-(7-methyl-2,3-dihydro-1,4-benzodioxin-6-yl-
)vinyl]-1,2,3,4-tetrahydroisoquinoline
##STR00241##
[0396] 6-[(E)-2-Bromovinyl]-7-methyl-2,3-dihydro-1,4-benzodioxine
was obtained from
7-methyl-2,3-dihydro-1,4-benzodioxine-6-carbaldehyde using the
protocol in Example AD above.
[0397]
6-Benzyloxy-7-methoxy-1-[(E)-2-(7-methyl-2,3-dihydro-1,4-benzodioxi-
n-6-yl)vinyl]-1,2,3,4-tetrahydroisoquinoline was obtained using the
same procedure as in Example AD above. LC-MS; M+1=444.
Example BD:
6-Benzyloxy-1-[(E)-2-(4-butoxy-3-methoxy-phenyl)vinyl]-7-methoxy-1,2,3,4--
tetrahydroisoquinoline
##STR00242##
[0399] 4-[(E)-2-bromovinyl]-1-butoxy-2-methoxy-benzene was obtained
from 4-butoxy-3-methoxy-benzaldehyde using the two step protocol
above in Example AD.
[0400]
6-benzyloxy-1-[(E)-2-(4-butoxy-3-methoxy-phenyl)vinyl]-7-methoxy-1,-
2,3,4-tetrahydroisoquinoline was obtained using the protocol in
Example AD above. LC-MS; M+1=474.
Example BE:
6-Benzyloxy-1-[(E)-2-(3-butoxy-4-methoxy-phenyl)vinyl]-7-methoxy-1,2,3,4--
tetrahydroisoquinoline
##STR00243##
[0402] 4-[(E)-2-bromovinyl]-2-butoxy-1-methoxy-benzene was obtained
from 3-butoxy-4-methoxy-benzaldehyde using the two step protocol in
Example AD above.
[0403]
6-benzyloxy-1-[(E)-2-(3-butoxy-4-methoxy-phenyl)vinyl]-7-methoxy-1,-
2,3,4-tetrahydroisoquinoline was obtained using the same protocol
as Example AD. LC-MS; M+1=474.
Example BF:
6-Benzyloxy-1-[(E)-2-(5-fluoro-4-methoxy-2-methyl-phenyl)vinyl]-7-methoxy-
-1,2,3,4-tetrahydroisoquinoline
##STR00244##
[0405] 4-[(E)-2-bromovinyl]-2-fluoro-1-methoxy-benzene was obtained
from 3-fluoro-4-methoxy-benzaldehyde using the 2 step protocol in
Example AD above.
[0406]
6-benzyloxy-1-[(E)-2-(5-fluoro-4-methoxy-2-methyl-phenyl)vinyl]-7-m-
ethoxy-1,2,3,4-tetrahydroisoquinoline was obtained using the same
protocol as Example AD above. LC-MS; M+1=434.
Example BG:
4-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
-N,N,3-trimethyl-aniline
##STR00245##
[0408] 4-[(E)-2-bromovinyl]-N,N,3-trimethyl-aniline was obtained
from 4-(dimethylamino)-2-methyl-benzaldehyde using
ethyl-2-(diethoxyphosphino)acetate in the alternate method for the
synthesis of cinnamic acids above. The resulting cinnamic acid was
converted to the 4-[(E)-2-bromovinyl]-N,N,3-trimethyl-aniline as in
Example AD.
[0409]
4-[(E)-2-(6-Benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)-
vinyl]-N,N,3-trimethyl-aniline was obtained using the same protocol
as in Example AD above. LC-MS; M+1=429
Example BH:
6-Benzyloxy-7-methoxy-1-[(E)-2-[2-methyl-5-(trifluoromethoxy)phenyl]vinyl-
]-1,2,3,4-tetrahydroisoquinoline
##STR00246##
[0411] 2-[(E)-2-bromovinyl]-1-methyl-4-(trifluoromethoxy)benzene
was synthesized from 2-methyl-5-(trifluoromethoxy)benzaldehyde
using the 2 step protocol in Example AD.
[0412]
6-Benzyloxy-7-methoxy-1-[(E)-2-[2-methyl-5-(trifluoromethoxy)phenyl-
]vinyl]-1,2,3,4-tetrahydroisoquinoline was synthesized through the
same protocol as Example AD above. LC-MS; M+1=470.
Example BI:
6-Benzyloxy-7-methoxy-1-[(E)-styryl]-1,2,3,4-tetrahydroisoquinoline
##STR00247##
[0414] [(E)-2-bromovinyl]benzene was obtained from benzaldehyde in
the same manner as Example AD.
[0415]
6-Benzyloxy-7-methoxy-1-[(E)-styryl]-1,2,3,4-tetrahydroisoquinoline
was obtained using the same protocol as shown in Example AD. LC-MS;
M+1=372.
Example BJ:
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-methoxyphenyl)vinyl]-1,2,3,4-tetrahydro-
isoquinoline
##STR00248##
[0417] 1-[(E)-2-bromovinyl]-4-methoxy-benzene was obtained from
4-methoxybenzaldehyde in the same manner as Example AD.
[0418]
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-methoxyphenyl)vinyl]-1,2,3,4-tetr-
ahydroisoquinoline was obtained using the same protocol as shown in
Example AD. LC-MS; M+1=402.
Example BK:
6-Benzyloxy-1-[(E)-2-(3-benzyloxyphenyl)vinyl]-7-methoxy-1,2,3,4-tetrahyd-
roisoquinoline
##STR00249##
[0420] 1-Benzyloxy-3-[(E)-2-bromovinyl]benzene was synthesized from
3-benzyloxybenzaldehyde using the two step protocol in Example AD
above.
[0421]
6-Benzyloxy-1-[(E)-2-(3-benzyloxyphenyl)vinyl]-7-methoxy-1,2,3,4-te-
trahydroisoquinoline was obtained using the same protocol in
Example AD above. LS-MS; M+1=478.
Example BL:
6-Benzyloxy-1-[(E)-2-(5-butoxy-4-methoxy-2-methyl-phenyl)vinyl]-7-methoxy-
-1,2,3,4-tetrahydroisoquinoline
##STR00250##
[0423] 1-[(E)-2-bromovinyl]-5-butoxy-4-methoxy-2-methyl-benzene was
synthesized from 5-butoxy-4-methoxy-2-methyl-benzaldehyde using the
2 step protocol in Example AD above.
[0424]
6-Benzyloxy-1-[(E)-2-(5-butoxy-4-methoxy-2-methyl-phenyl)vinyl]-7-m-
ethoxy-1,2,3,4-tetrahydroisoquinoline was synthesized using the
protocol in Example AD. LC-MS; M+1=488.
Example BM:
6-Benzyloxy-1-[(E)-2-(2,3-dihydrobenzofuran-5-yl)vinyl]-7-methoxy-1,2,3,4-
-tetrahydroisoquinoline
##STR00251##
[0426] 5-[(E)-2-Bromovinyl]-2,3-dihydrobenzofuran was synthesized
from 2,3-dihydrobenzofuran-5-carbaldehyde using the 2 step protocol
in Example AD.
[0427]
6-Benzyloxy-1-[(E)-2-(2,3-dihydrobenzofuran-5-yl)vinyl]-7-methoxy-1-
,2,3,4-tetrahydroisoquinoline was synthesized using the protocol in
Example AD above. LC-MS; M+1=414.
Example BN:
1-[(E)-2-(benzofuran-5-yl)vinyl]-6-benzyloxy-7-methoxy-1,2,3,4-tetrahydro-
isoquinoline
##STR00252##
[0429] 5-[(E)-2-bromovinyl]benzofuran was synthesized from
benzofuran-5-carbaldehyde using the two step protocol in Example AD
above.
[0430]
1-[(E)-2-(benzofuran-5-yl)vinyl]-6-benzyloxy-7-methoxy-1,2,3,4-tetr-
ahydroisoquinoline was synthesized using the protocol in Example AD
above. LC-MS; M+1=412
Example BO:
4-[5-[(E)-2-(B-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vin-
yl]-2-methoxy-4-methyl-phenoxy]butanoic Acid
##STR00253##
[0432] tert-Butyl
4-[5-[(E)-2-bromovinyl]-2-methoxy-4-methyl-phenoxy]butanoate was
synthesized from tert-butyl
4-(5-formyl-2-methoxy-4-methyl-phenoxy)butanoate by a 2 step
protocol in Example AD above.
[0433]
4-[5-[(E)-2-(B-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1--
yl)vinyl]-2-methoxy-4-methyl-phenoxy]butanoic acid was synthesized
through the protocol above in Example AD. LC-MS; M-1=416
Example BP:
6-Benzyloxy-1-[(E)-2-(2-fluoro-4,5-dimethoxy-phenyl)vinyl]-7-methoxy-1,2,-
3,4-tetrahydroisoquinoline
##STR00254##
[0435] To a solution of
1-[(E)-2-bromovinyl]-2-fluoro-4,5-dimethoxy-benzene[261 mg (1
mmol)] in Ether (15 ml) at -78.degree. C. was added 1.7 M
t-Butyllithium [1.2 ml (2.2 mmol)]. The mixture was stirred at
-78.degree. C. for 1 h then treated at -78.degree. with a mix of
6-benzyloxy-7-methoxy-3,4-dihydroisoquinoline [134 mg (0.5 mmol)]
and TMSCl [64 ul (0.5 mmol)] in THF (2 ml). The reaction was
stirred at -78.degree. C. for 1 h and then allowed to come to room
temperature overnight. The reaction was then quenched with sat
NH4Cl and diluted with 20 ml of EtOAc. The organic layer was
removed, washed with water, dried (MgSO4) and the solvent removed.
Yield=39 mg (9%) as TFA salt via prep chrom. MS (m/z): 450
[M+H]
Example BQ:
6-Benzyloxy-1-[(E)-2-(3,4-dimethoxyphenyl)vinyl]-7-methoxy-1,2,3,4-tetrah-
ydroisoquinoline
##STR00255##
[0437] To a solution of
1-[(E)-2-bromovinyl]-2-fluoro-4-methoxy-benzene [486 mg (0.2 mmol)]
in Ether (30 ml) at -78.degree. C. was added 1.7 M t-Butyllithium
[2.4 ml (4.4 mmol)]. The mixture was stirred at -78.degree. C. for
1 h then treated at -78.degree. with a mix of
6-benzyloxy-7-methoxy-3,4-dihydroisoquinoline [267 mg (1 mmol)] and
TMSCl [127 ul (1 mmol)] in THF (4 ml). The reaction was stirred at
-78.degree. C. for 1 h and then allowed to come to room temperature
overnight. The reaction was then quenched with sat NH.sub.4Cl and
diluted with 20 ml of EtOAc. The organic layer was removed, washed
with water, dried (MgSO.sub.4) and the solvent removed. Yield=42 mg
(5%) as TFA salt via prep chrom. MS (m/z): 432 [M+H]
Example BR:
6-Benzyloxy-1-[(E)-2-(2-fluoro-4-methoxy-phenyl)vinyl]-7-methoxy-1,2,3,4--
tetrahydroisoquinoline
##STR00256##
[0439] To a solution of
1-[(E)-2-bromovinyl]-2-fluoro-4-methoxy-benzene [462 mg (0.2 mmol)]
in Ether (30 ml) at -78.degree. C. was added 1.7 M t-Butyllithium
[2.4 ml (4.4 mmol)]. The mixture was stirred at -78.degree. C. for
1 h then treated at -78.degree. with a mix of
6-benzyloxy-7-methoxy-3,4-dihydroisoquinoline [267 mg (1 mmol)] and
TMSCl [127 ul (1 mmol)] in THF (4 ml). The reaction was stirred at
-78.degree. C. for 1 h and then allowed to come to room temperature
overnight. The reaction was then quenched with sat NH.sub.4Cl and
diluted with 20 ml of EtOAc. The organic layer was removed, washed
with water, dried (MgSO4) and the solvent removed. Yield=64 mg (8%)
as TFA salt via prep chrom. MS (m/z): 420 [M+H]
Example BS:
6-Benzyloxy-7-methoxy-1-[(E)-2-(3-methyl-2-thienyl)vinyl]-1,2,3,4-tetrahy-
droisoquinoline
##STR00257##
[0441] To a solution of 2-[(E)-2-bromovinyl]-3-methyl-thiophene
[203 mg (1 mmol)] in Ether (15 ml) at -78.degree. C. was added 1.7
M t-Butyllithium [1.2 ml (2.2 mmol)]. The mixture was stirred at
-78.degree. C. for 1 h then treated at -78.degree. with a mix of
6-benzyloxy-7-methoxy-3,4-dihydroisoquinoline [134 mg (0.5 mmol)]
and TMSCl [64 ul (0.5 mmol)] in THF (2 ml). The reaction was
stirred at -78.degree. C. for 1 h and then allowed to come to room
temperature overnight. The reaction was then quenched with sat
NH4Cl and diluted with 20 ml of EtOAc. The organic layer was
removed, washed with water, dried (MgSO4) and the solvent removed.
Yield=15 mg (4%) as TFA salt via prep chrom. MS (m/z): 392
[M+H]
Example BT:
6-Benzyloxy-1-[(E)-2-(1H-indazol-6-yl)vinyl]-7-methoxy-1,2,3,4-tetrahydro-
isoquinoline
##STR00258##
[0443] To a solution of
[5-[(E)-2-bromovinyl]indazol-1-yl]-triisopropyl-silane [379 mg (1
mmol)] in Ether (15 ml) at -78.degree. C. was added 1.7 M
t-Butyllithium [1.2 ml (2.2 mmol)]. The mixture was stirred at
-78.degree. C. for 1 h then treated at -78.degree. with a mix of
6-benzyloxy-7-methoxy-3,4-dihydroisoquinoline [134 mg (0.5 mmol)]
and TMSCl [64 ul (0.5 mmol)] in THF (2 ml). The reaction was
stirred at -78.degree. C. for 1 h and then allowed to come to room
temperature overnight. The reaction was then quenched with sat
NH.sub.4Cl and diluted with 20 ml of EtOAc. The organic layer was
removed, washed with water, dried (MgSO4) and the solvent removed.
Yield=15 mg (4%) as TFA salt via prep chrom. MS (m/z): 412
[M+H]
Example BU:
6-Benzyloxy-1-[(E)-2-(2,6-difluoro-4-methoxy-phenyl)vinyl]-7-methoxy-1,2,-
3,4-tetrahydroisoquinoline
##STR00259##
[0445] To a solution of
2-[(E)-2-bromovinyl]-1,3-difluoro-5-methoxy-benzene [248 mg (1
mmol)] in Ether (15 ml) at -78.degree. C. was added 1.7 M
t-Butyllithium [1.2 ml (2.2 mmol)]. The mixture was stirred at
-78.degree. C. for 1 h then treated at -78.degree. with a mix of
6-benzyloxy-7-methoxy-3,4-dihydroisoquinoline [134 mg (0.5 mmol)]
and TMSCl [64 ul (0.5 mmol)] in THF (2 ml). The reaction was
stirred at -78.degree. C. for 1 h and then allowed to come to room
temperature overnight. The reaction was then quenched with sat
NH.sub.4Cl and diluted with 20 ml of EtOAc. The organic layer was
removed, washed with water, dried (MgSO.sub.4) and the solvent
removed. Yield=10 mg (2.3%) as TFA salt via prep chrom. MS (m/z):
249 [M+H]
Example BV:
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-methoxy-2,5-dimethyl-phenyl)vinyl]-1,2,-
3,4-tetrahydroisoquinoline
##STR00260##
[0447] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and the
4-methoxy-2,5-dimethyl-benzaldehyde (125 mg, 0.84 mmol) in THF (10
mL) was cooled to -35.degree. C. with stirring under argon. To this
mixture was added a solution of lithium bis(trimethylsilyl)amide
(0.68 mL, 0.68 mmol, 1M in THF) and the reaction mixture was
stirred for 1 hour at -35.degree. C. The reaction was allowed to
warm up to room temperature and the organic solvent was evaporated
to give a residue. The residue was dissolved (or suspended) in 4M
HCl dioxane (5 mL) and stirred at room temperature until the
reaction was completed. The organic layer was evaporated to leave a
residue, which was purified by flash or reverse phase preparatory
chromatography. LC-MS; M+1=430.
Example BW:
6-Benzyloxy-1-[(E)-2-(5-isopropyl-4-methoxy-2-methyl-phenyl)vinyl]-7-meth-
oxy-1,2,3,4-tetrahydroisoquinoline
##STR00261##
[0449] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
5-isopropyl-4-methoxy-2-methyl-benzaldehyde (164 mg, 0.84 mmol) in
THF (10 mL) was cooled to -35.degree. C. with stirring under argon.
To this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=458.
Example BX:
6-Benzyloxy-1-[(E)-2-[5-(2,2-dimethylpropoxy)-4-methoxy-2-methyl-phenyl]v-
inyl]-7-methoxy-1,2,3,4-tetrahydroisoquinoline
##STR00262##
[0451] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
5-(2,2-dimethylpropoxy)-4-methoxy-2-methyl-benzaldehyde (196 mg,
0.84 mmol) in THF (10 mL) was cooled to -35.degree. C. with
stirring under argon. To this mixture was added a solution of
lithium bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF)
and the reaction mixture was stirred for 1 hour at -35.degree. C.
The reaction was allowed to warm up to room temperature and the
organic solvent was evaporated to give a residue. The residue was
dissolved (or suspended) in 4M HCl dioxane (5 mL) and stirred at
room temperature until the reaction was completed. The organic
layer was evaporated to leave a residue, which was purified by
flash or reverse phase preparatory chromatography. LC-MS;
M+1=502
Example BY:
6-Benzyloxy-7-methoxy-1-[(E)-2-[4-methoxy-2-methyl-5-(4-piperidylmethoxy)-
phenyl]vinyl]-1,2,3,4-tetrahydroisoquinoline
##STR00263##
[0453] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and isopropyl
4-[(5-formyl-2-methoxy-4-methyl-phenoxy)methyl]piperidine-1-carboxylate
(305 mg, 0.84 mmol) in THF (10 mL) was cooled to -35.degree. C.
with stirring under argon. To this mixture was added a solution of
lithium bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF)
and the reaction mixture was stirred for 1 hour at -35.degree. C.
The reaction was allowed to warm up to room temperature and the
organic solvent was evaporated to give a residue. The residue was
dissolved (or suspended) in 4M HCl dioxane (5 mL) and stirred at
room temperature until the reaction was completed. The organic
layer was evaporated to leave a residue, which was purified by
flash or reverse phase preparatory chromatography. LC-MS;
M+1=529
Example BZ:
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-methylsulfonylphenyl)vinyl]-1,2,3,4-tet-
rahydroisoquinoline
##STR00264##
[0455] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
4-methylsulfonylbenzaldehyde (155 mg, 0.84 mmol) in THF (10 mL) was
cooled to -35.degree. C. with stirring under argon. To this mixture
was added a solution of lithium bis(trimethylsilyl)amide (0.68 mL,
0.68 mmol, 1M in THF) and the reaction mixture was stirred for 1
hour at -35.degree. C. The reaction was allowed to warm up to room
temperature and the organic solvent was evaporated to give a
residue. The residue was dissolved (or suspended) in 4M HCl dioxane
(5 mL) and stirred at room temperature until the reaction was
completed. The organic layer was evaporated to leave a residue,
which was purified by flash or reverse phase preparatory
chromatography. LC-MS; M+1=450.
Example CA:
6-Benzyloxy-1-[(E)-2-(2,6-dimethoxy-3-pyridyl)vinyl]-7-methoxy-1,2,3,4-te-
trahydroisoquinoline
##STR00265##
[0457] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
2,6-dimethoxypyridine-3-carbaldehyde (140 mg, 0.84 mmol) in THF (10
mL) was cooled to -35.degree. C. with stirring under argon. To this
mixture was added a solution of lithium bis(trimethylsilyl)amide
(0.68 mL, 0.68 mmol, 1M in THF) and the reaction mixture was
stirred for 1 hour at -35.degree. C. The reaction was allowed to
warm up to room temperature and the organic solvent was evaporated
to give a residue. The residue was dissolved (or suspended) in 4M
HCl dioxane (5 mL) and stirred at room temperature until the
reaction was completed. The organic layer was evaporated to leave a
residue, which was purified by flash or reverse phase preparatory
chromatography. LC-MS; M+1=433.
Example CB:
6-Benzyloxy-1-[(E)-2-chroman-6-ylvinyl]-7-methoxy-1,2,3,4-tetrahydroisoqu-
inoline
##STR00266##
[0459] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
chromane-6-carbaldehyde (136 mg, 0.84 mmol) in THF (10 mL) was
cooled to -35.degree. C. with stirring under argon. To this mixture
was added a solution of lithium bis(trimethylsilyl)amide (0.68 mL,
0.68 mmol, 1M in THF) and the reaction mixture was stirred for 1
hour at -35.degree. C. The reaction was allowed to warm up to room
temperature and the organic solvent was evaporated to give a
residue. The residue was dissolved (or suspended) in 4M HCl dioxane
(5 mL) and stirred at room temperature until the reaction was
completed. The organic layer was evaporated to leave a residue,
which was purified by flash or reverse phase preparatory
chromatography. LC-MS; M+1=428
Example CC:
6-Benzyloxy-7-methoxy-1-[(E)-2-(7-methylchroman-8-yl)vinyl]-1,2,3,4-tetra-
hydroisoquinoline
##STR00267##
[0461] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
7-methylchromane-8-carbaldehyde (148 mg, 0.84 mmol) in THF (10 mL)
was cooled to -35.degree. C. with stirring under argon. To this
mixture was added a solution of lithium bis(trimethylsilyl)amide
(0.68 mL, 0.68 mmol, 1M in THF) and the reaction mixture was
stirred for 1 hour at -35.degree. C. The reaction was allowed to
warm up to room temperature and the organic solvent was evaporated
to give a residue. The residue was dissolved (or suspended) in 4M
HCl dioxane (5 mL) and stirred at room temperature until the
reaction was completed. The organic layer was evaporated to leave a
residue, which was purified by flash or reverse phase preparatory
chromatography. LC-MS; M+1=442.
Example CD:
1-[(E)-2-[5-(4-azidobutoxy)-4-methoxy-2-methyl-phenyl]vinyl]-6-benzyloxy--
7-methoxy-1,2,3,4-tetrahydroisoquinoline
##STR00268##
[0463] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
5-(4-azidobutoxy)-4-methoxy-2-methyl-benzaldehyde (221 mg, 0.84
mmol) in THF (10 mL) was cooled to -35.degree. C. with stirring
under argon. To this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=529.
Example CE:
6-Benzyloxy-7-methoxy-1-[(E)-2-(7-methylchroman-6-yl)vinyl]-1,2,3,4-tetra-
hydroisoquinoline
##STR00269##
[0465] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
7-methylchromane-6-carbaldehyde (148 mg, 0.84 mmol) in THF (10 mL)
was cooled to -35.degree. C. with stirring under argon. To this
mixture was added a solution of lithium bis(trimethylsilyl)amide
(0.68 mL, 0.68 mmol, 1M in THF) and the reaction mixture was
stirred for 1 hour at -35.degree. C. The reaction was allowed to
warm up to room temperature and the organic solvent was evaporated
to give a residue. The residue was dissolved (or suspended) in 4M
HCl dioxane (5 mL) and stirred at room temperature until the
reaction was completed. The organic layer was evaporated to leave a
residue, which was purified by flash or reverse phase preparatory
chromatography. LC-MS; M+1=442.
Example CF:
6-Benzyloxy-1-[(E)-2-chroman-8-ylvinyl]-7-methoxy-1,2,3,4-tetrahydroisoqu-
inoline
##STR00270##
[0467] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
chromane-8-carbaldehyde (136 mg, 0.84 mmol) in THF (10 mL) was
cooled to -35.degree. C. with stirring under argon. To this mixture
was added a solution of lithium bis(trimethylsilyl)amide (0.68 mL,
0.68 mmol, 1M in THF) and the reaction mixture was stirred for 1
hour at -35.degree. C. The reaction was allowed to warm up to room
temperature and the organic solvent was evaporated to give a
residue. The residue was dissolved (or suspended) in 4M HCl dioxane
(5 mL) and stirred at room temperature until the reaction was
completed. The organic layer was evaporated to leave a residue,
which was purified by flash or reverse phase preparatory
chromatography. LC-MS; M+1=428.
Example CG:
6-Benzyloxy-7-methoxy-1-[(E)-2-(6-methyl-2,3-dihydrobenzofuran-5-yl)vinyl-
]-1,2,3,4-tetrahydroisoquinoline
##STR00271##
[0469] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
6-methyl-2,3-dihydrobenzofuran-5-carbaldehyde (136 mg, 0.84 mmol)
in THF (10 mL) was cooled to -35.degree. C. with stirring under
argon. To this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=428.
Example CH: tert-Butyl
2-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
indole-1-carboxylate
##STR00272##
[0471] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
tert-butyl 2-formylindole-1-carboxylate (206 mg, 0.84 mmol) in THF
(10 mL) was cooled to -35.degree. C. with stirring under argon. To
this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=511.
Example CI: tert-Butyl
3-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
indole-1-carboxylate
##STR00273##
[0473] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
tert-butyl 3-formylindole-1-carboxylate (206 mg, 0.84 mmol) in THF
(10 mL) was cooled to -35.degree. C. with stirring under argon. To
this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=511
Example CJ:
6-Benzyloxy-1-[(E)-2-(1H-indol-3-yl)vinyl]-7-methoxy-1,2,3,4-tetrahydrois-
oquinoline
##STR00274##
[0475] The product was obtained from the reaction in Example CI.
LC-MS; M+1=411.
Example CK: tert-Butyl
4-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)etheny-
l]-1H-indole-1-carboxylate
##STR00275##
[0477] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
tert-butyl 4-formylindole-1-carboxylate (206 mg, 0.84 mmol) in THF
(10 mL) was cooled to -35.degree. C. with stirring under argon. To
this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=511.
Example CL:
6-Benzyloxy-1-[(E)-2-(1H-indol-4-yl)vinyl]-7-methoxy-1,2,3,4-tetrahydrois-
oquinoline
##STR00276##
[0479] The product was obtained from the reaction in Example CK.
LC-MS; M+1=411.
Example CM: tert-Butyl
5-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
indole-1-carboxylate
##STR00277##
[0481] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
tert-butyl 5-formylindole-1-carboxylate (206 mg, 0.84 mmol) in THF
(10 mL) was cooled to -35.degree. C. with stirring under argon. To
this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=511.
Example CN: tert-Butyl
7-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
indole-1-carboxylate
##STR00278##
[0483] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
tert-butyl 7-formylindole-1-carboxylate (206 mg, 0.84 mmol) in THF
(10 mL) was cooled to -35.degree. C. with stirring under argon. To
this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=511.
Example CO:
3-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
-2,6-difluoro-phenol
##STR00279##
[0485] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
2,4-difluoro-3-hydroxy-benzaldehyde (133 mg, 0.84 mmol) in THF (10
mL) was cooled to -35.degree. C. with stirring under argon. To this
mixture was added a solution of lithium bis(trimethylsilyl)amide
(0.68 mL, 0.68 mmol, 1M in THF) and the reaction mixture was
stirred for 1 hour at -35.degree. C. The reaction was allowed to
warm up to room temperature and the organic solvent was evaporated
to give a residue. The residue was dissolved (or suspended) in 4M
HCl dioxane (5 mL) and stirred at room temperature until the
reaction was completed. The organic layer was evaporated to leave a
residue, which was purified by flash or reverse phase preparatory
chromatography. LC-MS; M+1=424.
Example CP:
6-Benzyloxy-7-methoxy-1-[(E)-2-(3-methylsulfonylphenyl)vinyl]-1,2,3,4-tet-
rahydroisoquinoline
##STR00280##
[0487] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
3-methylsulfonylbenzaldehyde (155 mg, 0.84 mmol) in THF (10 mL) was
cooled to -35.degree. C. with stirring under argon. To this mixture
was added a solution of lithium bis(trimethylsilyl)amide (0.68 mL,
0.68 mmol, 1M in THF) and the reaction mixture was stirred for 1
hour at -35.degree. C. The reaction was allowed to warm up to room
temperature and the organic solvent was evaporated to give a
residue. The residue was dissolved (or suspended) in 4M HCl dioxane
(5 mL) and stirred at room temperature until the reaction was
completed. The organic layer was evaporated to leave a residue,
which was purified by flash or reverse phase preparatory
chromatography. LC-MS; M+1=450.
Example CQ:
6-Benzyloxy-7-methoxy-1-[(E)-2-(6-methoxy-2,3-dihydro-1,4-benzodioxin-7-y-
l)vinyl]-1,2,3,4-tetrahydroisoquinoline
##STR00281##
[0489] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
6-methoxy-2,3-dihydro-1,4-benzodioxine-7-carbaldehyde (163 mg, 0.84
mmol) in THF (10 mL) was cooled to -35.degree. C. with stirring
under argon. To this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=460
Example CR:
6-Benzyloxy-7-methoxy-1-[(E)-2-(6-methoxy-1,3-benzodioxol-5-yl)vinyl]-1,2-
,3,4-tetrahydroisoquinoline
##STR00282##
[0491] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
6-methoxy-1,3-benzodioxole-5-carbaldehyde (151 mg, 0.84 mmol) in
THF (10 mL) was cooled to -35.degree. C. with stirring under argon.
To this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=446.
Example CS: tert-Butyl
6-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
indole-1-carboxylate
##STR00283##
[0493] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
tert-butyl 6-formylindole-1-carboxylate (206 mg, 0.84 mmol) in THF
(10 mL) was cooled to -35.degree. C. with stirring under argon. To
this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=511.
Example CT:
2-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
-4,5-dimethoxy-N,N-dimethyl-aniline
##STR00284##
[0495] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
2-(dimethylamino)-4,5-dimethoxy-benzaldehyde (176 mg, 0.84 mmol) in
THF (10 mL) was cooled to -35.degree. C. with stirring under argon.
To this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=475
Example CU:
3-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
-N,N-dimethyl-pyridin-2-amine
##STR00285##
[0497] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
2-(dimethylamino)pyridine-3-carbaldehyde (126 mg, 0.84 mmol) in THF
(10 mL) was cooled to -35.degree. C. with stirring under argon. To
this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=416
Example CV: Ethyl
4-[5-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vin-
yl]-2-methoxy-phenoxy]butanoate
##STR00286##
[0499] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and ethyl
4-(5-formyl-2-methoxy-phenoxy)butanoate (223 mg, 0.84 mmol) in THF
(10 mL) was cooled to -35.degree. C. with stirring under argon. To
this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=532.
Example CW: tert-Butyl
N-[2-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vin-
yl]phenyl]carbamate
##STR00287##
[0501] A solution of tert-Butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate (100 mg, 0.169 mmol) and
tert-butyl N-(2-formylphenyl)carbamate (186 mg, 0.84 mmol) in THF
(10 mL) was cooled to -35.degree. C. with stirring under argon. To
this mixture was added a solution of lithium
bis(trimethylsilyl)amide (0.68 mL, 0.68 mmol, 1M in THF) and the
reaction mixture was stirred for 1 hour at -35.degree. C. The
reaction was allowed to warm up to room temperature and the organic
solvent was evaporated to give a residue. The residue was dissolved
(or suspended) in 4M HCl dioxane (5 mL) and stirred at room
temperature until the reaction was completed. The organic layer was
evaporated to leave a residue, which was purified by flash or
reverse phase preparatory chromatography. LC-MS; M+1=487.
Example CX:
2-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
aniline
##STR00288##
[0503] The product was obtained from the reaction in Example CW.
LC-MS; M+1=387.
Example CY:
(E)-6-(Benzyloxy)-7-methoxy-1-(4-methoxy-3-(trifluoromethyl)styryl)-1,2,3-
,4-tetrahydroisoquinoline
##STR00289##
[0505] This compound was prepared by the Methylenation reaction for
aldehydes and ketones using the new Julia-Kocienski olefination
reaction; (Kaori Ando et. al, Organic Letter, Apr. 1, 2015); Raju
Jannapu Reddy, et. al, JOC. To the solution of tert-butyl
6-(benzyloxy)-7-methoxy-1-(2-phenyl-2H-tetrazol-5-ylsulfonyl)methyl-3,4-d-
ihydroisoquinoline-2(1H)-carboxylate (0.2016 g, 0,340 mmol) and
4-methoxy-3-(trifluoromethyl) benzaldehyde (58 mgs, 0.284 mmol) in
anhydrous DMF (5 ml) under argon was added sodium tert-butoxide (82
mgs, 0.85 mmol) at room temperature. After stirring for 1 hr, the
reaction was quenched with aqueous NH.sub.4Cl and the mixture was
extracted with EtOAc (2.times.50 ml), the combined extracts were
washed with H2O, brine, dried (MgSO.sub.4), filtered and
concentrated to dryness. The crude obtained was treated with
1,2-dichloroethane and 4M HCl-in-Dioxane (v/v) monitored by LCMS,
upon completion, it was concentrated to dryness and purified by
HPLC to afford the TFA salt of the titled compound. M+H=470.
Example CZ:
(E)-6-(benzyloxy)-7-methoxy-1-(4-methoxy-3-methyl-5-(trifluoromethyl)styr-
yl)-1,2,3,4-tetrahydroisoquinoline
##STR00290##
[0507]
(E)-6-(Benzyloxy)-7-methoxy-1-(4-methoxy-3-methyl-5-(trifluoromethy-
l)styryl)-1,2,3,4-tetrahydroisoquinoline was prepared as described
in detail above using
4-methoxy-3-methyl-5-(trifluoromethyl)benzaldehyde (62 mgs, 0.28
mmol) to afford the titled compound. M+H=484.
Example DA:
(E)-6-(benzyloxy)-7-methoxy-1-(2-(trifluoromethyl)styryl)-1,2,3,4-tetrahy-
droisoquinoline
##STR00291##
[0509]
(E)-6-(Benzyloxy)-7-methoxy-1-(2-(trifluoromethyl)styryl)-1,2,3,4-t-
etrahydroisoquinoline was prepared as described above using
2-(trifluoromethyl)benzaldehyde (0.61 g, 0.35 mmol) to afford the
titled compound. M+H=440.
Example DB:
(E)-6-(benzyloxy)-7-methoxy-1-(3-(trifluoromethyl)styryl)-1,2,3,4-tetrahy-
droisoquinoline
##STR00292##
[0511]
(E)-6-(Benzyloxy)-7-methoxy-1-(3-(trifluoromethyl)styryl)-1,2,3,4-t-
etrahydroisoquinoline was prepared using
3-(trifluoromethyl)benzaldehyde (0.61 g, 0.35 mmol) to afford the
titled compound. M+H=440.
Example DC:
(E)-2-(2-(6-(benzyloxy)-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl)-
-N,N-dimethylamine
##STR00293##
[0513] To the stirred solution of 10 (0.2578 g, 0.44 mmol) and
2-(dimethylamino)benzaldehyde (0.2602 g, 1.74 mmol, 5 eq.) in
anhydrous THF (10 ml), under argon at -35.degree. C. was added
sodium bis(trimethylsilyl)amide (1.0M in THF, 1.7 ml) dropwise. The
resulting pale yellow solution was stirred vigorously for an
additional 1 hr and diluted with sat. ammonium chloride, and the
mixture was extracted with ethyl acetate. The organic layer was
washed with water, brine, dried (MgSO4), filtered, concentrated to
dryness, residue obtained subjected to boc-deprotection using 4M
HCl-in-Dioxane and 1,2-Dichloroethane. The crude after
concentration was purified by the Waters LCMS prepsystem to afford
the titled compound as the TFA salt. M+H=415.
Example DD:
(E)-(benzyloxy)-7-methoxy-1-(2-(2-methoxypyrimidin-5-yl)vinyl)-1,2,3,4-te-
trahydroisoquinoline
##STR00294##
[0515]
(E)-(Benzyloxy)-7-methoxy-1-(2-(2-methoxypyrimidin-5-yl)vinyl)-1,2,-
3,4-tetrahydroisoquinoline was prepared as described above using
2-methoxypyrimidine-5-carbaldehyde (0.1940 g, 1.40 mmol) to afford
the titled compound. M+H=404.
Example DE:
(E)-6-(benzyloxy)-7-methoxy-1-(2-(2-methoxyethoxy)styryl)-1,2,3,4-tetrahy-
droisoquinoline
##STR00295##
[0517]
(E)-6-(Benzyloxy)-7-methoxy-1-(2-(2-methoxyethoxy)styryl)-1,2,3,4-t-
etrahydroisoquinoline was prepared using
2-(2-methoxyethoxy)benzaldehyde (0.2776 g, 1.54 mmol) to afford the
titled compound as the TFA salt. M+H=446.
Example DF:
(E)-6-(benzyloxy)-1-(2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)vinyl)-7-met-
hoxy-1,2,3,4-tetrahydroisoquinoline
##STR00296##
[0519]
(E)-6-(Benzyloxy)-1-(2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)vinyl)-
-7-methoxy-1,2,3,4-tetrahydroisoquinoline was prepared using
2,2-difluorobenzo[d][1,3]dioxol-5-carbaldehyde (0.2444 g, 1.31
mmol) to afford the titled compound. M+H=452.
Example DG:
(E)-6-(benzyloxy)-7-methoxy-1-(2-methoxystyryl)-1,2,3,4-tetrahydroisoquin-
oline
##STR00297##
[0521]
(E)-6-(Benzyloxy)-7-methoxy-1-(2-methoxystyryl)-1,2,3,4-tetrahydroi-
soquinoline was prepared using 2-methoxybenzaldehyde (0.1985 g,
1.46 mmol) to afford the titled compound. M+H=402.
Example DH:
(E)-4-(2-(2-(6-(benzyloxy)-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)v-
inyl)phenyl)morpholine
##STR00298##
[0523]
(E)-4-(2-(2-(6-(Benzyloxy)-7-methoxy-1,2,3,4-tetrahydroisoquinolin--
1-yl)vinyl)phenyl)morpholine was prepared using
2-morpholinobenzaldehyde (0.2218 g, 1.16 mmol) to afford the titled
compound. M+H=457.
Example DI:
(E)-6-(benzyloxy)-7-methoxy-1-(2-(6-methoxynaphthalen-2-yl)vinyl)-1,2,3,4-
-tetrahydroisoquinoline
##STR00299##
[0525]
(E)-6-(Benzyloxy)-7-methoxy-1-(2-(6-methoxynaphthalen-2-yl)vinyl)-1-
,2,3,4-tetrahydroisoquinoline was prepared using
6-methoxy-2-naphthaldehyde (0.2063 g, 1.11 mmol) to afford the
titled compound. M+H=452
Example DJ:
(E)-6-(benzyloxy-7-methoxy-1-(4-(pyridine-3-yl)styryl)-1,2,3,4-tetrahydro-
isoquinoline
##STR00300##
[0527]
(E)-6-(Benzyloxy-7-methoxy-1-(4-(pyridine-3-yl)styryl)-1,2,3,4-tetr-
ahydroisoquinoline was prepared using 4-(pyridine-3-yl)benzaldehyde
(0.2201 g, 1.201 mmol) to afford the titled compound.
Example DK:
(E)-1-(4-(1H-imidazol-1-yl)styryl)-6-(benzyloxy)-7-methoxy-1,2,3,4-tetrah-
ydroisoquinoline
##STR00301##
[0529]
(E)-1-(4-(1H-Imidazol-1-yl)styryl)-6-(benzyloxy)-7-methoxy-1,2,3,4--
tetrahydroisoquinoline was prepared using
4-(1H-imidazol-1-yl)benzaldehyde 23 (0.2536 g, 1.5 mmol) to afford
the titled compound.
Example DL:
(E)-7-(2-(6-(benzyloxy)-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)viny-
l)quinoline
##STR00302##
[0531]
(E)-7-(2-(6-(benzyloxy)-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-y-
l)vinyl)quinoline was prepared using quinolone-6-carbaldehyde
(0.2789 g, 1.8 mmol) to afford the titled compound. M+H=423
Example DM:
(E)-6-(benzyloxy)-7-methoxy-1-(4-(2-methyl-1H-imidazol-1-yl)styryl)-1,2,3-
,4-tetrahydroisoquinoline
##STR00303##
[0533]
(E)-6-(Benzyloxy)-7-methoxy-1-(4-(2-methyl-1H-imidazol-1-yl)styryl)-
-1,2,3,4-tetrahydroisoquinoline was prepared using
4-(2-methyl-1H-imidazol-1-yl)benzaldehyde (0.3112 g, 1.67 mmol) to
afford the titled compound. M+H=452.
Example DN:
(E)-6-(benzyloxy)-7-methoxy-1-(2-(2-(3-methoxyphenyl)pyrimidin-5-yl)vinyl-
-1,2,3,4-tetrahydroisoquinoline
##STR00304##
[0535]
(E)-6-(Benzyloxy)-7-methoxy-1-(2-(2-(3-methoxyphenyl)pyrimidin-5-yl-
)vinyl-1,2,3,4-tetrahydroisoquinoline was prepared using
2-(3-methoxyphenyl)pyrimidine-5-carbaldehyde (0.2996 g, 1.40 mmol)
to afford the titled compound. M+H=480.
Example DO:
(E)-6-(benzyloxy)-1-(4-(4-ethylpiperazin-1-yl)styryl)-7-methoxy-1,2,3,4-t-
etrahydroisoquinoline
##STR00305##
[0537]
(E)-6-(Benzyloxy)-1-(4-(4-ethylpiperazin-1-yl)styryl)-7-methoxy-1,2-
,3,4-tetrahydroisoquinoline was prepared using
4-(4-ethylpiperazin-1-yl)benzaldehyde (0.3742 g, 1.71 mmol) to
afford the titled compound. M+H=484.
Example DP:
6-(Benzyloxy)-7-methoxy-1-[(E)-2-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl}-
ethenyl]-1,2,3,4-tetrahydroisoquinoline
##STR00306##
[0539] To a solution of tert-butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate [118 mg (0.2 mmol)] in THF (5 ml)
with 1-methylpyrrolo[2,3-b]pyridine-3-carbaldehyde [96 mg (0.6
mmol)] was added at -38.degree. C. 1M LiN(TMSi).sub.2 [600 ul (0.6
mmol)]. The reaction was stirred at -38.degree. C. for 60 min and
then at room temperature for 30 min longer. The reaction was
quenched with sat NH.sub.4Cl (10 ml), extracted with EtOAc (20 ml),
dried (MgSO.sub.4) and the solvent removed. The residue was treated
with 2 ml of 4NHCl in dioxane for 1 h, rotary evaporated to dryness
and chromatographed via reverse phase chromatography. Yield=3 mg
(3.5%) as TFA salt via prep chrom. MS (m/z): 426 [M+H]
Example DQ:
6-(Benzyloxy)-7-methoxy-1-[(E)-2-[3-(pyridin-4-yl)phenyl]ethenyl]-1,2,3,4-
-tetrahydroisoquinoline
##STR00307##
[0541] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 3-(4-pyridyl)benzaldehyde the reaction
afforded the desired adduct.
[0542] Yield=18 mg (20%) as TFA salt via prep chrom. MS (m/z): 449
[M+H]
Example DR:
6-(Benzyloxy)-7-methoxy-1-[(E)-2-(1,3-thiazol-4-yl)ethenyl]-1,2,3,4-tetra-
hydroisoquinoline
##STR00308##
[0544] Using the same procedure outlined in Example DP at the same
scale with the aldehyde thiazole-4-carbaldehyde the reaction
afforded the desired adduct.
[0545] Yield=11 mg (14%) as TFA salt via prep chrom. MS (m/z): 379
[M+H]
Example DS:
6-(Benzyloxy)-7-methoxy-1-[(E)-2-[4-(pyrimidin-5-yl)phenyl]ethenyl]-1,2,3-
,4-tetrahydroisoquinoline
##STR00309##
[0547] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-pyrimidin-5-ylbenzaldehyde the reaction
afforded the desired adduct. Yield=10 mg (11%) as TFA salt via prep
chrom. MS (m/z): 450 [M+H]
Example DT:
6-(Benzyloxy)-7-methoxy-1-[(E)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]ethenyl-
]-1,2,3,4-tetrahydroisoquinoline
##STR00310##
[0549] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-(1,2,4-triazol-1-yl)benzaldehyde the
reaction afforded the desired adduct. Yield=10 mg (11%) as TFA salt
via prep chrom. MS (m/z): 439 [M+H]
Example DU:
1-[(E)-2-(1-Benzothiophen-2-yl)ethenyl]-6-(benzyloxy)-7-methoxy-1,2,3,4-t-
etrahydroisoquinoline
##STR00311##
[0551] Using the same procedure outlined in Example DP at the same
scale with the aldehyde benzothiophene-2-carbaldehyde the reaction
afforded the desired adduct. Yield=17 mg (20%) as TFA salt via prep
chrom. MS (m/z): 428 [M+H]
Example DV:
6-(Benzyloxy)-7-methoxy-1-[(E)-2-(1,3-thiazol-2-yl)ethenyl]-1,2,3,4-tetra-
hydroisoquinoline
##STR00312##
[0553] Using the same procedure outlined in Example DP at the same
scale with the aldehyde thiazole-2-carbaldehyde the reaction
afforded the desired adduct.
[0554] Yield=15 mg (20%) as TFA salt via prep chrom. MS (m/z): 379
[M+H]
Example DW:
6-(Benzyloxy)-7-methoxy-1-[(E)-2-[4-(4-methylpiperazin-1-yl)phenyl]etheny-
l]-1,2,3,4-tetrahydroisoquinoline
##STR00313##
[0556] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-(4-methylpiperazin-1-yl)benzaldehyde the
reaction afforded the desired adduct. Yield=3.3 mg (4%) as TFA salt
via prep chrom. MS (m/z): 470 [M+H]
Example DX:
6-(Benzyloxy)-7-methoxy-1-[(E)-2-[2-(piperidin-1-yl)phenyl]ethenyl]-1,2,3-
,4-tetrahydroisoquinoline
##STR00314##
[0558] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 2-(1-piperidyl)benzaldehyde the reaction
afforded the desired adduct.
[0559] Yield=11 mg (12%) as TFA salt via prep chrom. MS (m/z): 455
[M+H]
Example DY:
5-[(E)-2-(6-Benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
-4-methyl-thiazole
##STR00315##
[0561] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-methylthiazole-5-carbaldehyde the
reaction afforded the desired adduct.
[0562] Yield=8 mg (10%) as TFA salt via prep chrom. MS (m/z): 393
[M+H]
Example DZ:
6-Benzyloxy-7-methoxy-1-[(E)-2-[4-(2-pyridyl)phenyl]vinyl]-1,2,3,4-tetrah-
ydroisoquinoline
##STR00316##
[0564] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-(2-pyridyl)benzaldehyde the reaction
afforded the desired adduct.
[0565] Yield=10 mg (11%) as TFA salt via prep chrom. MS (m/z): 449
[M+H]
Example EA:
6-Benzyloxy-7-methoxy-1-[(E)-2-[4-(1-piperidyl)phenyl]vinyl]-1,2,3,4-tetr-
ahydroisoquinoline
##STR00317##
[0567] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-(1-piperidyl)benzaldehyde the reaction
afforded the desired adduct.
[0568] Yield=5 mg (6%) as TFA salt via prep chrom. MS (m/z): 455
[M+H]
Example EB:
6-Benzyloxy-7-methoxy-1-[(E)-2-(6-methoxybenzofuran-5-yl)vinyl]-1,2,3,4-t-
etrahydroisoquinoline
##STR00318##
[0570] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 6-methoxybenzofuran-5-carbaldehyde the
reaction afforded the desired adduct. Yield=20 mg (23%) as TFA salt
via prep chrom. MS (m/z): 442 [M+H]
Example EC:
2-[3-[(E)-2-(6-Benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vin-
yl]phenyl]oxazole
##STR00319##
[0572] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 3-oxazol-2-ylbenzaldehyde the reaction
afforded the desired adduct.
[0573] Yield=20 mg (23%) as TFA salt via prep chrom. MS (m/z): 439
[M+H]
Example ED:
2-[4-[(E)-2-(6-Benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vin-
yl]phenyl]oxazole
##STR00320##
[0575] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-oxazol-2-ylbenzaldehyde the reaction
afforded the desired adduct.
[0576] Yield=10 mg (11%) as TFA salt via prep chrom. MS (m/z): 439
[M+H]
Example EE: Ethyl
2-[4-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vin-
yl]phenyl]oxazole-4-carboxylate
##STR00321##
[0578] Using the same procedure outlined in Example DP at the same
scale with the aldehyde ethyl
2-(4-formylphenyl)oxazole-4-carboxylate the reaction afforded the
desired adduct. Yield=20 mg (20%) as TFA salt via prep chrom. MS
(m/z): 511 [M+H]
Example EF: Ethyl
2-[3-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vin-
yl]phenyl]oxazole-4-carboxylate
##STR00322##
[0580] Using the same procedure outlined in Example DP at the same
scale with the aldehyde ethyl
2-(3-formylphenyl)oxazole-4-carboxylate the reaction afforded the
desired adduct. Yield=25 mg (24%) as TFA salt via prep chrom. MS
(m/z): 511 [M+H]
Example EG:
6-Benzyloxy-1-[(E)-2-(2,3-dihydrobenzofuran-6-yl)vinyl]-7-methoxy-1,2,3,4-
-tetrahydroisoquinoline
##STR00323##
[0582] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 2,3-dihydrobenzofuran-6-carbaldehyde the
reaction afforded the desired adduct. Yield=25 mg (30%) as TFA salt
via prep chrom. MS (m/z): 414 [M+H]
Example EH:
6-Benzyloxy-1-[(E)-2-(2,4-dimethoxy-5-methyl-phenyl)vinyl]-7-methoxy-1,2,-
3,4-tetrahydroisoquinoline
##STR00324##
[0584] To a solution of tert-butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate [118 mg (0.2 mmol)] in THF (5 ml)
with 2,4-dimethoxy-5-methyl-benzaldehyde [36 mg (0.2 mmol)] was
added at room temperature Na t-butoxide [58 mg (0.6 mmol)]. The
reaction was stirred at room temperature for 60 min. The reaction
was quenched with sat NH.sub.4Cl (10 ml), extracted with EtOAc (20
ml), dried (MgSO.sub.4) and the solvent removed. The residue was
treated for 1 h with 3NHCl/EtOAc at room temperature then rotary
evaporated to a brown oil which was taken up into EtOAc and washed
with 2N NaOH. The organic layer was dried (MgSO.sub.4) and the
solvent removed. The residue was chromatographed via reverse phase
chromatography. Yield=3.1 mg (3.5%) as TFA salt via prep chrom. MS
(m/z): 446 [M+H]
Example EI:
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-methoxy-3-methyl-phenyl)vinyl]-1,2,3,4--
tetrahydroisoquinoline
##STR00325##
[0586] To a solution of tert-butyl
6-benzyloxy-7-methoxy-1-[(1-phenyltetrazol-5-yl)sulfonylmethyl]-3,4-dihyd-
ro-1H-isoquinoline-2-carboxylate [118 mg (0.2 mmol)] in THF (5 ml)
with 4-methoxy-3-methyl-benzaldehyde [30 mg (0.2 mmol)] was added
at room temperature Na t-butoxide [58 mg (0.6 mmol)]. The reaction
was stirred at room temperature for 60 min. The reaction was
quenched with sat NH.sub.4Cl (10 ml), extracted with EtOAc (20 ml),
dried (MgSO4) and the solvent removed. The residue was treated for
1 h with 3NHCl/EtOAc at room temperature then rotary evaporated to
a brown oil which was taken up into EtOAc and washed with 2N NaOH.
The organic layer was dried (MgSO.sub.4) and the solvent removed.
The residue was chromatographed via reverse phase chromatography.
Yield=7.2 mg (9%) as TFA salt via prep chrom. MS (m/z): 416
[M+H]
Example EJ:
6-Benzyloxy-7-methoxy-1-[(E)-2-(3-methoxyphenyl)vinyl]-1,2,3,4-tetrahydro-
isoquinoline
##STR00326##
[0588] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 3-methoxybenzaldehyde the reaction afforded
the desired adduct.
[0589] Yield=37 mg (45%) as TFA salt via prep chrom. MS (m/z): 402
[M+H]
Example EK:
6-Benzyloxy-1-[(E)-2-(2,5-dimethoxyphenyl)vinyl]-7-methoxy-1,2,3,4-tetrah-
ydroisoquinoline
##STR00327##
[0591] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 2,5-dimethoxybenzaldehyde the reaction
afforded the desired adduct.
[0592] Yield=50 mg (57%) as TFA salt via prep chrom. MS (m/z): 432
[M+H]
Example EL:
6-Benzyloxy-7-methoxy-1-[(E)-2-(4-methoxy-2,3-dimethyl-phenyl)vinyl]-1,2,-
3,4-tetrahydroisoquinoline
##STR00328##
[0594] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-methoxy-2,3-dimethyl-benzaldehyde the
reaction afforded the desired adduct. Yield=20 mg (23%) as TFA salt
via prep chrom. MS (m/z): 430 [M+H]
Example EM:
6-Benzyloxy-7-methoxy-1-[(E)-2-[4-methoxy-3-(1-piperidylmethyl)phenyl]vin-
yl]-1,2,3,4-tetrahydroisoquinoline
##STR00329##
[0596] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-methoxy-2,3-dimethyl-benzaldehyde the
reaction afforded the desired adduct. Yield=10 mg (10%) as TFA salt
via prep chrom. MS (m/z): 499 [M+H]
Example EN:
6-Benzyloxy-7-methoxy-1-[(E)-2-[4-methoxy-3-[(2-methylimidazol-1-yl)methy-
l]phenyl]vinyl]-1,2,3,4-tetrahydroisoquinoline
##STR00330##
[0598] Using the same procedure outlined in Example DP at the same
scale with the aldehyde
4-methoxy-3-[(2-methylimidazol-1-yl)methyl]benzaldehyde the
reaction afforded the desired adduct. Yield=8.2 mg (8%) as TFA salt
via prep chrom. MS (m/z): 496 [M+H]
Example EO:
6-Benzyloxy-7-methoxy-1-[(E)-2-[4-methoxy-3-(2,2,2-trifluoroethoxymethyl)-
phenyl]vinyl]-1,2,3,4-tetrahydroisoquinoline
##STR00331##
[0600] Using the same procedure outlined in Example DP at the same
scale with the aldehyde
4-methoxy-3-(2,2,2-trifluoroethoxymethyl)benzaldehyde the reaction
afforded the desired adduct. Yield=9 mg (9%) as TFA salt via prep
chrom. MS (m/z): 514 [M+H]
Example EP:
(E)-6-(benzyloxy)-1-(3-(ethoxymethyl)-4-methoxystyryl)-7-methoxy-1,2,3,4--
tetrahydroisoquinoline
##STR00332##
[0602] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-methoxy-3-(methoxymethyl)benzaldehyde the
reaction afforded the desired adduct. Yield=11 mg (10%) as TFA salt
via prep chrom. MS (m/z): 460 [M+H]
Example EQ:
4-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
benzoic Acid
##STR00333##
[0604] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-formylbenzoic acid the reaction afforded
the desired adduct. Yield=11 mg (13%) as TFA salt via prep chrom.
MS (m/z): 416 [M+H]
Example ER:
3-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
benzoic Acid
##STR00334##
[0606] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 3-formylbenzoic acid the reaction afforded
the desired adduct. Yield=21 mg (25%) as TFA salt via prep chrom.
MS (m/z): 416 [M+H]
Example ES:
2-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
benzoic Acid
##STR00335##
[0608] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 2-formylbenzoic acid the reaction afforded
the desired adduct. Yield=2.6 mg (3% overall) as TFA salt via prep
chrom. MS (m/z): 416 [M+H]
Example ET: Ethyl
2-[(E)-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)vinyl]-
benzoate
##STR00336##
[0610] Using the same procedure outlined in Example DP at the same
scale with the aldehyde ethyl 2-formylbenzoate the reaction
afforded the desired adduct. Yield=11.7 mg (13% overall) as TFA
salt via prep chrom. MS (m/z): 444 [M+H]
Example EU:
6-Benzyloxy-7-methoxy-1-[(E)-2-[4-methoxy-3-(phenoxymethyl)phenyl]vinyl]--
1,2,3,4-tetrahydroisoquinoline
##STR00337##
[0612] Using the same procedure outlined in Example DP at the same
scale with the aldehyde 4-methoxy-3-(phenoxymethyl)benzaldehyde the
reaction afforded the desired adduct. Yield=7.3 mg (6% overall) as
TFA salt via prep chrom. MS (m/z): 508 [M+H]
Data for Biological Examples
Protocol for MT-2 Spread Assay
[0613] The present assay was used to screen candidate antiviral
compounds by quantification of virus spread and production over
several rounds of infection in vitro. MT-2, a HIV-1 permissive
human T-cell line, was seeded in microtiter plates and was
simultaneously treated with serially diluted compound and
inoculated with a HIV-1 NL4-3 viral clone engineered to express
Renilla luciferase in place of Nef. Following treatment, the
culture was incubated for 96 hours. After the incubation, media was
collected and used to estimate relative infectivity on the
indicator cell line, TZM-bl. Additionally, viral spread was
quantified by measuring luciferase activity via a commercially
available luciferase substrate. In parallel, MT-2 cells were seeded
and inoculated with mock virus in the presence of serially diluted
compound. Compound toxicity was quantified 96 hours after treatment
with AlamarBlue.
Compound Treatment and Infection:
[0614] MT-2 (NIH Aids reagent program 237) cells were grown and
maintained in an incubator at 37.degree. C. with 5% CO.sub.2 using
a basal medium of RPMI-1640 supplemented with 10% FBS. Cells were
seeded in 100 .mu.l at 2.times.10.sup.4 cells/well in white walled
96-well microtiter plates. Candidate compounds were 3-fold serially
diluted in the appropriate solvent. Solvent without compound was
used as a no drug reference. Cells were inoculated at a
multiplicity of 0.027 with an HIV-1 NL4-3 virus stock engineered to
express Renilla luciferase in place of Nef. Diluted virus stock was
first added to serially diluted compound. Compound and virus were
delivered to cells in an equal volume (100 .mu.l) and treated
cultures were returned to the incubator for 96 hours. In parallel,
plates for cytotoxicity estimates were prepared in the same way
except cells were plated in clear walled 96-well microtiter plates
and were mock infected.
Infectivity Assay:
[0615] At 96 hours post infection, 100 .mu.l virus containing
culture supernatant was collected from the treated and infected
cultures and serially diluted in DMEM supplemented with 10% FBS, 1%
sodium pyruvate, and 20 .mu.g/ml DEAE dextran. One day prior,
TZM-bl (ATCC PTA-5659) were cultured in basal medium of DMEM
supplemented with 10% FBS and 1% sodium pyruvate and seeded at
7.5.times.10.sup.3 cells/well in black walled 96-well microtiter
plates. Diluted virus containing culture supernatant was
transferred to TZM-bl cultures and incubated for 48 hours at
37.degree. C. with 5% CO.sub.2. Infected TZM-bl cultures were fixed
for 5 minutes with a 1% formaldehyde/0.2% gluteraldehyde/PBS
solution then washed three times with PBS. Fixed cultures were
incubated at 37.degree. C. for 25 minutes with a 200 .mu.g/ml MUG
(4-Methylumbelliferyl .beta.-D-glucopyranoside)/DMEM solution. The
reaction was stopped with an equal volume of 1M sodium carbonate
and read at 360, 449 nm on fluorescence plate reader (Biotek).
(Viral Spread) Luciferase Assay:
[0616] At 96 hours post infection, 100 .mu.l of culture supernatant
was removed from the treated and infected cultures and EnduRen live
cell substrate (Promega) was added at a final concentration 1.3
.mu.g/ml. Cells were incubated for 1.5 hours at 37.degree. C. with
5% CO.sub.2 then read on a luminescence plate reader (Biotek).
Cytotoxicity Assay:
[0617] At 96 hours post treatment, 20 .mu.l AlamarBlue
proliferation reagent was added to 200 .mu.l treated and mock
infected cultures and incubated for 3 hours at 37.degree. C. with
5% CO.sub.2 then read at 545, 590 nm on fluorescence plate reader
(Biotek).
Analysis:
[0618] For all assays, data was imported into Accelrys Assay
Explorer 3.3. In Assay Explorer, % inhibition (antiviral or
cytotoxicity) was calculated using the solvent control as a
reference by the following equation:
1-(Signal.sub.Compound/Signal.sub.Reference). The % Inhibition and
compound concentration data was fitted using the following
4-parameter logistic model (Assay Explorer model 42):
Y = D + ( A - D 1 + ( X C ) B ) ##EQU00001##
where X is compound concentration, Y is % inhibition, D is the
maximum % Inhibition (constrained to 100%), C is IC50 value or
inflection point, B is the hill slope, and A is the minimum %
inhibition (constrained to 0%). The IC50 value is reported as the
EC50 or CC50 depending on the assay endpoint. EC50 represents the
effective concentration at which virus replication is inhibited by
50 percent. CC50 represents the concentration that results in the
death of 50 percent of the host cells. The selectivity or
therapeutic index (SI or TI), is the ratio of CC50 over EC50 and
represents the relative effectiveness in inhibiting viral
replication compared to inducing cell death.
TABLE-US-00001 TABLE Code Structure Name EC.sub.50, .mu.M
CC.sub.50, .mu.M SI A 1-[2-(3,4-dimethoxyphenyl)ethyl]- 10 >10 1
6,7-dimethoxy-1,2,3,4- tetrahydroisoquinoline B
[6-benzyloxy-1-[(E)-2-(3- 10 5 0.5 benzyloxy-4-methoxy-
phenyl)vinyl]-7-methoxy-3,4- dihydro-1H-isoquinolin-2-yl]-
pyrazin-2-yl-methanone C 1-[(E)-2-(5-benzyloxy-4-methoxy- 9.76
10.96 1.1 2-methyl-phenyl)vinyl]-6,7- dimethoxy-1,2,3,4-
tetrahydroisoquinoline D 7-benzyloxy-1-[(E)-2-(4-benzyloxy- 8.92
>10 >1.1 3-methoxy-phenyl)vinyl]-2-butyl-6-
methoxy-3,4-dihydro-1H- isoquinoline E
6-benzyloxy-1-[(E)-2-(5-benzyloxy- 8.47 7.17 0.8
4-methoxy-2-methyl-phenyl)vinyl]- 7-methoxy-2-methyl-3,4-dihydro-
1H-isoquinoline F (6-amino-2-pyridyl)-[6-benzyloxy- 5.05 100 19.8
1-[(E)-2-(5-benzyloxy-4-methoxy- 2-methyl-phenyl)vinyl]-7-methoxy-
3,4-dihydro-1H-isoquinolin-2- yl]methanone G
6-benzyloxy-1-[(E)-2-(3-benzyloxy- 5 5 1
4-methoxy-phenyl)vinyl]-2-butyl-7- methoxy-3,4-dihydro-1H-
isoquinoline H [6-benzyloxy-1-[(E)-2-(5- 4.48 100 22.3
benzyloxy-4-methoxy-2-methyl- phenyl)vinyl]-7-methoxy-3,4-
dihydro-1H-isoquinolin-2-yl]- pyrazin-2-yl-methanone I methyl
6-benzyloxy-1-[(E)-2-(4,5- 4.48 100 22.3
dimethoxy-2-methyl-phenyl)vinyl]- 7-methoxy-3,4-dihydro-1H-
isoquinoline-2-carboxylate J 6-benzyloxy-1-[(E)-2-(5-benzyloxy-
4.22 5.36 1.27 2-tert-butyl-4-methoxy-
phenyl)vinyl]-7-methoxy-1,2,3,4- tetrahydroisoquinoline K
(2-amino-3-pyridyl)-[6-benzyloxy- 2.88 100 34.72
1-[(E)-2-(5-benzyloxy-4-methoxy- 2-methyl-phenyl)vinyl]-7-methoxy-
3,4-dihydro-1H-isoquinolin-2- yl]methanone L methyl
6-benzyloxy-1-[(E)-2-(3- 2.81 >20 7.11 benzyloxy-4-methoxy-
phenyl)vinyl]-7-methoxy-3,4- dihydro-1H-isoquinoline-2- carboxylate
M [6-benzyloxy-1-[(E)-2-(5- 2.09 100 47.8
benzyloxy-4-methoxy-2-methyl- phenyl)vinyl]-7-methoxy-3,4-
dihydro-1H-isoquinolin-2-yl]-(2- pyridyl)methanone N
(2-amino-4-pyridyl)-[6-benzyloxy- 2.03 100 49.3
1-[(E)-2-(5-benzyloxy-4-methoxy- 2-methyl-phenyl)vinyl]-7-methoxy-
3,4-dihydro-1H-isoquinolin-2- yl]methanone O
6-benzyloxy-1-[(E)-2-(5-benzyloxy- 2.011 >10 >5
4-methoxy-2-methyl-phenyl)vinyl]- N-tert-butyl-7-methoxy-3,4-
dihydro-1H-isoquinoline-2- carboxamide P
(6-amino-3-pyridyl)-[6-benzyloxy- 1.69 100 59.17
1-[(E)-2-(5-benzyloxy-4-methoxy- 2-methyl-phenyl)vinyl]-7-methoxy-
3,4-dihydro-1H-isoquinolin-2- yl]methanone Q
6-benzyloxy-1-[2-(5-benzyloxy-4- 1.36 5.15 3.8
methoxy-2-methyl-phenyl)ethyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline R 6-benzyloxy-1-[(E)-2-(5-benzyloxy- 1.18
39.31 33.1 4-methoxy-2-methyl-phenyl)vinyl]-
7-methoxy-3,4-dihydro-1H- isoquinoline-2-carboxamide S
7-benzyloxy-1-[(E)-2-(4-benzyloxy- 0.992 8.25 8.3
3-methoxy-phenyl)vinyl]-6- methoxy-1,2,3,4- tetrahydroisoquinoline
T [6-benzyloxy-1-[(E)-2-(5- 0.93 100 107
benzyloxy-4-methoxy-2-methyl- phenyl)vinyl]-7-methoxy-3,4-
dihydro-1H-isoquinolin-2-yl]-(3- pyridyl)methanone U
[6-benzyloxy-1-[(E)-2-(5- 0.87 >100 >115
benzyloxy-4-methoxy-2-methyl- phenyl)vinyl]-7-methoxy-3,4-
dihydro-1H-isoquinolin-2-yl]-(4- pyridyl)methanone V
6-benzyloxy-1-[(E)-2-(3-benzyloxy- 0.78 6.68 8.5
4-methoxy-phenyl)vinyl]-7- methoxy-2-methyl-3,4-dihydro-1H-
isoquinoline W 6-benzyloxy-7-methoxy-1-[(E)-2- 0.69 4 5.8
(o-tolyl)vinyl]-1,2,3,4- tetrahydroisoquinoline X
6-benzyloxy-1-[(E)-2-(4-fluoro-2- 0.62 5.3 8.53
methyl-phenyl)vinyl]-7-methoxy- 1,2,3,4-tetrahydroisoquinoline Y
tert-butyl 6-benzyloxy-1-[(E)-2-(5- 0.39 28.1 71.2
benzyloxy-4-methoxy-2-methyl- phenyl)vinyl]-7-methoxy-3,4-
dihydro-1H-isoquinoline-2- carboxylate Z
6-benzyloxy-7-methoxy-1-[(E)-2- 0.35 100 17.1 [4-methoxy-2-
(trifluoromethyl)phenyl]vinyl]- 1,2,3,4-tetrahydroisoquinoline AA
6-benzyloxy-1-[(E)-2-(5-benzyloxy- 0.148 3.89 26.3
2-ethyl-4-methoxy-phenyl)vinyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline AB 6-benzyloxy-1-[(E)-2-(3-benzyloxy- 0.146
3.96 27.1 4-methoxy-phenyl)vinyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline AC 6-benzyloxy-1-[(E)-2-(5-benzyloxy- 0.0872
1.8993 21.8 2-chloro-4-methoxy-phenyl)vinyl]- 7-methoxy-1,2,3,4-
tetrahydroisoquinoline AD 6-benzyloxy-1-[(E)-2-(5-benzyloxy- 0.084
3.22 38.1 2-methyl-phenyl)vinyl]-7-methoxy-
1,2,3,4-tetrahydroisoquinoline AE
6-benzyloxy-1-[(E)-2-(5-benzyloxy- 0.44 33.53 76.5
4-methoxy-2-methyl-phenyl)vinyl]- 7-methoxy-3,4-dihydroisoquinoline
AF 6-benzyloxy-1-[(E)-2-(5-benzyloxy- 0.083 3.873 48.2
4-methoxy-2-methyl-phenyl)vinyl]- 7-methoxy-1,2,3,4-
tetrahydroisoquinoline AG 6-benzyloxy-7-methoxy-1-[(E)-2- 0.0771
9.83 127.4 (4-methoxy-2-methyl-phenyl)vinyl]-
1,2,3,4-tetrahydroisoquinoline AH 6-benzyloxy-1-[(E)-2-(4,5- 0.0133
2.404 180.8 dimethoxy-2-methyl-phenyl)vinyl]- 7-methoxy-1,2,3,4-
tetrahydroisoquinoline AI 6-(benzyloxy)-7-methoxy-1-[(E)-2- 1.5 5.6
3.9 [4-methoxy-2-(4- methoxybutoxy)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline AJ 6-(benzyloxy)-7-methoxy-1-[(E)-2-
2.74 5 1.83 [2-methyl-4- (trifluoromethoxy)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline AK 6-(benzyloxy)-7-methoxy-1-[(E)-2-
8.87 10 1.1 (1-methyl-1H-pyrazol-5-yl)ethenyl]-
1,2,3,4-tetrahydroisoquinoline AL
6-(benzyloxy)-1-[(E)-2-(1-ethyl-1H- 2.95 24.2 8.2
pyrazol-4-yl)ethenyl]-7-methoxy- 1,2,3,4-tetrahydroisoquinoline AM
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.22 6 27.3
(3,4,5-trimethoxyphenyl)ethenyl]- 1,2,3,4-tetrahydroisoquinoline AN
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.14 3.7 26.8
(7-methoxy-1-benzofuran-4- yl)ethenyl]-1,2,3,4-
tetrahydroisoquinoline AO 6-(benzyloxy)-7-methoxy-1-[(E)-2- 1.13
9.94 8.8 (4-methoxy-1-benzofuran-7- yl)ethenyl]-1,2,3,4-
tetrahydroisoquinoline AP 6-(benzyloxy)-1-[(E)-2-[4- 0.97 1.64 1.7
(benzyloxy)-3,5- dimethoxyphenyl]ethenyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline AQ 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.0151
1.98 131.1 (2,4,5-trimethoxyphenyl)ethenyl]-
1,2,3,4-tetrahydroisoquinoline AR
6-(benzyloxy)-1-[(E)-2-(3-bromo-4- 0.8 6.2 8.2
methoxyphenyl)ethenyl]-7- methoxy-1,2,3,4- tetrahydroisoquinoline
AS 6-(benzyloxy)-1-[(E)-2-[5- 4.22 5.36 1.3
(benzyloxy)-2-tert-butyl-4- methoxyphenyl]ethenyl]-7-
methoxy-1,2,3,4- tetrahydroisoquinoline AT
6-(benzyloxy)-1-[(E)-2-(3,5- 0.77 4.85 6.3
dimethoxyphenyl)ethenyl]-7- methoxy-1,2,3,4- tetrahydroisoquinoline
AU 6-benzyloxy-7-methoxy-1-[(E)-2- 1.65 3.22 2
(2-methoxy-4-pyridyl)vinyl]-1,2,3,4- tetrahydroisoquinoline AV
6-(benzyloxy)-1-[(E)-2-(2,4- 0.14 5.5 39.3
dimethoxyphenyl)ethenyl]-7- methoxy-1,2,3,4- tetrahydroisoquinoline
AW 6-(benzyloxy)-7-methoxy-1-[(E)-2- 3.28 11.36 3.5
(pyridin-4-yl)ethenyl]-1,2,3,4- tetrahydroisoquinoline AX
6-benzyloxy-7-methoxy-1-[(E)-2- 3.28 11.36 3.5
(6-methoxy-3-pyridyl)vinyl]-1,2,3,4- tetrahydroisoquinoline AY
6-(benzyloxy)-1-[5-(benzyloxy)-4- 4.88 5.14 1.1
methoxy-2-methylphenyl]-7- methoxy-1,2,3,4- tetrahydroisoquinoline
AZ tert-butyl N-({2-[6-(benzyloxy)-7- 2.77 9.48 12.3
methoxy-1,2,3,4- tetrahydroisoquinolin-1-
yl]phenyl}methyl)carbamate BA 6-(benzyloxy)-7-methoxy-1-[(E)-2-
0.497 3.33 6.7 (4-methoxy-2,6- dimethylphenyl)ethenyl]-1,2,3,4-
tetrahydroisoquinoline BB 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.0544
2.98 54.9 (6-methyl-2H-1,3-benzodioxol-5- yl)ethenyl]-1,2,3,4-
tetrahydroisoquinoline BC 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.0271
2.43 90.6 (7-methyl-2,3-dihydro-1,4-
benzodioxin-6-yl)ethenyl]-1,2,3,4- tetrahydroisoquinoline BD
6-(benzyloxy)-1-[(E)-2-(4-butoxy-3- 0.408 3.62 8.9
methoxyphenyl)ethenyl]-7- methoxy-1,2,3,4- tetrahydroisoquinoline
BE 6-(benzyloxy)-1-[(E)-2-(3-butoxy-4- 0.0998 3.75 37.6
methoxyphenyl)ethenyl]-7- methoxy-1,2,3,4- tetrahydroisoquinoline
BF 6-(benzyloxy)-1-[(E)-2-(3-fluoro-4- 1.02 33.507 32.85
methoxyphenyl)ethenyl]-7- methoxy-1,2,3,4- tetrahydroisoquinoline
BG 4-[(E)-2-[6-(benzyloxy)-7-methoxy- 1.65 4.44 2.69
1,2,3,4-tetrahydroisoquinolin-1- yl]ethenyl]-N,N,3-trimethylaniline
BH 6-(benzyloxy)-7-methoxy-1-[(E)-2- 1.93 5.3 2.75 [2-methyl-5-
(trifluoromethoxy)phenyl]ethenyl]- 1,2,3,4-tetrahydroisoquinoline
BI 6-(benzyloxy)-7-methoxy-1-[(E)-2- 2.2 10 4.5
phenylethenyl]-1,2,3,4- tetrahydroisoquinoline BJ
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.477 20.901 43.54
(4-methoxyphenyl)ethenyl]-
1,2,3,4-tetrahydroisoquinoline BK 6-(benzyloxy)-1-[(E)-2-[3- 0.26 4
15.4 (benzyloxy)phenyl]ethenyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline BL 6-(benzyloxy)-1-[(E)-2-(5-butoxy-4- 0.052
1.1 21.2 methoxy-2-methylphenyl)ethenyl]- 7-methoxy-1,2,3,4-
tetrahydroisoquinoline BM 6-(benzyloxy)-1-[(E)-2-(2,3- 0.146 20.43
139.8 dihydro-1-benzofuran-5- yl)ethenyl]-7-methoxy-1,2,3,4-
tetrahydroisoquinoline BN 1-[(E)-2-(1-benzofuran-5- 0.84 20.65 24.8
yl)ethenyl]-6-(benzyloxy)-7- methoxy-1,2,3,4-
tetrahydroisoquinoline BO 4-{5-[(E)-2-[6-(benzyloxy)-7- 0.234 8.96
38.3 methoxy-1,2,3,4- tetrahydroisoquinolin-1-yl]ethenyl]-
2-methoxy-4- methylphenoxy}butanoic acid BP
6-(benzyloxy)-1-[(E)-2-(2-fluoro- 2.03 5.61 2.76
4,5-dimethoxyphenyl)ethenyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline BQ 6-(benzyloxy)-1-[(E)-2-(3,4- 0.198 8.7
43.5 dimethoxyphenyl)ethenyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline BR 6-(benzyloxy)-1-[(E)-2-(2-fluoro-4- 1.14
10 8.77 methoxyphenyl)ethenyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline BS 6-(benzyloxy)-7-methoxy-1-[(E)-2- 2.87
11.31 3.94 (3-methylthiophen-2-yl)ethenyl]-
1,2,3,4-tetrahydroisoquinoline BT 6-(benzyloxy)-1-[(E)-2-(1H- 0.613
7.98 13.02 indazol-6-yl)ethenyl]-7-methoxy-
1,2,3,4-tetrahydroisoquinoline BU 6-(benzyloxy)-1-[(E)-2-(2,6- 1.02
10.56 10.4 difluoro-4-methoxyphenyl)ethenyl]- 7-methoxy-1,2,3,4-
tetrahydroisoquinoline BV 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.304
2.63 8.7 (4-methoxy-2,5- dimethylphenyl)ethenyl]-1,2,3,4-
tetrahydroisoquinoline BW 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.84
1.88 2.2 [4-methoxy-2-methyl-5-(propan-2-
yl)phenyl]ethenyl]-1,2,3,4- tetrahydroisoquinoline BX
6-(benzyloxy)-1-[(E)-2-[5-(2,2- 0.35 3.4 9.71
dimethylpropoxy)-4-methoxy-2- methylphenyl]ethenyl]-7-methoxy-
1,2,3,4-tetrahydroisoquinoline BY 6-(benzyloxy)-7-methoxy-1-[(E)-2-
0.397 1.97 5 [4-methoxy-2-methyl-5-(piperidin-
4-ylmethoxy)phenyl]ethenyl]- 1,2,3,4-tetrahydroisoquinoline BZ
6-(benzyloxy)-1-[(E)-2-(4- 1 1 1 methanesulfonylphenyl)ethenyl]-7-
methoxy-1,2,3,4- tetrahydroisoquinoline CA
6-(benzyloxy)-1-[(E)-2-(2,6- 0.64 15.3 23.9
dimethoxypyridin-3-yl)ethenyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline CB 6-(benzyloxy)-1-[(E)-2-(3,4- 1.55 5.36
3.5 dihydro-2H-1-benzopyran-6- yl)ethenyl]-7-methoxy-1,2,3,4-
tetrahydroisoquinoline CC 6-(benzyloxy)-7-methoxy-1-[(E)-2- 1.18
5.44 4.6 (7-methyl-3,4-dihydro-2H-1-
benzopyran-8-yl)ethenyl]-1,2,3,4- tetrahydroisoquinoline CD
1-[(E)-2-[5-(4-azidobutoxy)-4- 0.088 1.63 18.5
methoxy-2-methylphenyl]ethenyl]- 6-(benzyloxy)-7-methoxy-1,2,3,4-
tetrahydroisoquinoline CE 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.125
4.87 38.9 (7-methyl-3,4-dihydro-2H-1-
benzopyran-6-yl)ethenyl]-1,2,3,4- tetrahydroisoquinoline CF
6-(benzyloxy)-1-[(E)-2-(3,4- 0.49 9.1 18.6
dihydro-2H-1-benzopyran-8- yl)ethenyl]-7-methoxy-1,2,3,4-
tetrahydroisoquinoline CG 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.14
4.8 34.3 (6-methyl-2,3-dihydro-1- benzofuran-5-yl)ethenyl]-1,2,3,4-
tetrahydroisoquinoline CH tert-butyl 2-[(E)-2-[6-(benzyloxy)-7-
0.58 3.48 6 methoxy-1,2,3,4- tetrahydroisoquinolin-1-yl]ethenyl]-
1H-indole-1-carboxylate CI tert-butyl 3-[(E)-2-[6-(benzyloxy)-7-
0.23 4.98 21.7 methoxy-1,2,3,4-
tetrahydroisoquinolin-1-yl]ethenyl]- 1H-indole-1-carboxylate CJ
6-(benzyloxy)-1-[(E)-2-(1H-indol-3- 0.47 6.55 13.9
yl)ethenyl]-7-methoxy-1,2,3,4- tetrahydroisoquinoline CK tert-butyl
4-[(E)-2-[6-(benzyloxy)-7- 0.805 5.99 7.4 methoxy-1,2,3,4-
tetrahydroisoquinolin-1-yl]ethenyl]- 1H-indole-1-carboxylate CL
6-(benzyloxy)-1-[(E)-2-(1H-indol-4- 1.5 7.2 4.66
yl)ethenyl]-7-methoxy-1,2,3,4- tetrahydroisoquinoline CM tert-butyl
5-[(E)-2-[6-(benzyloxy)-7- 1.3 10 7.7 methoxy-1,2,3,4-
tetrahydroisoquinolin-1-yl]ethenyl]- 1H-indole-1-carboxylate CN
tert-butyl 7-[(E)-2-[6-(benzyloxy)-7- 1.83 19.6 11 methoxy-1,2,3,4-
tetrahydroisoquinolin-1-yl]ethenyl]- 1H-indole-1-carboxylate CO
3-[(E)-2-[6-(benzyloxy)-7-methoxy- 6 10 1.7
1,2,3,4-tetrahydroisoquinolin-1- yl]ethenyl]-2,6-difluorophenol CP
6-(benzyloxy)-1-[(E)-2-(3- 3.07 20.6 6.7
methanesulfonylphenyl)ethenyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline CQ 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.06
1.4 23.7 (7-methoxy-2,3-dihydro-1,4-
benzodioxin-6-yl)ethenyl]-1,2,3,4- tetrahydroisoquinoline CR
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.12 3.3 27.2
(6-methoxy-2H-1,3-benzodioxol-5- yl)ethenyl]-1,2,3,4-
tetrahydroisoquinoline CS tert-butyl 6-[(E)-2-[6-(benzyloxy)-7-
0.912 6.15 6.7 methoxy-1,2,3,4-
tetrahydroisoquinolin-1-yl]ethenyl]- 1H-indole-1-carboxylate CT
2-[(E)-2-[6-(benzyloxy)-7-methoxy- 0.2 8.9 45
1,2,3,4-tetrahydroisoquinolin-1- yl]ethenyl]-4,5-dimethoxy-N,N-
dimethylaniline CU 3-[(E)-2-[6-(benzyloxy)-7-methoxy- 1.4 19.9 14
1,2,3,4-tetrahydroisoquinolin-1- yl]ethenyl]-N,N-dimethylpyridin-2-
amine CV ethyl 4-{5-[(E)-2-[6-(benzyloxy)-7- 0.1 2.7 20
methoxy-1,2,3,4- tetrahydroisoquinolin-1-yl]ethenyl]-
2-methoxyphenoxy}butanoate CW tert-butyl N-{2-[(E)-2-[6- 5.4 23.6
4.3 (benzyloxy)-7-methoxy-1,2,3,4- tetrahydroisoquinolin-1-
yl]ethenyl]phenyl}carbamate CX 2-[(E)-2-[6-(benzyloxy)-7-methoxy-
1.4 20.8 14 1,2,3,4-tetrahydroisoquinolin-1- yl]ethenyl]aniline CY
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.697 4 5.7 [4-methoxy-3-
(trifluoromethyl)phenyl]ethenyl]- 1,2,3,4-tetrahydroisoquinoline CZ
6-(benzyloxy)-7-methoxy-1-[(E)-2- 2.188 4 1.8
[4-methoxy-3-methyl-5- (trifluoromethyl)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline DA 6-(benzyloxy)-7-methoxy-1-[(E)-2-
2.34 10 4.3 [2-(trifluoromethyl)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline DB 6-(benzyloxy)-7-methoxy-1-[(E)-2-
2.67 10 3.7 [3-(trifluoromethyl)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline DC
2-[(E)-2-[6-(benzyloxy)-7-methoxy- 0.83 10 12.1
1,2,3,4-tetrahydroisoquinolin-1- yl]ethenyl]-N,N-dimethylaniline DD
6-(benzyloxy)-7-methoxy-1-[(E)-2- 11.06 100 9
(2-methoxypyrimidin-5-yl)ethenyl]- 1,2,3,4-tetrahydroisoquinoline
DE 6-(benzyloxy)-7-methoxy-1-[(E)-2- 1.44 10 6.9
[2-(2-methoxyethoxy)phenyl]ethenyl]- 1,2,3,4-tetrahydroisoquinoline
DF 6-(benzyloxy)-1-[(E)-2-(2,2- 5.44 10 1.8
difluoro-2H-1,3-benzodioxol-5- yl)ethenyl]-7-methoxy-1,2,3,4-
tetrahydroisoquinoline DG 6-(benzyloxy)-7-methoxy-1-[(E)-2- 2.2 9
4.1 (2-methoxyphenyl)ethenyl]- 1,2,3,4-tetrahydroisoquinoline DH
6-(benzyloxy)-7-methoxy-1-[(E)-2- 5.26 17.8 3.4
[2-(morpholin-4-yl)phenyl]ethenyl]- 1,2,3,4-tetrahydroisoquinoline
DI 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.628 5.84 9.2
(6-methoxynaphthalen-2- yl)ethenyl]-1,2,3,4- tetrahydroisoquinoline
DJ 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.393 5.86 15
[4-(pyridin-3-yl)phenyl]ethenyl]- 1,2,3,4-tetrahydroisoquinoline DK
6-(benzyloxy)-1-[(E)-2-[4-(1H- 0.107 9.13 85
imidazol-1-yl)phenyl]ethenyl]-7- methoxy-1,2,3,4-
tetrahydroisoquinoline DL 7-[(E)-2-[6-(benzyloxy)-7-methoxy- 0.0969
7 72 1,2,3,4-tetrahydroisoquinolin-1- yl]ethenyl]quinoline DM
6-(benzyloxy)-7-methoxy-1-[(E)-2- 1.52 21.1 14
[4-(2-methyl-1H-imidazol-1- yl)phenyl]ethenyl]-1,2,3,4-
tetrahydroisoquinoline DN 6-(benzyloxy)-7-methoxy-1-[(E)-2- 2.4
17.1 7.1 [2-(3-methoxyphenyl)pyrimidin-5- yl]ethenyl]-1,2,3,4-
tetrahydroisoquinoline DO 6-(benzyloxy)-1-[(E)-2-[4-(4- 0.496 3.61
7.3 ethylpiperazin-1- yl)phenyl]ethenyl]-7-methoxy-
1,2,3,4-tetrahydroisoquinoline DP 6-(benzyloxy)-7-methoxy-1-[(E)-2-
0.015 1.3 92 {1-methyl-1H-pyrrolo[2,3-b]pyridin-
3-yl}ethenyl]-1,2,3,4- tetrahydroisoquinoline DQ
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.126 4.4 35
[3-(pyridin-4-yl)phenyl]ethenyl]- 1,2,3,4-tetrahydroisoquinoline DR
6-(benzyloxy)-7-methoxy-1-[(E)-2- 4.82 25.4 5.3
(1,3-thiazol-4-yl)ethenyl]-1,2,3,4- tetrahydroisoquinoline DS
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.116 7.39 64
[4-(pyrimidin-5-yl)phenyl]ethenyl]- 1,2,3,4-tetrahydroisoquinoline
DT 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.157 7.39 47
[4-(1H-1,2,4-triazol-1- yl)phenyl]ethenyl]-1,2,3,4-
tetrahydroisoquinoline DU 1-[(E)-2-(1-benzothiophen-2- 10.1 16.3
1.6 yl)ethenyl]-6-(benzyloxy)-7- methoxy-1,2,3,4-
tetrahydroisoquinoline DV 6-(benzyloxy)-7-methoxy-1-[(E)-2- 29.5
21.8 0.74 (1,3-thiazol-2-yl)ethenyl]-1,2,3,4-
tetrahydroisoquinoline DW 6-(benzyloxy)-7-methoxy-1-[(E)-2- 1.24
2.31 1.9 [4-(4-methylpiperazin-1- yl)phenyl]ethenyl]-1,2,3,4-
tetrahydroisoquinoline DX 6-(benzyloxy)-7-methoxy-1-[(E)-2- 4.2
5.38 1.3 [2-(piperidin-1-yl)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline DY 6-(benzyloxy)-7-methoxy-1-[(E)-2-
5.51 21.6 3.9 (4-methyl-1,3-thiazol-5-yl)ethenyl]-
1,2,3,4-tetrahydroisoquinoline DZ 6-(benzyloxy)-7-methoxy-1-[(E)-2-
0.65 5.8 8.9 [4-(pyridin-2-yl)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline EA 6-(benzyloxy)-7-methoxy-1-[(E)-2-
2.1 4.8 2.3 [4-(piperidin-1-yl)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline EB 6-(benzyloxy)-7-methoxy-1-[(E)-2-
0.3 6 20 (6-methoxy-1-benzofuran-5- yl)ethenyl]-1,2,3,4-
tetrahydroisoquinoline EC 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.93
7.5 8 [3-(1,3-oxazol-2-yl)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline ED 6-(benzyloxy)-7-methoxy-1-[(E)-2-
0.58 7.5 13 [4-(1,3-oxazol-2-yl)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline EE ethyl
2-{4-[(E)-2-[6-(benzyloxy)-7- 0.99 5.9 2.8 methoxy-1,2,3,4-
tetrahydroisoquinolin-1- yl]ethenyl]phenyl}-1,3-oxazole-4-
carboxylate EF ethyl 2-{3-[(E)-2-[6-(benzyloxy)-7- 1 5.9 6
methoxy-1,2,3,4- tetrahydroisoquinolin-1-
yl]ethenyl]phenyl}-1,3-oxazole-4- carboxylate EG
6-(benzyloxy)-1-[(E)-2-(2,3- 0.9 19.3 21.4 dihydro-1-benzofuran-6-
yl)ethenyl]-7-methoxy-1,2,3,4- tetrahydroisoquinoline EH
6-(benzyloxy)-1-[(E)-2-(2,4- 0.066 3.59 54.5 dimethoxy-5-
methylphenyl)ethenyl]-7-methoxy- 1,2,3,4-tetrahydroisoquinoline EI
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.34 11.8 35.3 (4-methoxy-3-
methylphenyl)ethenyl]-1,2,3,4- tetrahydroisoquinoline EJ
6-(benzyloxy)-7-methoxy-1-[(E)-2- 2.98 10 3.3
(3-methoxyphenyl)ethenyl]- 1,2,3,4-tetrahydroisoquinoline EK
6-(benzyloxy)-1-[(E)-2-(2,5- 0.38 3.6 9.5
dimethoxyphenyl)ethenyl]-7- methoxy-1,2,3,4- tetrahydroisoquinoline
EL 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.15 3.25 21.7 (4-methoxy-2,3-
dimethylphenyl)ethenyl]-1,2,3,4- tetrahydroisoquinoline EM
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.32 1.8 5.6
[4-methoxy-3-(piperidin-1- ylmethyl)phenyl]ethenyl]-1,2,3,4-
tetrahydroisoquinoline EN 6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.189
4.03 21.3 {4-methoxy-3-[(2-methyl-1H- imidazol-1-
yl)methyl]phenyl}ethenyl]-1,2,3,4- tetrahydroisoquinoline EO
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.504 1.94 3.8
{4-methoxy-3-[(2,2,2- trifluoroethoxy)methyl]phenyl}ethenyl]-
1,2,3,4-tetrahydroisoquinoline EP 6-(benzyloxy)-7-methoxy-1-[(E)-2-
0.846 4 4.7 [4-methoxy-3- (methoxymethyl)phenyl]ethenyl]-
1,2,3,4-tetrahydroisoquinoline EQ
4-[(E)-2-[6-(benzyloxy)-7-methoxy- 7.04 10 1.4
1,2,3,4-tetrahydroisoquinolin-1- yl]ethenyl]benzoic acid ER
3-[(E)-2-[6-(benzyloxy)-7-methoxy- 10 10 1
1,2,3,4-tetrahydroisoquinolin-1- yl]ethenyl]benzoic acid ES
2-[(E)-2-[6-(benzyloxy)-7-methoxy- 8.62 10 1.2
1,2,3,4-tetrahydroisoquinolin-1- yl]ethenyl]benzoic acid ET ethyl
2-[(E)-2-[6-(benzyloxy)-7- 2.48 9.9 4 methoxy-1,2,3,4-
tetrahydroisoquinolin-1- yl]ethenyl]benzoate EU
6-(benzyloxy)-7-methoxy-1-[(E)-2- 0.24 5.1 21.3 [4-methoxy-3-
(phenoxymethyl)phenyl]ethenyl]- 1,2,3,4-tetrahydroisoquinoline
[0619] It is understood that the examples and embodiments described
herein are for illustrative purposes only and that various
modifications or changes in light thereof will be suggested to
persons skilled in the art and are to be included within the spirit
and purview of this application and scope of the appended claims.
It is to be understood that the present invention covers all
combinations of aspects and/or embodiments, as well as suitable,
convenient and preferred groups described herein. All publications,
patents, and patent applications cited herein are hereby
incorporated by reference in their entirety for all purposes.
[0620] The invention is further illustrated by the Examples that
follow. The Examples are not intended to define or limit the scope
of the invention.
* * * * *